



Sunday, September 23, 2018

S01

07:00 - 12:00 IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening (Ticketed Session) **Room 203 BD**

Topics: Screening and Early Detection
Moderation: J. Field, UK; J. Mulshine, USA

07:00 - 07:30 **S01.01 - Breakfast**

07:30 - 07:35 **S01.02 - Introductions & Welcome**

Session I: The Backbone to our Knowledge on Lung Cancer Screening

07:35 - 07:50 **S01.04 - Lung Cancer Screening: 1999 to Date - What Have We Learnt?**

David Yankelevitz, NY/USA

07:50 - 08:00 **S01.05 - Discussion**

Session II: Future Integration of Biomarkers in the Selection of High Risk Individuals for Lung Cancer Screening

08:00 - 08:50 **S01.07 - The U19 Plans for Integration of Biomarkers into Future Lung Cancer Screening**

Rayjean Hung, Canada; Paul Brennan, France; Christopher Amos, USA

08:50 - 09:00 **S01.08 - Discussion**

Session III: European Strategy for the Implementation of Lung Cancer Screening

09:00 - 09:20 **S01.10 - EU Position Statement on Lung Cancer Screening**

Matthijs Oudkerk, Netherlands



09:20 - 09:30 **S01.11 - Discussion**

09:30 - 09:50 **S01.12 - Coffee break**

Session IV: Lung Cancer Screening Requires Infra-Structural Organisation and an Integrated Smoking Cessation Plan

09:50 - 10:05 **S01.14 - Coordination of the Lung Cancer CT Screening Experience**
Joelle Fathi, USA

10:05 - 10:20 **S01.15 - Integration of Smoking Cessation into Lung Cancer Screening**
Kate Brain, UK

10:20 - 10:30 **S01.16 - Discussion**

10:30 - 11:30 **Session V: Panel Discussion: Next Steps for Lung Screening?**

Claudia Henschke, NY/USA; Kwun Fong, Australia; Motoyasu Sagawa, Japan; Matthew Callister, UK; Nasser Altorki, USA; Bruce Pyenson, USA; Andrea Borondy Kitts, USA

11:30 - 11:50 **S01.18 - IASLC Leads the International Collaboration on Data Sharing (IASLC- ELIC-CCTRR)**
John Field, UK; James Mulshine, IL/USA

11:50 - 12:00 **S01.19 - Discussion**

12:00 **S01.20 - Networking Lunch**

JCSE01

07:30 - 11:15	Perspectives for Lung Cancer Early Detection	Room 202 BD
Topics: Screening and Early Detection Moderation: F. Hirsch, USA; Y.-L. Wu, China; T. Mok, Hong Kong		

07:30 - 08:00 **JCSE01.01 - Breakfast and Poster Viewing**

- 08:00 - 08:20 **JCSE01.02 - Necessity for Early Detection in Lung Cancer and Initial Attempts for Early Detection**
Annette McWilliams, Australia
- 08:20 - 08:40 **JCSE01.03 - CT Screening for Early Detection (NLST, UKLS, NELSON, ITALUNG, DANTE, Others)**
Matthijs Oudkerk, Netherlands
- 08:40 - 09:00 **JCSE01.04 - Risk Modeling for the Early Detection of Tin Miner Lung Cancer in China**
You-lin Qiao, China
- 09:00 - 09:20 **JCSE01.05 - Biomarkers and Liquid Biopsy for Early Detection of Lung Cancer**
K C Allen Chan, China
- 09:20 - 09:40 **JCSE01.06 - Incorporating Artificial Intelligence for Early Detection of Lung Cancer**
Jie Hu, China
- 09:40 - 09:50 **JCSE01.07 - Discussion**
- 09:50 - 10:15 **JCSE01.08 - Coffee Break and Poster Viewing**
- 10:15 - 10:25 **JCSE01.09 - Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC**
Yi-Long Wu, China
- 10:25 - 10:35 **JCSE01.10 - A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients**
Shun Lu, China
- 10:35 - 10:45 **JCSE01.11 - Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients**
Jianhua Chang, China
- 10:45 - 11:00 **JCSE01.12 - Discussant Oral Abstracts**
Daniel Tan, Singapore
- 11:00 - 11:15 **JCSE01.13 - Discussant Poster Abstracts**
Bob Li, NY/USA

**Poster Abstracts**

JCSE01.14 - Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues

Xu Wang, China

JCSE01.15 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

Chunwei Xu, China

JCSE01.16 - Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

Zheng Wang, China

JCSE01.17 - Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Changli Wang, China

JCSE01.18 - A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506)

Qing Zhou, China

JCSE01.19 - ALTER-0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Baohui Han, China

JCSE01.20 - Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation

Lei Zhao, China

JCSE01.21 - Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients

Shuyuan Wang, China

JCSE01.22 - Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination

Ying Chen, China

JCSE01.22a - Tislelizumab Combined with Chemotherapy as First-Line Treatment in Chinese Patients with Advanced Lung Cancer

Jie Wang, China

11:15 - 11:15

JCSE01.23 - Closing Remarks



08:00 - 09:30	IASLC Foundation Walk supported by Lung Cancer Canada (Ticketed Event)	Room 201 F
----------------------	---	-------------------

08:00 - 09:00	Registration Opens	
---------------	--------------------	--

09:00 - 10:30	Shotgun Start	
---------------	---------------	--

10:30 - 12:00	Celebration and Breakfast/Snacks	
---------------	----------------------------------	--

WS01

08:00 - 11:15	Cancer Genomics Workshop (Ticketed Session)	Room 201 BD
----------------------	--	--------------------

08:00 - 08:15	WS01.01 - Introduction to the Workshop	
---------------	--	--

08:15 - 09:30	WS01.02 - Exercise 1: Cancer Gene Panels: Methods and Application	
---------------	---	--

09:30 - 09:45	WS01.03 - Break	
---------------	-----------------	--

09:45 - 11:00	WS01.04 - Exercise 2: Cancer Gene Panels: Result Interpretation and Clinical Utility	
---------------	--	--

11:00 - 11:15	WS01.05 - Questions/Panel Discussion	
---------------	--------------------------------------	--

WS02

08:00 - 11:15	Mesothelioma Workshop Topics: Mesothelioma	Room 205 AC
----------------------	--	--------------------

Session 1: Surgery for Mesothelioma
Harvey Pass, NY/USA



08:00 - 08:15 **WS02.02 - What Are the Most Important Unmet Needs in the Surgical Management of Mesothelioma?**
Valerie Rusch, NY/USA

08:15 - 08:30 **WS02.03 - Who Are the High-Risk Patients for Surgical Failure in Mesothelioma?**
Harvey Pass, NY/USA

08:30 - 08:45 **WS02.04 - SMART, Where It Is Going**
Marc De Perrot, Canada

08:45 - 09:00 **WS02.05 - Reliability of MM Diagnosis and Role of BAP1 Staining**
Francoise Galateau-Salle, France

09:00 - 09:05 **WS02.06 - Q&A**

Session 2: Immunotherapy in Mesothelioma

Paul Baas, Netherlands

09:05 - 09:20 **WS02.08 - The Microenvironment and Mesothelioma**
Prasad Adusumilli, NY/USA

09:20 - 09:35 **WS02.09 - PDL-1 and Mesothelioma**
Raphael Bueno, MA/USA

09:35 - 09:50 **WS02.10 - An Overview of Present and Future Immunotherapy Trials in Mesothelioma: Progress and Problems**
Aaron Mansfield, MN/USA

09:50 - 10:05 **WS02.11 - Window of Opportunity Immunotherapy Trials in Mesothelioma: Design and Translation**
Anne Tsao, TX/USA

10:05 - 10:10 **WS02.12 - Q&A**

Session 3: Transcriptome Changes and Mutations in Mesothelioma - Somatic, Germline, BAP1 and more

David Jablons, USA



- 10:10 - 10:25 **WS02.14 - BAP1 Mutations: Mechanisms and Significance**
Michele Carbone, HI/USA
- 10:25 - 10:40 **WS02.15 - Novel Approaches for Targeting BAP1**
Marjorie Zauderer, NY/USA
- 10:40 - 10:55 **WS02.16 - Genome-wide Silencing Screen in Mesothelioma Cells Reveals that Loss of Function of BAP1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition: Implication for Therapy**
Emanuela Felley-Bosco, Switzerland
- 10:55 - 11:10 **WS02.17 - A Subset of Mesotheliomas with Improved Survival Occurring in Carriers of BAP1 and of other Germline Mutations**
Haining Yang, USA
- 11:10 - 11:15 **WS02.18 - Q&A**

WS03

08:00 - 11:15	Radiation Workshop (Ticketed Session)	Room 206 BD
----------------------	--	--------------------

08:00 - 11:15 **WS03.01 - Radiation Workshop (Ticketed Session)**

WS04

08:00 - 11:30	Endoscopic Diagnosis and Staging of Lung Cancer - Interventional Pulmonology Hands-On Workshop (Ticketed Session)	Room 205 B
	Topics: Interventional Diagnostics/Pulmonology	

08:00 - 08:35 **WS04.01 - Welcome and Introduction**

08:35 - 09:10 **WS04.02 - EBUS-TBNA - Role in Invasive Mediastinal Staging**

09:10 - 09:45 **WS04.03 - Combined EBUS/EUS Mediastinal Staging**

09:45 - 10:20 **WS04.04 - Radial Probe EBUS - Methods and Results**

10:20 - 10:55 **WS04.05 - Navigational Bronchoscopy**

10:55 - 11:30 **WS04.06 - Hands-On Session on 6 stations**

WS05

08:00 - 11:30 **Roche Scientific Symposium: Clinical Decision Support for Management of Lung Cancer Patients and Future Directions in the Era of Precision Medicine (Sign Up Required)** **Room 206 F**

08:00 - 08:15 **WS05.01 - Welcome & Introduction**

08:15 - 08:45 **WS05.02 - Protein-based Biomarkers as Tools to Support Clinical Decision Making for Lung Cancer Patients with Results from the Laboratory**
Rafael Molina, Spain

08:45 - 09:15 **WS05.03 - Using Immunohistochemistry in Differential Diagnosis and Predictive Assessment of Lung Cancer**
Mark Kockx, Belgium

09:15 - 09:45 **WS05.04 - Clinical Utility of Liquid Biopsy to EGFR Mutation Detection in NSCL**
Adrian Sacher, Canada

09:45 - 10:00 **WS05.05 - Break**

10:00 - 10:30 **WS05.06 - Circulating Tumor DNA: Solid Tumor MRD Detection and Potential Clinical Utility**
Aadel Chaudhuri, USA

10:30 - 11:00 **WS05.07 - University of Missouri's Experience with the NAVIFY Tumor Board Solution in HemOnc Tumor Board**
Richard Hammer, USA

11:00 - 11:30 **WS05.08 - Panel Discussion**



YI01

08:00 - 11:30	Young Investigators Session	Room 106
Moderation: J. Yeung, Canada; K. Clarke, UK		
08:00 - 08:10	YI01.01 - Introduction to the IASLC - Why You Should be a Member Clarissa Mathias, Brazil	
08:10 - 08:20	YI01.02 - Planning a Career in Lung Cancer - Clinical Trials Roy Herbst, CT/USA	
08:20 - 08:30	YI01.03 - Planning a Career in Lung Cancer - Science Yolonda Colson, USA	
08:30 - 08:40	YI01.04 - Planning a Career in Lung Cancer - Bench to Beside Pasi Jänne, MA/USA	
08:40 - 08:50	YI01.05 - Planning a Career in Lung Cancer - Education Barbara Melosky, Canada	
08:50 - 09:00	YI01.06 - Community Oncology Parneet Cheema, Canada	
09:00 - 09:10	YI01.07 - Making the Most of your Cooperative Group Rolf Stahel, Switzerland	
09:10 - 09:30	YI01.08 - Panel Discussion	
09:30 - 09:45	YI01.09 - Break	
09:45 - 10:00	YI01.10 - Knowing your Statistics Mary Redman, WA/USA	
10:00 - 10:15	YI01.11 - How to get your Paper Published Alex Adjei, NY/USA	
10:15 - 10:30	YI01.12 - Writing a Successful Abstract Michael Boyer, ACT/Australia	



10:30 - 10:45	YI01.13 - How to give a Great Presentation Tony Mok, Hong Kong
10:45 - 11:00	YI01.14 - How to write a Successful Grant Application Dean Fennell, UK
11:00 - 11:15	YI01.15 - Panel Discussion
11:15 - 11:20	YI01.16 - Young investigator Experience Fabio Moraes, Brazil
11:20 - 11:30	YI01.17 - Getting the most out of WCLC 2018 Andrea Bezjak, ON/Canada; Gail Darling, ON/Canada; Natasha Leighl, ON/Canada
11:30	YI01.18 - Close

ISS01

09:45 - 11:15	Symposium Supported by Takeda: New Insights and Clinical Implications for the Treatment of ALK+ NSCLC	Room 105
----------------------	--	-----------------

09:45 - 11:15	New Insights and Clinical Implications for the Treatment of ALK+ NSCLC
---------------	--

ISS02

11:30 - 13:00	Symposium Supported by Incyte: Novel Immunotherapy Strategies in Lung Cancer	Room 107
----------------------	---	-----------------

11:30 - 13:00	Novel Immunotherapy Strategies in Lung Cancer
---------------	---



WS06

12:00 - 18:00	ITONF Workshop: Excellence in Thoracic Oncology Care Topics: Nursing and Allied Professionals	Room 206 BD
12:00 - 12:30	WS06.01 - ITONF Membership Meeting & Luncheon Melissa Culligan, PA/USA	
12:30 - 13:00	WS06.02 - Keynote Speaker: Lung Cancer and Mesothelioma Nursing Care in Canada Massey Nematollahi, Canada	
13:00 - 13:30	WS06.03 - Panel Discussion: Managing Hope and Expectations in Thoracic Oncology Maria Guerin, UK; Bethany Taylor, UK; Beth Eaby-Sandy, PA/USA	
13:30 - 13:50	WS06.04 - Tag, Tweet or Follow: Top Tips for using Social Media in your Clinical Practice Liz Darlison, UK	
13:50 - 14:15	WS06.05 - UPDATE: Immunotherapy, Targeted Therapy and Combination Therapy Clinical Trials in Lung Cancer and Mesothelioma Buerkley Rose, USA; Rebecca Lau, Australia	
14:15 - 14:30	WS06.06 - Break	
14:30 - 15:00	WS06.07 - Global Issues in Lung Cancer and Mesothelioma in 2018 Andrea Serena, Switzerland; Lorraine Creech, UK	
15:00 - 15:45	WS06.08 - UPDATE: Advances in Local Treatments for Lung Cancer and Mesothelioma (Radiation and Surgery) Mary Duffy, Australia; Jenny Mitchell, UK; Anastasia Bykova, Canada	
15:45 - 16:00	WS06.09 - Break	
16:00 - 16:30	WS06.10 - Nurse-led TeleHealth in Thoracic Oncology Sarah Cubbin, UK; John Mcphelim, UK	
16:30 - 17:00	WS06.11 - UPDATE: Toxicity Management of Immunotherapy Treatments in Lung Cancer and Mesothelioma Kathleen Gamblin, GA/USA; John Mcphelim, UK; Anne Fraser, New Zealand; Marianne Davies, CT/USA	



17:00 - 17:30 **WS06.12 - 2017-18 Year in Review: Scientific Poster Session**
Maria Guerin, UK

ISS03

13:00 - 14:30 **Symposium Supported by Lilly Oncology: Steering Improved Outcomes in Non-driver Mutation Lung Cancer: Progress and Challenges** Room 106

13:00 - 14:30 **Steering Improved Outcomes in Non-driver Mutation Lung Cancer: Progress and Challenges**

ISS04

14:30 - 16:00 **Symposium Supported by Bristol-Myers Squibb: Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers** Room 105

14:30 - 16:00 **Refining the Focus in Lung Cancer: New Data and Emerging Biomarkers**

ISS05

16:00 - 17:30 **Symposium provided by Oakstone Publishing, LLC and PeerVoice, supported by an educational grant from AstraZeneca: EGFR-Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care** Room 107

16:00 - 17:30 **EGFR-Mutant NSCLC: Evolving Treatment Paradigms and Game Changers for Current and Future Front-Line Care**

PR01

16:00 - 17:30 **Press Conference** Room 202 BD

16:00 - 17:30 **Press Conference**

17:45 - 18:45 **IASLC Foundation Concert (Ticketed Event)** Glenn Gould Studio

17:45 - 18:45 **IASLC Foundation Concert (Ticketed Event)**



OC01

19:00 - 20:30 **Opening Ceremony** **Plenary Hall**

19:00 - 19:10 **OC01.01 - Eradicating Lung Cancer**
Prabat Jha, Canada

20:30 - 22:00 **Welcome Reception** **Exhibit Hall**

20:30 - 22:00 **Welcome Reception**



Monday, September 24, 2018

ISS06

07:00 - 08:00 **Symposium Supported by Medscape: NTRK Fusions in NSCLC - Practice Changing in 2018 and Beyond?** **Room 106**

07:00 - 08:00 **NTRK Fusions in NSCLC - Practice Changing in 2018 and Beyond?**

ISS07

07:00 - 08:00 **Symposium Supported by Clinical Care Options, LLC: Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC** **Room 107**

07:00 - 08:00 **Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC**

ISS08

07:00 - 08:00 **Symposium Supported by Foundation Medicine: Implementing Liquid Biopsies into Clinical Practice: Challenges, Achievements and Progress** **Plenary Hall**

07:00 - 08:00 **Implementing Liquid Biopsies into Clinical Practice: Challenges, Achievements and Progress**

MTE01

07:00 - 08:00 **Preclinical Models of Lung Cancer (Ticketed Session)** **Room 206 F**
Topics: Biology

07:00 - 07:30 **MTE01.01 - GEMM of Lung Cancer**
Sarah Best, VIC/Australia

07:30 - 08:00 **MTE01.02 - Lung Patient Derived Xenograft and Organoid**
Nadeem Moghal, ON/Canada



MTE02

07:00 - 08:00 Update on WHO Classification and Staging of Lung Cancer (Ticketed Session) Room 203 BD
Topics: Pathology

07:00 - 07:30 **MTE02.01 - Update on WHO Classification and Staging of Lung Cancer**
Sanja Dacic, PA/USA

07:30 - 08:00 **MTE02.02 - Update on WHO Classification and Staging of Lung Cancer**
Teh-Ying Chou, Taiwan

MTE03

07:00 - 08:00 Clinical Trial Design with Novel Lung Cancer Therapy (Ticketed Session) Room 105
Topics: Targeted Therapy

07:00 - 07:30 **MTE03.01 - Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)**
Peter Ellis, Canada

07:30 - 08:00 **MTE03.02 - Novel Trial Design for Precision Medicine**
Fiona Blackhall, UK

MTE04

07:00 - 08:00 Comparison of Various Risk Models (Ticketed Session) Room 205 AC
Topics: Screening and Early Detection

07:00 - 07:30 **MTE04.01 - Comparisons of Risk Models**
Christine Berg, USA

07:30 - 08:00 **MTE04.02 - Where Should Health Programs Set Threshold for Tailored Screening?**
James Mulshine, IL/USA

MTE05

07:00 - 08:00 Role of Pneumonectomy in N2 Disease (Ticketed Session) Room 202 BD
Topics: Treatment of Locoregional Disease - NSCLC

07:00 - 07:30 **MTE05.01 - Role of Pneumonectomy in N2 Disease**
Jessica Donington, NY/USA



07:30 - 08:00 **MTE05.02 - Role of Pneumonectomy in N2 Disease**
Paula Ugalde, QC/Canada

MTE06

07:00 - 08:00 Symptom Management in Mesothelioma (Ticketed Session) Room 206 BD
Topics: Mesothelioma

07:00 - 07:30 **MTE06.01 - Role of Pleurectomy in Palliation of Symptoms**
John Edwards, UK

07:30 - 08:00 **MTE06.02 - How to Register Toxicity and Guide Patients**
Liz Darlison, UK

MTE07

07:00 - 08:00 Management of Pleural Recurrence (Ticketed Session) Room 201 F
Topics: Thymoma/Other Thoracic Malignancies

07:00 - 07:30 **MTE07.01 - From Radiation Oncology Perspective**
Andreas Rimner, NY/USA

07:30 - 08:00 **MTE07.02 - From Surgical Perspective**
Robert Korst, USA

MTE08

07:00 - 08:00 Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges (Ticketed Session) Room 205 B
Topics: Nursing and Allied Professionals

07:00 - 08:00 **MTE08.01 - Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges**
Linda Sarna, CA/USA



MTE09

07:00 - 08:00 **Management of Advanced Wild-Type Lung Cancer in Special Situations (Ticketed Session)** **Room 206 AC**
Topics: Advanced NSCLC

07:00 - 07:30 **MTE09.01 - Evidence Based Management of the Patient over 80**
Elisabeth Quiox, France

07:30 - 08:00 **MTE09.02 - Management of the PS 2 Patient**
Joan Schiller, VA/USA

MTE10

07:00 - 08:00 **Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous (Ticketed Session)** **Room 201 BD**
Topics: Interventional Diagnostics/Pulmonology

07:00 - 08:00 **MTE10.01 - Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous**
Felix Herth, Germany

PL01

08:15 - 09:45 **Patients First** **Plenary Hall**
Moderation: A. Bezjak, Canada; P. Bunn, Jr., USA

08:15 - 08:25 **PL01.01 - When Breath Becomes Air**
Lucy Kalanithi, USA

08:25 - 08:40 **PL01.02 - Science that Matters**
David Carbone, OH/USA

08:40 - 08:55 **PL01.03 - Trials that Matter!**
Tony Mok, Hong Kong

08:55 - 09:10 **PL01.04 - Getting Drugs to Patients Faster: A Global View**
Solange Peters, Switzerland

09:10 - 09:25 **PL01.05 - Conquering Lung Cancer - The IASLC Vision**
Giorgio Scagliotti, Italy



09:25 - 09:40 **PL01.06 - Patients First**
Tish Vigna, Canada

MA01

10:30 - 12:00 **Early Stage Lung Cancer: Questions and Controversies** **Room 202 BD**
Topics: Treatment of Early Stage/Localized Disease
Moderation: W. Hanna, Canada; M. Tsuboi, Japan

10:30 - 10:35 **MA01.01 - Proposal on Incorporating Lymphovascular Invasion as a T-Descriptor for Stage I Non-Small Cell Lung Cancer**
Shuyuan Wang, China

10:35 - 10:40 **MA01.02 - Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk-Based Stratification for Surveillance**
Yusuke Takahashi, NY/USA

10:40 - 10:45 **MA01.03 - An Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non-Small Cell Lung Cancer**
Aditya Juloori, OH/USA

10:45 - 11:00 **MA01.04 - Discussant - MA 0.01, MA 0.02, MA 0.03**
Deepali Jain, India

11:00 - 11:05 **MA01.05 - Opioids and Sleep Medication Use After Surgery for Early Stage Lung Cancer: A SEER-Medicare Analysis**
Stephanie Tuminello, USA

11:05 - 11:10 **MA01.06 - Evaluation of Safety and Efficacy in Surgical Treatment for Octogenarian Lung Cancer Patients by Multicenter Prospective Study: JACS1303**
Tomohiro Haruki, Japan

11:10 - 11:15 **MA01.07 - Validation of RTOG 0813 Normal Tissue Constraints for Pulmonary Toxicity in SBRT for Central Non-Small Cell Lung Cancer**
Kyle Verdecchia, OH/USA

11:15 - 11:30 **MA01.08 - Discussant - MA 01.05, MA 01.06, MA 01.07**
Biniam Kidane, MB/Canada



- 11:30 - 11:35 **MA01.09 - Risk Factors of Radiation-Induced Lymphopenia (RIL) and Its Prognostic Significance in Small Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy**
Jian He, China
- 11:35 - 11:40 **MA01.10 - Toxicity and Local Control in “Ultra-Central” Lung Tumors Treated With SBRT or High-Dose Hypofractionated RT**
Chunyu Wang, USA
- 11:40 - 11:45 **MA01.11 - Salvage SBRT for Local Recurrence After Primary Surgical Resection of Early Stage Non-Small Cell Lung Cancer**
Sarah Sittenfeld, USA
- 11:45 - 12:00 **MA01.12 - Discussant - MA 01.09, MA 01.10, MA 01.11**
Drew Moghanaki, USA

MA02

- | | | |
|----------------------|--|--------------------|
| 10:30 - 12:00 | Improving Outcomes for Patients with Lung Cancer
Topics: Advanced NSCLC, Screening and Early Detection
Moderation: L. Corrales, Costa Rica; R. Burkes, Canada | Room 201 BD |
|----------------------|--|--------------------|
- 10:30 - 10:35 **MA02.01 - ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events**
Terry Ng, USA
- 10:35 - 10:40 **MA02.02 - Multistate Healthcare Network Underutilizes Valuable End-of-Life Resources in Stage IV Non-Small Cell Lung Cancer**
Candice Wilshire, WA/USA
- 10:40 - 10:45 **MA02.03 - ASTRIS: A Real-World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC**
Yi-Long Wu, China
- 10:45 - 11:00 **MA02.04 - Discussant - MA 02.01, MA 02.02, MA 02.03**
Alona Zer, Israel
- 11:00 - 11:05 **MA02.05 - A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC**
Rajnish Nagarkar, India



- 11:05 - 11:10 **MA02.06 - A Randomized, Double-Blind, Placebo-Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC**
Ligang Xing, China
- 11:10 - 11:15 **MA02.07 - Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial**
Kumar Prabhaskar, India
- 11:15 - 11:20 **MA02.08 - The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial**
Jenny Turcott, Mexico
- 11:20 - 11:35 **MA02.09 - Discussant - MA 02.05, MA 02.06, MA 02.07, MA 02.08**
Paul Wheatley-Price, Canada
- 11:35 - 11:40 **MA02.10 - The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System**
Heidi Hamann, USA
- 11:40 - 11:45 **MA02.11 - Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)**
Doreen Ezeife, Canada
- 11:45 - 12:00 **MA02.12 - Discussant - MA 02.10, MA 02.11**
William Evans, ON/Canada

MA03

- 10:30 - 12:00 Lung Cancer Screening - Next Step** Room 206 AC
Topics: Screening and Early Detection
Moderation: A. Tremblay, Canada; S. Janes, UK
- 10:30 - 10:35 **MA03.01 - Manchester Lung Cancer Screening: Results of the First Incidence Screening Round**
Haval Balata, UK
- 10:35 - 10:40 **MA03.02 - Prospective Evaluation of the Clinical Utility of the International Lung Screen Trial Lung Nodule Management Protocol**
Stephen Lam, Canada
- 10:40 - 10:45 **MA03.03 - Prolonged Low-Dose Computed Tomography (LDCT) Screening Beyond 5 Years Reduces Overall and Lung Cancer Specific Mortality**
Ugo Pastorino, Italy



- 10:45 - 11:00 **MA03.04 - Discussant - MA 03.01, MA 03.02, MA 03.03**
Denise Aberle, USA
- 11:00 - 11:05 **MA03.05 - New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial**
Marjolein Heuvelmans, Netherlands
- 11:05 - 11:10 **MA03.06 - Descriptive Epidemiology of Significant Incidental Findings in a Large Clinical Lung Cancer Screening Program**
Shawn Regis, MA/USA
- 11:10 - 11:15 **MA03.07 - Development and Validation of Deep Learning Model for Recognition of Histologic Subtype of Lung Adenocarcinoma from CT Images**
Yunlang She, China
- 11:15 - 11:30 **MA03.08 - Discussant - MA 03.05, MA 03.06, MA 03.07**
Richard Booton, UK
- 11:30 - 11:35 **MA03.09 - Transcriptome-Wide Association Study Reveals Candidate Causal Genes for Lung Cancer**
Alisson Clemenceau, QC/Canada
- 11:35 - 11:40 **MA03.10 - Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer**
Shamus Carr, MD/USA
- 11:40 - 11:45 **MA03.11 - Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas**
Angela Guirao, Spain
- 11:45 - 12:00 **MA03.12 - Discussant - MA 03.09, MA 03.10, MA 03.11**
Luis Montuenga, Spain

MS01

- 10:30 - 12:00** **Cancer Pathways, Targeted Therapy and Resistance** **Room 206 F**
Topics: Biology
Moderation: G. Riely, USA; W. Lam, Canada
- 10:30 - 10:50 **MS01.01 - Defects of the SWI/SNF OR MYC/MAX Pathways: Effects in Cell Differentiation and Therapeutic Opportunities**
Montse Sanchez-Cespedes, Spain



- 10:50 - 11:10 **MS01.02 - Targeting Negative Feedback Regulators to Hyperactivate Oncogenic Signaling**
William Lockwood, BC/Canada
- 11:10 - 11:30 **MS01.03 - Stimulating Anti-Tumor Immunity Through Enhancing T-Cell Activation**
Kwok-Kin Wong, USA
- 11:30 - 11:50 **MS01.04 - Addressing Drug Resistance Beyond Kinase Domain Mutations**
Robert Doebele, CO/USA
- 11:50 - 12:00 **MS01.05 - Q&A**

MS02

- | | | |
|---------------|---|----------|
| 10:30 - 12:00 | The Future of IO
Topics: Immunooncology
Moderation: Y. Ohe, Japan; R. Hui, Australia | Room 106 |
|---------------|---|----------|
- 10:30 - 10:45 **MS02.01 - What Is/Will Be the Optimal Duration of Therapy with IO?**
David Spigel, TN/USA
- 10:45 - 11:00 **MS02.02 - Combination Therapies: Where Are We in 2018?**
Martin Reck, Germany
- 11:00 - 11:15 **MS02.03 - Next Generation IO in Lung Cancer**
Solange Peters, Switzerland
- 11:15 - 11:30 **MS02.04 - Optimizing Clinical Trial Designs in Immunotherapy**
Vassiliki Papadimitrakopoulou, TX/USA
- 11:30 - 11:45 **MS02.05 - Convincing Policy Makers to Afford Immunotherapy**
Carlos Gil Ferreira, Brazil
- 11:45 - 12:00 **MS02.06 - Q&A**



MS03

10:30 - 12:00 **New Frontiers in Oligometastases** **Room 203 BD**
 Topics: Oligometastatic NSCLC
 Moderation: J. Patel, USA; E. Lim, UK

10:30 - 10:45 **MS03.01 - The Biology of Oligometastases: What Have We learned?**
 David Palma, Canada

10:45 - 11:00 **MS03.02 - Biomarkers in Oligometastatic Patients i. Monitoring Diseases Response - Imaging vs Serum**
 Max Diehn, CA/USA

11:00 - 11:15 **MS03.03 - Investigations into Alternative Clinical Endpoints for OM Beyond Survival**
 Alexander Louie, Canada

11:15 - 11:30 **MS03.04 - Treatment of Oligoprogression: Real Progress or False Hope?**
 Fiona Mcdonald, UK

11:30 - 11:45 **MS03.05 - Integration of Immunotherapy in the Oligometastatic Paradigm**
 Shankar Siva, VIC/Australia

11:45 - 12:00 **MS03.06 - Q&A**

MS04

10:30 - 12:00 **Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates** **Room 206 BD**
 Topics: Advocacy
 Moderation: C. Aldige, USA; C. Sit, Canada

10:30 - 10:45 **MS04.01 - Collecting Data in the Real World - How Can Patient Groups Work with Researchers in Defining and Collecting Real-World Evidence?**
 Taofeek Owonikoko, GA/USA

10:45 - 11:00 **MS04.02 - How Is Lung Cancer Screening Evolving to Be More Efficient and Effective?**
 David Baldwin, UK

11:00 - 11:15 **MS04.03 - Exploring Smoking Stigma, Negativity and Lung Cancer - What Can Be Done?**
 Stefania Vallone, Italy



11:15 - 11:30 **MS04.04 - E-Cigarettes - What Do Lung Cancer Advocates Need to Know?**

Matthew Peters, NSW/Australia

11:30 - 12:00 **MS04.05 - Panel Discussion**

OA01

10:30 - 12:00 Improving Outcomes in Locoregional NSCLC I Room 107

Topics: Treatment of Locoregional Disease - NSCLC
Moderation: G. Rocco, Italy; R. Carlson, Canada

10:30 - 10:40 **OA01.01 - 10-Year Updated Analysis of NRG Oncology/RTOG 0214: A Phase III Comparison of PCI vs. Observation in Patients with LA-NSCLC.**

Alexander Sun, Canada

10:40 - 10:50 **OA01.02 - The Estimate of Shrinking Field and SIB Radiotherapy Guided by 18F-FDG PET/CT in Locally Advanced NSCLC Patients: A Phase 2 Randomized Clinical**

Yaping Xu, China

10:50 - 11:00 **OA01.03 - Interaction Between Dose and Calcifications Is a Predictor for Overall Survival in Lung Cancer Patients Receiving Radiotherapy**

Alan McWilliam, UK

11:00 - 11:15 **OA01.04 - Discussant - OA 01.01, OA 01.02, OA 01.03**

John Armstrong, Ireland

11:15 - 11:25 **OA01.05 - Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG**

Mariano Provencio, Spain

11:25 - 11:35 **OA01.06 - DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer**

Steven Lin, TX/USA

11:35 - 11:45 **OA01.07 - Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC**

Greg Durm, IN/USA

11:45 - 12:00 **OA01.08 - Discussant - OA 01.05, OA 01.06, OA 01.07**

Corey Langer, PA/USA



OA02

10:30 - 12:00	Novel Therapies in ROS1, HER2 and EGFR	Room 105
	Topics: Targeted Therapy Moderation: R. Heist, USA; B. Xia, China	
10:30 - 10:40	OA02.01 - Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) Robert Doebele, CO/USA	
10:40 - 10:50	OA02.02 - Safety and Preliminary Clinical Activity of Roprectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC Jessica Lin, MA/USA	
10:50 - 11:00	OA02.03 - Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 Sai-Hong Ou, CA/USA	
11:00 - 11:15	OA02.04 - Discussant - OA 02.01, OA 02.02, OA 02.03 Shengxiang Ren, China	
11:15 - 11:25	OA02.05 - CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial Melissa Johnson, TN/USA	
11:25 - 11:35	OA02.06 - A Phase II Trial of Pozotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) John Heymach, TX/USA	
11:35 - 11:45	OA02.07 - Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or -Mutated Advanced Non-Small-Cell Lung Cancer Junji Tsurutani, Japan	
11:45 - 12:00	OA02.08 - Discussant - OA 02.05, OA 02.06, OA 02.07 Daniel Costa, MA/USA	



OA03

10:30 - 12:00	Advances in Lung Cancer Pathology Topics: Pathology Moderation: G. Chen, China; G. Pelosi, Italy	Room 205 B
10:30 - 10:40	OA03.01 - The Immunophenotyping and Genomic Characteristics of Pulmonary Sarcomatoid Carcinoma: Pleomorphic, Spindle Cell and Giant Cell Carcinoma Chunyan Wu, China	
10:40 - 10:50	OA03.02 - Nationwide Comparative Study Of PD-L1 IHC Assays on Lung Cancer: Initial Report Of LC-SCRUM-IBIS Project Noriko Motoi, Japan	
10:50 - 11:00	OA03.03 - Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study Keith Kerr, UK	
11:00 - 11:15	OA03.04 - Discussant - OA 03.01, OA 03.02, OA 03.03 Julien Adam, France	
11:15 - 11:25	OA03.05 - Characterization of the Immunologic Intra-Tumor Heterogeneity in Early Stages of Non-Small Cell Lung Cancer by Multiplex Immunofluorescence Alejandro Francisco Cruz, USA	
11:25 - 11:35	OA03.06 - Extraction of Radiomic Values from Lung Adenocarcinoma with Near-Pure Histological Subtypes Mong-Wei Lin, Taiwan	
11:35 - 11:45	OA03.07 - Three-Dimensional Immunofluorescence Analysis of Dynamic Vessel Co-Option of Spread Through Air Spaces (STAS) in Lung Cancer Yukako Yagi, NY/USA	
11:45 - 12:00	OA03.08 - Discussant - OA 03.05, OA 03.06, OA 03.07 David Rimm, CT/USA	

OA04

10:30 - 12:00	Improving Access and Outcomes in Lung Cancer Management Topics: Nursing and Allied Professionals Moderation: M. Culligan, USA; P. Garrido, Spain	Room 201 F
----------------------	---	-------------------



- 10:30 - 10:40 **OA04.01 - What is the Cost of a Strong Evidence for the Treatment of Advanced Non-Small Cell Lung Cancer?**
Pedro Aguiar Jr, Brazil
- 10:40 - 10:50 **OA04.02 - Demographic, Psychosocial, and Behavioral Associations with Cancer Screening Among a Homeless Population**
Lovoria Williams, USA
- 10:50 - 11:00 **OA04.03 - The Role of Comprehensive Genomic Profiling in the Community Setting**
Kimberly Rohan, IL/USA
- 11:00 - 11:15 **OA04.04 - Discussant - OA 04.01, OA 04.02, OA 04.03**
Jhanelle Gray, FL/USA
- 11:15 - 11:25 **OA04.05 - An Early Rehabilitation Intervention for Enhancing Oxygenation from Lung Cancer Surgery**
Wei Ling Hsiao, Taiwan
- 11:25 - 11:35 **OA04.06 - Perceptions of Non-Participation in a Rehabilitation Intervention After Surgery for Non-Small Cell Lung Cancer**
Mai Schoenau, Denmark
- 11:35 - 11:45 **OA04.07 - Early Initiated Postoperative Rehabilitation Reduces Fatigue in Patients with Operable Lung Cancer: A Randomized Trial**
Morten Quist, Denmark
- 11:45 - 12:00 **OA04.08 - Discussant - OA 04.05, OA 04.06, OA 04.07**
Pippa Labuc, UK

PC01

- | | | |
|----------------------|---|--------------------|
| 10:30 - 12:00 | Controversies in Mesothelioma
Topics: Mesothelioma
Moderation: N. Bouchard, Canada; N. Van Zandwijk, Australia | Room 205 AC |
|----------------------|---|--------------------|
- 10:30 - 10:45 **PC01.01 - PRO Intrapleural Chemotherapy Is It the Future?**
Isabelle Opitz, Switzerland
- 10:45 - 11:00 **PC01.02 - CON Intrapleural Chemotherapy Is It the Future?**
David Rice, TX/USA

- 11:00 - 11:15 **PC01.03 - PRO IO in Mesothelioma Should Only Be Given on Clinical Trials**
Penelope Bradbury, ON/Canada
- 11:15 - 11:30 **PC01.04 - CON in Mesothelioma Should Only Be Given on Clinical Trials**
Evan Alley, USA
- 11:30 - 11:45 **PC01.05 - PRO Radiation Options: Are We SMART Enough?**
John Cho, Canada
- 11:45 - 12:00 **PC01.06 - CON Radiation Options: Are We SMART Enough?**
Charles Simone, USA

ISS09

12:00 - 13:30 Symposium Supported by Merck: Pembrolizumab: The Evolving Standard of Care Plenary Hall
in Advanced and Early-Stage Lung Cancer

12:00 - 13:30 **Pembrolizumab: The Evolving Standard of Care in Advanced and Early-Stage Lung Cancer**

JTO

12:00 - 13:30 Meet the JTO Editor Room 206 BD

12:00 - 13:30 **JTO.01 - Meet the JTO Editor**
Alex Adjei, NY/USA

ES01

13:30 - 15:00 Advances in Lung Cancer Screening Through Imaging Room 206 F
Topics: Screening and Early Detection
Moderation: H. Schmidt, Canada; D. Aberle, USA

13:30 - 13:50 **ES01.01 - Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and
Machine Parameters**
Ricardo Avila, USA



- 13:50 - 14:10 **ES01.02 - Image Interpretation and Advances from the Perspective of the Radiologist**
David Yankelevitz, NY/USA
- 14:10 - 14:30 **ES01.03 - Deep Machine Learning for Screening LDCT**
Bram Van Ginneken, Netherlands
- 14:30 - 14:50 **ES01.04 - Multi-Phasic Screening - Can We Address Competing Causes of Morbidity * Mortality Such as Coronary Artery Disease and COPD**
Rozemarijn Vliegenthart, Netherlands
- 14:50 - 15:00 **ES01.05 - Q&A**

MA04

13:30 - 15:00 **Novel Approaches with IO** **Room 107**
Topics: Immunooncology
Moderation: T. Montella, Brazil; R. Sangha, Canada

- 13:30 - 13:35 **MA04.01 - Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts**
Victor Moreno, Spain
- 13:35 - 13:40 **MA04.02 - Responses and Durability in NSCLC Treated with Pegilodecakin and Anti-PD-1**
Edward Garon, USA
- 13:40 - 13:45 **MA04.03 - Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry**
Oliver Gautschi, Switzerland
- 13:45 - 14:00 **MA04.04 - Discussant - MA 04.01, MA 04.02, MA 04.03**
Jose Pacheco, USA
- 14:00 - 14:05 **MA04.05 - Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%**
Mark Awad, MA/USA
- 14:05 - 14:10 **MA04.06 - PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction**
Gabiella Sozzi, Italy



- 14:10 - 14:15 **MA04.07 - MicroRNA-Based Liquid Biopsy Combines with PD-L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients**
Mattia Boeri, Italy
- 14:15 - 14:30 **MA04.08 - Discussant - MA 04.05, MA 04.06, MA 04.07**
Patrick Forde, MD/USA
- 14:30 - 14:35 **MA04.09 - Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)**
Valerie Rusch, NY/USA
- 14:35 - 14:40 **MA04.10 - Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC**
Filiz Oezkan, USA
- 14:40 - 14:45 **MA04.11 - Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade**
Kellie Smith, MD/USA
- 14:45 - 15:00 **MA04.12 - Discussant - MA 04.09, MA 04.10, MA 04.11**
Alex Adjei, NY/USA

MA05

- 13:30 - 15:00 Improving Outcomes in Locoregional NSCLC II** **Room 105**
Topics: Treatment of Locoregional Disease - NSCLC
Moderation: J. Martin, Canada; D. Schellenberg, Canada
- 13:30 - 13:35 **MA05.01 - E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC**
Jyoti Patel, IL/USA
- 13:35 - 13:40 **MA05.02 - PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT**
Johan Vansteenkiste, Belgium
- 13:40 - 13:45 **MA05.03 - Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma**
Raj Vaghjiani, USA
- 13:45 - 14:00 **MA05.04 - Discussant - MA 05.01, MA 05.02, MA 05.03**
Scott Gettinger, CT/USA



- 14:00 - 14:05 **MA05.05 - Photon-Based Cardiac Sparing Via Volumetric Modulated Arc Therapy in Thoracic Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer**
Matthew Ferris, USA
- 14:05 - 14:10 **MA05.06 - Locally Advanced Lung Cancer Radiotherapy in Deep Inspiration Breath Hold: Dosimetric Benefits from a Prospective Trial**
Mirjana Josipovic, Denmark
- 14:10 - 14:15 **MA05.07 - Dose Escalated Chemo-RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial**
Jan Nyman, Sweden
- 14:15 - 14:30 **MA05.08 - Discussant - MA 05.05, MA 05.06, MA 05.07**
Benjamin Lok, Canada
- 14:30 - 14:35 **MA05.09 - PFS and Cardiac-Toxicity-Adjusted-PFS As Predictors of OS in Locally Advanced NSCLC Treated with Concurrent Chemoradiation**
Chen Hu, MD/USA
- 14:35 - 14:40 **MA05.10 - The Pathologic Response of Locally Advanced NSCLC Treated with Concomitant Chemoradiation to 60 Gy in Image Guided Radiation Therapy (IGRT)**
Sarit Appel, Israel
- 14:40 - 14:45 **MA05.11 - Radiomics Analysis Using SVM Predicts Mediastinal Lymph Nodes Status of Squamous Cell Lung Cancer by Pre-Treatment Chest CT Scan**
Wu Nan, China
- 14:45 - 15:00 **MA05.12 - Discussant - MA 05.09, MA 05.10, MA 05.11**
Matthew Hatton, UK

MA06

- 13:30 - 15:00 PDL1, TMB and DNA Repair** Room 206 AC
Topics: Biology
Moderation: N. Motoi, Japan; J. Adam, France
- 13:30 - 13:35 **MA06.01 - The Intrinsic PD-L1 Promotes Cellular Invasiveness Via their PD-1 Receptor in Lung Adenocarcinoma Cells**
Wen-Pin Su, Taiwan



- 13:35 - 13:40 **MA06.02 - Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON**
Marcelo Negrao, USA
- 13:40 - 13:45 **MA06.03 - PD-1 and Id-1 Combined Blockade Impacts Tumor Growth and Survival Through PD-L1 Expression and Tumor Infiltration by Immune-Related Cells**
Ignacio Gil-Bazo, Spain
- 13:45 - 14:00 **MA06.04 - Discussant - MA 06.01, MA 06.02, MA 06.03**
Akihiko Yoshida, Japan
- 14:00 - 14:05 **MA06.05 - The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact**
Rachel Shemesh, Israel
- 14:05 - 14:10 **MA06.06 - An Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents' Anti-Tumor Efficacy**
Zachary Tano, NY/USA
- 14:10 - 14:15 **MA06.07 - Genetic and Epigenetic Alterations are Associated with Tumor Mutation Burden in Non-Small Cell Lung Cancer**
Liang-Liang Cai, China
- 14:15 - 14:30 **MA06.08 - Discussant - MA 06.05, MA 06.06, MA 06.07**
Jyoti Patel, IL/USA
- 14:30 - 14:35 **MA06.09 - XRCC6BP1: A DNA Repair Gene in Cisplatin Resistant Lung Cancer Stem Cells That May Predict Survival Outcomes in Patients**
Martin Barr, Ireland
- 14:35 - 14:40 **MA06.10 - Germline Mutation in ATM Affect Lung Cancer Risk with High Effect**
Xuemei Ji, NH/USA
- 14:40 - 14:45 **MA06.11 - Distinct Origins of Lymphatic and Brain Metastasis in Lung Cancer**
Tao Jiang, China
- 14:45 - 15:00 **MA06.12 - Discussant - MA 06.09, MA 06.10, MA 06.11**
Rebecca Heist, USA



MA07

Time	Topic	Room
13:30 - 15:00	Towards Survivorship: The Landscape, Supports and Barriers Topics: Advocacy Moderation: K. Hasegawa, Japan; P. Wheatley-Price, Canada	Room 205 AC
13:30 - 13:35	MA07.01 - No Longer Outliers: Understanding the Needs of Long-Term Lung Cancer Survivors Maureen Rigney, DC/USA	
13:35 - 13:40	MA07.02 - Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete-Choice Experiment Andrea Ferris, USA	
13:40 - 13:45	MA07.03 - Attitudes to Lung Cancer in Europe: Findings from a Global Consumer Survey Jesme Fox, UK	
13:45 - 14:00	MA07.04 - Discussant - MA 07.01, MA 07.02, MA 07.03 Govind Babu Kanakasetty, India	
14:00 - 14:05	MA07.05 - Psychosocial Needs and Programs of Cancer Patients/Survivors and Their Relatives: Unmet Needs from an International Study Csaba Dégi, Romania	
14:05 - 14:10	MA07.06 - Telephonic Communication In Palliative Care For Better Management Of Terminal Cancer Patients In Rural India - An NGO Based Approach. Nabanita Mandal, India	
14:10 - 14:15	MA07.07 - Identifying the Severity of Psychosocial Symptoms Among Patients Diagnosed with Lung Cancer. Do We Really Need Emotional Support Groups? Arooj Fatima, Pakistan	
14:15 - 14:30	MA07.08 - Discussant - MA 07.05, MA 07.06, MA 07.07 Kim Norris, USA	
14:30 - 14:35	MA07.09 - Willingness to Perform Multiple Biopsies to Improve Quality of Lung Cancer Care: Understanding the Oncologists' Perspective Upal Basu Roy, MD/USA	
14:35 - 14:40	MA07.10 - Utilizing a Personalized Navigation Program to Identify Barriers and Increase Clinical Trial Participation Among Lung Cancer Patients Andrew Ciupek, USA	



- 14:40 - 14:45 **MA07.11 - Drug Price Comparison in Advanced Lung Cancer - High Cost Prices is Accompanied by Patient Benefits?**
Luciene Bonan, Brazil
- 14:45 - 15:00 **MA07.12 - Discussant - MA 07.09, MA 07.10, MA 07.11**
Jennifer King, DC/USA

MS05

- 13:30 - 15:00 Diagnostic Dilemma in Lung Cancer** **Room 201 BD**
Topics: Pathology
Moderation: D. Hwang, Canada; J. Botling, Sweden

- 13:30 - 13:50 **MS05.01 - Staging and Pathology of Multiple Lung Nodules**
Alain Borczuk, NY/USA
- 13:50 - 14:10 **MS05.02 - Defining Invasion in Minimally Invasive Adenocarcinoma**
Masayuki Noguchi, Japan
- 14:10 - 14:30 **MS05.03 - Tumor Heterogeneity in Lung Cancer**
Elisabeth Brambilla, France
- 14:30 - 14:50 **MS05.04 - Diagnosis and Classification in Biopsies**
Andre Moreira, NY/USA
- 14:50 - 15:00 **MS05.05 - Q&A**

MS06

- 13:30 - 15:00 Practical Issues in the Management of Oligometastatic NSCLC** **Room 206 BD**
Topics: Oligometastatic NSCLC
Moderation: M. Macneil, Canada; U. Pastorino, Italy

- 13:30 - 13:45 **MS06.01 - The Role of Radiation in Treating the Mets**
Hak Choy, TX/USA
- 13:45 - 14:00 **MS06.02 - The Role of Interventional Pulmonology and Radiology**
Kwun Fong, Australia



- 14:00 - 14:15 **MS06.03 - The Role of Surgical Resection**
Boris Sepesi, TX/USA
- 14:15 - 14:30 **MS06.04 - Systemic Therapy for Oligometts: Before, During, or After Local Therapies?**
Ross Camidge, USA
- 14:30 - 14:45 **MS06.05 - The Special Case of Brain Metastases: Systemic Therapy, Radiation or Both?**
Laurie Gaspar, CO/USA
- 14:45 - 15:00 **MS06.06 - Q&A**

MS07

- 13:30 - 15:00 Antibody-Drug Conjugates in Advanced NSCLC Room 205 B**
Topics: Advanced NSCLC
Moderation: N. Blais, Canada; E. Santos, USA

- 13:30 - 13:50 **MS07.01 - Basic Science**
David Gerber, TX/USA
- 13:50 - 14:10 **MS07.02 - Pharmacology**
Christian Rolfo, Belgium
- 14:10 - 14:30 **MS07.03 - Clinical Data**
Thomas Stinchcombe, NC/USA
- 14:30 - 14:50 **MS07.04 - Future Directions**
Silvia Novello, Italy
- 14:50 - 15:00 **MS07.05 - Q&A**

MS08

- 13:30 - 15:00 Lung Cancer in the Real World Room 201 F**
Topics: Treatment in the Real World - Support, Survivorship, Systems Research
Moderation: A. Wozniak, USA; R. Kelly, USA
- 13:30 - 13:45 **MS08.01 - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies - European Perspective**
Yolande Lievens, Belgium



- 13:45 - 14:00 **MS08.02 - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies - US Perspective**
Gideon Blumenthal, USA
- 14:00 - 14:15 **MS08.03 - Sources of Real World Data: Research Designs, Statistical Modelling and Quality Assurance Requirements**
Mary Redman, WA/USA
- 14:15 - 14:30 **MS08.04 - The ASCO Perspective**
Bruce Johnson, MA/USA
- 14:30 - 14:45 **MS08.05 - The ESTRO Perspective**
Umberto Ricardi, Italy
- 14:45 - 15:00 **MS08.06 - Discussion**

OA05

- | | | |
|----------------------|--|-----------------|
| 13:30 - 15:00 | Clinical Trials in IO
Topics: Advanced NSCLC
Moderation: S. Owen, Canada; D. Moro-Sibilot, France | Room 106 |
|----------------------|--|-----------------|
- 13:30 - 13:40 **OA05.01 - Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy**
Matthew Hellmann, USA
- 13:40 - 13:50 **OA05.02 - Epcadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037**
Liza Villaruz, PA/USA
- 13:50 - 14:00 **OA05.03 - Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC**
Ben Creelan, FL/USA
- 14:00 - 14:15 **OA05.04 - Discussant - OA 05.01, OA 05.02, OA 05.03**
Martin Edelman, MD/USA
- 14:15 - 14:25 **OA05.05 - Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial**
Fabrice Barlesi, France



- 14:25 - 14:35 **OA05.06 - CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC**
Julie Brahmer, MD/USA
- 14:35 - 14:45 **OA05.07 - IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC**
Vassiliki Papadimitrakopoulou, TX/USA
- 14:45 - 15:00 **OA05.08 - Discussant - OA 05.05, OA 05.06, OA 05.07**
Hossein Borghaei, USA

OA06

- | | | |
|---------------|---|-------------|
| 13:30 - 15:00 | Early Stage Lung Cancer: Outcomes and Interventions
Topics: Treatment of Early Stage/Localized Disease
Moderation: P. Van Schil, Belgium; H. Kato, Japan | Room 202 BD |
|---------------|---|-------------|
- 13:30 - 13:40 **OA06.01 - Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)**
Kathy Albain, USA
- 13:40 - 13:50 **OA06.02 - Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Non-Small Cell Lung Cancer: Oncologic Outcome of a Randomized Trial**
Dongrong Situ, China
- 13:50 - 14:00 **OA06.03 - Sublobar Resection is Equivalent to Lobectomy for Screen Detected Lung Cancer**
Brendon Stiles, NY/USA
- 14:00 - 14:15 **OA06.04 - Discussant - OA 06.01, OA 06.02, OA 06.03**
Valerie Rusch, NY/USA
- 14:15 - 14:25 **OA06.05 - Do SBRT Planning and Delivery Factors Influence Local Control for Early Stage Non-Small Cell Lung Cancer (e-NSCLC)?**
Gregory Videtic, OH/USA
- 14:25 - 14:35 **OA06.06 - MISSILE-NSCLC: A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early-Stage Non-Small Cell Lung Cancer**
David Palma, Canada



- 14:35 - 14:45 **OA06.07 - Predictors and Consequences of Refusing Surgery for Clinical Stage I NSCLC: A National Cancer Database Analysis**
Brendon Stiles, NY/USA
- 14:45 - 15:00 **OA06.08 - Discussant - OA 06.05, OA 06.06, OA 06.07**
Steven Lin, TX/USA

PC02

13:30 - 15:00 **Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON** **Room 203 BD**
Topics: Small Cell Lung Cancer/NET
Moderation: Q. Chu, Canada; W. Eberhardt, Germany

- 13:30 - 13:50 **PC02.01 - Surgery - PRO**
Elliot Wakeam, Canada
- 13:50 - 14:10 **PC02.02 - Surgery - CON**
Cecile Le Pechoux, France
- 14:10 - 14:30 **PC02.03 - BID Radiation - CON**
Ben Slotman, Netherlands
- 14:30 - 14:50 **PC02.04 - BID Radiation - PRO**
Jeffrey Bogart, USA
- 14:50 - 15:00 **PC02.05 - Q&A**

MA08

15:15 - 16:45 **Clinical Trials in Brain Metastases** **Room 203 BD**
Topics: Advanced NSCLC
Moderation: E. Fillion, Canada; B. Melosky, Canada

- 15:15 - 15:20 **MA08.01 - Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)**
ZhenZhou Yang, China
- 15:20 - 15:25 **MA08.02 - Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High-Risk Lung Cancer Patients: EGFR and ALK Mutations**
Oscar Arrieta, Mexico



- 15:25 - 15:30 **MA08.03 - EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis**
Wenhua Liang, China
- 15:30 - 15:45 **MA08.04 - Discussant - MA 08.01, MA 08.02, MA 08.03**
Nasser Hanna, IN/USA
- 15:45 - 15:50 **MA08.05 - Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study**
Todd Bauer, TN/USA
- 15:50 - 15:55 **MA08.06 - Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases**
Janet Espirito, TX/USA
- 15:55 - 16:00 **MA08.07 - Real World Data of Osimertinib in Patients with Central Nervous System (CNS) Metastasis in ASTRIS Korean Subset.**
Jin-Hyoung Kang, Republic of Korea
- 16:00 - 16:15 **MA08.08 - Discussant - MA 08.05, MA 08.06, MA 08.07**
Myung-Ju Ahn, Republic of Korea
- 16:15 - 16:20 **MA08.09 - Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients**
Lizza Hendriks, Netherlands
- 16:20 - 16:25 **MA08.10 - Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases**
Margaux Geier, France
- 16:25 - 16:30 **MA08.11 - Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC**
Raafat Alameddine, Canada
- 16:30 - 16:45 **MA08.12 - Discussant - MA 08.09, MA 08.10, MA 08.11**
Arjun Sahgal, Canada



MA09

15:15 - 16:45	Lung Cancer Surgical and Molecular Pathology	Room 202 BD
	Topics: Pathology Moderation: D. Jain, India; D. Lin, China	
15:15 - 15:20	MA09.01 - Correlation of Pre-Operative Cancer Imaging Techniques with Post-Operative Macro and Microscopic Lung Pathology Images Stephen Harrow, UK	
15:20 - 15:25	MA09.02 - Tumor Size and Frozen Section Should Be Considered Jointly to Predict the Final Pathology for Lung Adenocarcinoma Erjia Zhu, China	
15:25 - 15:30	MA09.03 - Multiple Pathological Variables Predict Efficacy of Adjuvant Chemotherapy in Primary Lung Adenocarcinoma John Le Quesne, UK	
15:30 - 15:45	MA09.04 - Discussant - MA 09.01, MA 09.02, MA 09.03 Natasha Rekhtman, NY/USA	
15:45 - 15:50	MA09.05 - Can We Predict Radiosensitivity in Non-Small Cell Lung Cancer? Juvenal Baena, UK	
15:50 - 15:55	MA09.06 - The Newly Recognized Filigree Pattern of Micropapillary (MIP) Lung Adenocarcinoma (LADC) is as Clinically Important as the Classical Pattern Katsura Emoto, USA	
15:55 - 16:00	MA09.07 - Developing a Pathological Grading System in Predicting Prognosis for Invasive Mucinous Adenocarcinomas Wei-Chin Chang, Taiwan	
16:00 - 16:15	MA09.08 - Discussant - MA 09.05, MA 09.06, MA 09.07 Lucian Chirieac, MA/USA	
16:15 - 16:20	MA09.09 - EBUS-TBNA in Assessing PD-L1 Expression in NSCLC Jason Agulnik, Canada	
16:20 - 16:25	MA09.10 - Molecular Profiling and PD-L1 Status in 900 Cases of Surgically Resected Non-Small Cell Lung Cancer with Clinical and Pathological Correlation Zhaolin Xu, Canada	



16:25 - 16:30 **MA09.11 - Genomic Landscape and its Correlation with TMB, CD8 TILs and PD-L1 Expression in Chinese Lung Squamous Cell Carcinoma**
Tao Jiang, China

16:30 - 16:45 **MA09.12 - Discussant - MA 09.09, MA 09.10, MA 09.11**
Philippe Joubert, Canada

MS09

15:15 - 16:45 Tumour Board - Tissue Acquisition and Staging Room 206 BD
Topics: Interventional Diagnostics/Pulmonology
Moderation: S. Murgu, USA; E. Edell, USA

15:15 - 15:35 **MS09.01 - Cases Prepared by Drs. Edell/Murgu**
Neal Navani, UK

15:35 - 15:55 **MS09.02 - Cases Prepared by Drs. Edell/Murgu**
Karin Steinke, Australia

15:55 - 16:15 **MS09.03 - Cases Prepared by Drs. Edell/Murgu**
Kazuhiro Yasufuku, ON/Canada

16:15 - 16:35 **MS09.04 - Cases Prepared by Drs. Edell/Murgu**
David Hwang, Canada

16:35 - 16:45 **MS09.05 - Q&A**

MS10

15:15 - 16:45 Part Solid Nodules, GGN and STAS Room 206 F
Topics: Treatment of Early Stage/Localized Disease
Moderation: P. Van Schil, Belgium; N. Peled, Israel

15:15 - 15:30 **MS10.01 - Radiographic Differences Between Presumed AIS and MIA**
Mini Pakkal, Canada

15:30 - 15:45 **MS10.02 - Importance of CT in the Pathologic Assessment of Tumor Sized in Subsolid and Part-Solid Adenocarcinoma**
Erik Thunnissen, Netherlands



- 15:45 - 16:00 **MS10.03 - CT Versus Needle Biopsy Assessment Before Resection of Part Solid Nodules**
Young Tae Kim, Republic of Korea
- 16:00 - 16:15 **MS10.04 - Therapeutic Implications of Spread Through Air Spaces (STAS)**
William Travis, USA
- 16:15 - 16:30 **MS10.05 - Should We Resect GGNs**
Kenji Suzuki, Japan
- 16:30 - 16:45 **MS10.06 - Q&A**

MS11

- 15:15 - 16:45 Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control** Room 206 AC
Topics: Prevention and Tobacco Control
Moderation: A. Rosell, Spain; L. Zhang, China
- 15:15 - 15:35 **MS11.01 - Identifying Consequences of Stigma on Lung Cancer Care Delivery and Patient Outcomes**
Heidi Hamann, USA
- 15:35 - 15:55 **MS11.02 - Stigma of Tobacco and Lung Cancer: A South American Perspective**
- 15:55 - 16:15 **MS11.03 - Prevalence of Perceived Lung Cancer Stigma Among Medical and Nursing Students**
Jamie Studts, KY/USA
- 16:15 - 16:35 **MS11.04 - Taking a Smoking History in the Context of Lung Cancer Treatment: Missed Opportunities for Stigma-Reducing Empathic Encounters with Throacic Oncologists**
Peter Harper, USA
- 16:35 - 16:45 **MS11.05 - Q&A**



MS12

15:15 - 16:45	Immunotherapy and RT Topics: Treatment of Locoregional Disease - NSCLC Moderation: Y.-L. Wu, China; J. Salama, USA	Room 105
15:15 - 15:35	MS12.01 - Biology IO+RT Dirk De Ruyscher, Belgium	
15:35 - 15:55	MS12.02 - Clinical Data Available Feng-Ming (Spring) Kong, AL/USA	
15:55 - 16:15	MS12.03 - Ongoing Studies Francoise Mornex, France	
16:15 - 16:35	MS12.04 - Implications for Routine Practice Paul Mitchell, Australia	
16:35 - 16:45	MS12.05 - Q&A	

OA07

15:15 - 16:45	Oligometastasis: What Should Be the State-Of-The-Art? Topics: Oligometastatic NSCLC Moderation: Y. Ung, Canada; P. Mulvenna, UK	Room 107
15:15 - 15:25	OA07.01 - Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT) Joshua Bauml, PA/USA	
15:25 - 15:35	OA07.02 - ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI Oscar S H Chan, China	
15:35 - 15:45	OA07.03 - Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases Tao Jiang, China	
15:45 - 16:00	OA07.04 - Discussant - OA 07.01, OA 07.02, OA 07.03 Gregory Videtic, OH/USA	



- 16:00 - 16:10 **OA07.05 - Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIs**
Yaping Xu, China
- 16:10 - 16:20 **OA07.06 - Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.**
Fang Hu, China
- 16:20 - 16:30 **OA07.07 - PFS and OS Beyond 5 years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)**
Dirk De Ruyscher, Belgium
- 16:30 - 16:45 **OA07.08 - Discussant - OA 07.05, OA 07.06, OA 07.07**
Sue Yom, CA/USA

OA08

- | | | |
|----------------------|---|--------------------|
| 15:15 - 16:45 | Mesothelioma: Immunotherapy and microRNA for Diagnosis and Treatment
Topics: Mesothelioma
Moderation: D. Fennell, UK; J. Cho, Canada | Room 201 BD |
|----------------------|---|--------------------|
- 15:15 - 15:25 **OA08.01 - Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)**
Takashi Nakano, Japan
- 15:25 - 15:35 **OA08.02 - DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result**
Anna Nowak, Australia
- 15:35 - 15:45 **OA08.03 - Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis**
Arpita Desai, USA
- 15:45 - 16:00 **OA08.04 - Discussant - OA 08.01, OA 08.02, OA 08.03**
Thomas John, Australia
- 16:00 - 16:10 **OA08.05 - Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) -Defining the Hot, the Warm and the Cold Tumours.**
Bibhusal Thapa, VIC/Australia



- 16:10 - 16:20 **OA08.06 - Tumour Suppressor MicroRNAs Modulate Drug Resistance by Targeting Anti-Apoptotic Pathways in Malignant Pleural Mesothelioma (MPM)**
Yuen Yee Cheng, Australia
- 16:20 - 16:30 **OA08.07 - In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-of-Origin Markers**
Brenda Minatel, BC/Canada
- 16:30 - 16:45 **OA08.08 - Discussant - OA 08.05, OA 08.06, OA 08.07**
Emanuela Felley-Bosco, Switzerland

OA09

- | | | |
|----------------------|--|-------------------|
| 15:15 - 16:45 | Prevention and Cessation
Topics: Prevention and Tobacco Control
Moderation: J. Jett, USA; P. Ugalde, Canada | Room 205 B |
|----------------------|--|-------------------|
- 15:15 - 15:25 **OA09.01 - 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario's Regional Cancer Centres**
William Evans, ON/Canada
- 15:25 - 15:35 **OA09.02 - Acceptance of Smoking Cessation Services in Cancer Care Ontario's Lung Cancer Screening Pilot for People at High Risk**
William Evans, ON/Canada
- 15:35 - 15:45 **OA09.03 - Discussions Between Health Professionals and Smokers About E-Cigarettes: Results from the ITC Policy Evaluation Project**
Shannon Gravely, ON/Canada
- 15:45 - 16:00 **OA09.04 - Discussant - OA 09.01, OA 09.02, OA 09.03**
Betty Tong, USA
- 16:00 - 16:10 **OA09.05 - Potential Reduction in Lung Cancer Mortality in the US from 2015-2065: A Comparative Modeling Approach**
Jihyoun Jeon, MI/USA
- 16:10 - 16:20 **OA09.06 - Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study**
Laura Mezquita, France



16:20 - 16:30 **OA09.07 - Association Between Outdoor Air Pollution and Lung Cancer in Female Never Smokers**
Renelle Myers, MB/Canada

16:30 - 16:45 **OA09.08 - Discussant - OA 09.05, OA 09.06, OA 09.07**
Doug Arenberg, MI/USA

PC03

15:15 - 16:45 Controversies in Management of Resectable Thymoma **Room 205 AC**
Topics: Thymoma/Other Thoracic Malignancies
Moderation: N. Ikeda, Japan; A. Bezjak, Canada

15:15 - 15:25 **PC03.01 - Post-Operative Radiation Therapy or NOT: PRO**
Conrad Falkson, Canada

15:25 - 15:35 **PC03.02 - Post-Operative Radiation Therapy or NOT: CON**
Daniel Gomez, USA

15:35 - 15:45 **PC03.03 - Discussion**

15:45 - 15:55 **PC03.04 - Debate on Standard Surgical Approaches - Minimally Invasive Thymectomy**
Shaf Keshavjee, Canada

15:55 - 16:05 **PC03.05 - Debate on Standard Surgical Approaches - Open Thymectomy**
Meinoshin Okumura, Japan

16:05 - 16:15 **PC03.06 - Discussion**

16:15 - 16:25 **PC03.07 - Adjuvant Chemotherapy for Thymic Carcinoma - YES**
Giulia Pasello, Italy

16:25 - 16:35 **PC03.08 - Adjuvant Chemotherapy for Thymic Carcinoma - NO**
Sukhmani Padda, CA/USA

16:35 - 16:45 **PC03.09 - Discussion**



PC04

15:15 - 16:45	Targeted Therapy for NSCLC Topics: Targeted Therapy Moderation: Z. Piotrowska, USA; B. Solomon, Australia	Room 106
15:15 - 15:27	PC04.01 - Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First) James Chih-Hsin Yang, Taiwan	
15:27 - 15:39	PC04.02 - Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First Karen Reckamp, CA/USA	
15:39 - 15:51	PC04.03 - Adjuvant Targeted Therapy for pts with Genomic Alterations - Yes Shun Lu, China	
15:51 - 16:03	PC04.04 - Adjuvant Targeted Therapy for pts with Genomic Alterations - No Lecia Sequist, MA/USA	
16:03 - 16:15	PC04.05 - NGS/Whole Exome Sequencing for Routine Use Daniel Tan, Singapore	
16:15 - 16:27	PC04.06 - Focused Panels for Molecular Profiling for Routine Use Fernando Lopez-Rios, Spain	
16:27 - 16:45	PC04.07 - Q&A	

P1.01

16:45 - 18:00	Advanced NSCLC	Exhibit Hall
	P1.01-01 - ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea Beung Chul Ahn, Republic of Korea	
	P1.01-02 - Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 Scott Antonia, FL/USA	
	P1.01-03 - Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases Oscar Arrieta, Mexico	

**P1.01-04 - Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients**

Fabrice Barlesi, France

P1.01-05 - Metformin in Combination with Crizotinib for The Treatment of EML4-ALK+ Lung Cancer.

Abigail Bland, New Zealand

P1.01-06 - Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy - Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients.

Douglas Blayney, CA/USA

P1.01-07 - Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy

Angela Botticella, France

P1.01-08 - Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1

Nicole Bouchard, Canada

P1.01-09 - Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) \geq 50%: KEYNOTE-598

Michael Boyer, ACT/Australia

P1.01-10 - Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy

Ilaria Caturegli, USA

P1.01-11 - Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers

Keunchil Park, Republic of Korea

P1.01-12 - SWitch Maintenance PEmbroliZumab in Patients with Metastatic Non-Small Cell Lung Cancer (SWIPE)

Haris Charalambous, Cyprus

P1.01-13 - A Study of S-1 Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Yuh-Min Chen, Taiwan

P1.01-14 - Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis

Lorenza Landi, Italy

P1.01-15 - ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial

Biagio Ricciuti, Italy

P1.01-16 - First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials.

Mark Doherty, Canada



P1.01-17 - Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy.

Narjust Duma, MN/USA

P1.01-18 - Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.

Roberto Ferrara, France

P1.01-19 - Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases.

Ronan Flippot, France

P1.01-20 - Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009).

Tatsuro Fukuhara, Japan

P1.01-21 - Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC

Marina Garassino, Italy

P1.01-22 - Effect of Basal Lymphopenia on Outcome of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

Giulia Galli, Italy

P1.01-23 - High PD-L1 Expression is Less Common Than Expected Among Advanced NSCLC in Brazil. Are We Missing the Target?

Ana Gelatti, Brazil

P1.01-24 - Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy

Daniel Glick, BC/Canada

P1.01-25 - Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

Yasuhiro Goto, Japan

P1.01-26 - Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials.

Donna Graham, UK



P1.01-27 - Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation

Xiaorong Dong, China

P1.01-28 - Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC

Balazs Halmos, NY/USA

P1.01-29 - Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

Baohui Han, China

P1.01-30 - Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients with ALK Rearrangement: A Retrospective Study and Literature Review

Baohui Han, China

P1.01-31 - Weekly Regimen of PAXUS-PM, a Novel Cremophor-Free, with Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer in Vietnam

Mi-Ryung Jin, Republic of Korea

P1.01-32 - A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease

Masaki Hanibuchi, Japan

P1.01-33 - Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)

Toshiyuki Harada, Japan

P1.01-34 - Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-Naïve Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

Akito Hata, Japan

P1.01-35 - Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome

Tomoyuki Hida, USA

P1.01-36 - Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy

Chen-Hao Hsiao, Taiwan

P1.01-37 - BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study

Xingsheng Hu, China

**P1.01-38 - A Phase II with a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC**

Yiqing Huang, Singapore

P1.01-39 - Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Meijuan Huang, China

P1.01-40 - Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323

Kentaro Ito, Japan

P1.01-41 - A Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer

Pasi Jänne, MA/USA

P1.01-42 - Real-World Evaluation of Tolerability in Older Adult Patients (≥ 75 years old) with EGFR-mutated NSCLC

Shirley Jiang, Canada

P1.01-43 - Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients with EGFR Activating Mutations

Ying Jin, China

P1.01-44 - Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis

Shruti Kate, India

P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Saadettin Kılıçkap, Turkey

P1.01-46 - Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer

Chul Kim, USA

P1.01-47 - Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Chul Kim, USA

**P1.01-48 - Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression**

Tatsunori Kiriu, Japan

P1.01-49 - irAE, Possible Predictive Markers for Immune Checkpoint Inhibitors

Kazutoshi Komiya, Japan

P1.01-50 - Real World Experience of Nivolumab in Patients with Metastatic Non-small Cell Lung Cancer (mNSCLC)

Doran Ksienski, BC/Canada

P1.01-51 - Real world Experience of Pembrolizumab in Patients with Metastatic Non-small Cell Lung Cancer (mNSCLC)

Doran Ksienski, BC/Canada

P1.01-52 - BR-34- Randomized Trial of Durvalumab & Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC

Swati Kulkarni, ON/Canada

P1.01-53 - Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Lorenza Landi, Italy

P1.01-54 - A Phase I/II Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Natasha Leighl, ON/Canada

P1.01-55 - Unique Genetic Profiles from Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC with Leptomeningeal Metastases

Yangsi Li, China

P1.01-56 - Concurrent Mutations in Chinese Lung Cancer Patients Carrying HER2 Genomic Aberrations

Xuefang Xia, China

P1.01-57 - The Role of EGFR Mutation as a Prognostic Factor in Survival After Diagnosis of Brain Metastasis in NSCLC: A Systematic Review and Meta-Analysis

Wenya Li, China

P1.01-58 - Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Naixin Liang, China



P1.01-59 - A Better Real-World Practice for ROS1 Positive NSCLC Patients, Driven by the Targeted Next Generation Sequencing (NGS) and the Targeted TKI

Yongchang Zhang, China

P1.01-60 - Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC

Chien-Chung Lin, Taiwan

P1.01-61 - Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

Zhefeng Liu, China

P1.01-62 - The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients

Shun Lu, China

P1.01-63 - Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer

Margarita Majem Tarruella, Spain

P1.01-64 - Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC

Melina Marmarelis, PA/USA

P1.01-65 - PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (≥ 75) Non-Squamous NSCLC (LOGIK1201)

RIICHIRO Maruyama, Japan

P1.01-66 - Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial.

Julien Mazieres, France

P1.01-67 - Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients

Laura Mezquita, France

P1.01-68 - Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients

Laura Mezquita, France

P1.01-69 - Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer



Xabier Mielgo-Rubio, Spain

P1.01-70 - Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)

Daniel Morgensztern, USA

P1.01-71 - Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center

Nathaniel Myall, USA

P1.01-72 - FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC

Jürgen Wolf, Germany

P1.01-73 - Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung Cancer) Trial: An Italian Experience.

Silvia Novello, Italy

P1.01-74 - MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition.

Michael Offin, NY/USA

P1.01-75 - Utility of cfDNA Testing for Acquired Resistance: The Memorial Sloan Kettering Experience with Plasma EGFR T790M Clinical Testing.

Michael Offin, NY/USA

P1.01-76 - A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

Paul Paik, NY/USA

P1.01-77 - Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA

Cheol-Kyu Park, Republic of Korea

P1.01-78 - The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib

Tejas Patil, CO/USA

P1.01-79 - CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC

Luis Paz-Ares, Spain



P1.01-80 - ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients with EGFRm and NSCLC Treated with Osimertinib

Zosia Piotrowska, MA/USA

P1.01-81 - Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Gregory Riely, NY/USA

P1.01-82 - Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts

Julia Roeper, Germany

P1.01-83 - IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated with Atezolizumab + Bevacizumab

Jeffrey Rothenstein, ON/Canada

P1.01-84 - High Basal Serum EGF Levels Predicts Response to CIMAvax-EGF, a Therapeutic Vaccine for Advanced NSCLC

Orestes Santos Morales, Cuba

P1.01-85 - The Prevalence of Different EGFR exon20 Mutations in 12,833 Chinese Lung Cancer Patients

Yang W Shao, Canada

P1.01-86 - BTCRC-LUN15-017: Phase-Ib Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC after Progression on Platinum Based Therapy

Ardaman Shergill, IL/USA

P1.01-87 - A Phase 1b Study of TRC105 In Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer

Garrett Sherwood, AL/USA

P1.01-88 - Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Lu Shun, China

P1.01-89 - Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM

Veena Singh, CA/USA

P1.01-90 - A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)



Yong Song, China

P1.01-91 - A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer

Julian Surujballi, Canada

P1.01-92 - A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Kensuke Suzuki, Japan

P1.01-93 - Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+

Santiago Ponce Aix, Spain

P1.01-94 - Phase I Trial to Establish Maximum Tolerated Dose Safety and Pharmacokinetic Profile of Oral Paclitaxel

Satheesh Thungappa, India

P1.01-95 - Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement—A Single Chinese Cancer Institute Experience

Jialei Wang, China

P1.01-96 - Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy

Da Wu, China

P1.01-97 - Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC

Yi-Long Wu, China

P1.01-98 - A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions

Yi-Long Wu, China

P1.01-99 - Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China

Chong-Rui Xu, China

P1.01-100 - Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC

Yaping Xu, China

**P1.01-101 - Survival Benefit of Sequential Therapy in ALK Positive Oligoprogressive NSCLC Patients After Crizotinib Resistance**

Haiyan Xu, China

P1.01-102 - Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort

Tadaaki Yamada, Japan

P1.01-103 - Leukocyte Telomere Length as a Novel Biomarker in Advanced Lung Adenocarcinoma Patients Treated with Gefitinib

Ming Yang, China

P1.01-104 - Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC

Patricia Young, CA/USA

P1.01-105 - Lung Cancer Patients with Concurrent EGFR and MET Mutations: A Retrospective Analysis of 29 Cases

Zhaoxia Wang, China

P1.01-106 - Pembrolizumab Randomized, Phase 1 Study in Chinese Patients with Advanced NSCLC: KEYNOTE-032.

Li Zhang, China

P1.01-107 - The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Li Zhang, China

P1.01-108 - Management of Anlotinib-Related Adverse Events: Data from ALTER 0303

Li Zhang, China

P1.01-109 - Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

Hongyun Zhao, China

P1.01-110 - Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated with Afatinib

Shen Zhao, China

P1.01-111 - EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer



Chao Zhao, China

P1.01-112 - Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients with EGFRm Advanced NSCLC

Caicun Zhou, China

P1.01-113 - Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer

Youcai Zhu, China

P1.02

16:45 - 18:00

Advocacy

Exhibit Hall

P1.02-01 - Imaging of Lung Cancer at the University College Hospital, Ibadan, Nigeria: Does Nuclear Medicine Have Anything to Offer?

Olusegun Ayeni, South Africa

P1.02-02 - 'Listen to Your Lungs' - An Awareness Campaign from The Marie Keating Foundation

Anne-Marie Baird, Australia

P1.02-04 - The EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand & Improve Treatments for EGFR+ Lung Cancer

Jill Feldman, USA

P1.02-03 - The Role of Lung Cancer Advocacy Organizations in Biomarker Testing

Winfield Boerckel, USA

P1.02-05 - ALK Positive Lung Cancer: Patient Engagement and Partnership

Shelly Engfer-Triebebach, NY/USA

P1.02-06 - Usefulness of Workshop to Promote Communication Between Patient and Family

Kazuo Hasegawa, Japan

P1.02-07 - The Role of Volunteers in Quality Palliative Care Delivery for Advance Lung Cancer

Aditya Manna, India

P1.02-08 - Hope for People Living with Metastatic Lung Cancer

Aditya Manna, India



P1.02-09 - Identifying Gaps in Messaging for Biomarker Testing in the Lung Cancer Community: Need for Consistent and Actionable Messaging

Upal Basu Roy, MD/USA

P1.02-10 - "We Are Ambassadors for Survivors:" Experiences of Lung Cancer Support Group Attendees and Facilitators

Maureen Rigney, DC/USA

P1.02-11 - Lung Cancer Symptom Awareness: Findings from a Global Consumer Survey

Maureen Rigney, DC/USA

P1.03

16:45 - 18:00

Biology

Exhibit Hall

P1.03-01 - Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer

Shuitu Feng, China

P1.03-02 - Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer

Jianhui Huang, China

P1.03-03 - Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study

Zhangzhou Huang, China

P1.03-04 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients

Chunwei Xu, China

P1.03-05 - Transcriptome Landscape of Lung Adenocarcinoma Patients Revealed Distinct Trajectory Patterns

Yuqing Lou, China

P1.03-06 - Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

Quxia Zhang, China

P1.03-07 - A Comparison of Consistency of Detecting HER2 Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients



Chunwei Xu, China

P1.03-08 - Detection of PTCH1 Gene Variants in Non-Small Cell Lung Cancer Patients from China

Quxia Zhang, China

P1.03-09 - ROS1 Rearrangement in Pulmonary Sarcomatoid Carcinoma: A Retrospective Study of the Real World

Chunwei Xu, China

P1.03-10 - The Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients

Quxia Zhang, China

P1.03-11 - Analysis of T-Cell Repertoires in Benign and Malignant Solitary Pulmonary Nodules to Evaluate Tumor Immune Microenvironment

Min Li, China

P1.03-12 - PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers

Boris Sepesi, TX/USA

P1.03-13 - eIF2B, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer

Daiki Goto, Japan

P1.03-14 - Interaction Between Celecoxib and Cisplatin is Dependent on the p53 Status in Human NSCLC Cell Lines

Weiyang Li, China

P1.03-15 - TMS Reduced Gefitinib Resistance in NSCLCs Via Suppressing MAPK/Akt/Bcl-2 Pathway by Upregulation of miR-345 and miR-498

Ping Liu, China

P1.03-16 - Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer via Blocking CCL2 Expression

Baohui Han, China

P1.03-17 - Functional Mechanism of GLDC Gene Alternative Splicing in Non-Small Cell Lung Cancer

Kewei Ma, China



P1.03-18 - Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 Expression by Matrix Stiffness

Ayako Miyazawa, Japan

P1.03-19 - Antibody Blockade of Integrin Alpha-V-Beta-6 (avb6) as a Novel Treatment for NSCLC

Banu Rudran, UK

P1.03-20 - The Novel SFN Inhibitors Aprepitant and Ticagrelor Exert Anti-Tumor Effects Through Blocking of Oncoprotein Ubiquitination

Aya Shiba, Japan

P1.03-21 - Huaier Aqueous Extract Induces Lung Adenocarcinoma Cell Apoptosis Through Excessive Activation Of MEK/ERK Signaling Pathway

Zhao Shilei, China

P1.03-22 - MiR-125b Plays a Tumor Suppressor Role in Inflammation-Related Non-Small Cell Lung Cancer via Repressing IGF-1 Signal Pathway

Yanwei Zhang, China

P1.03-23 - The Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study

Xiaohui Chen, China

P1.03-24 - TMPRSS4: A Novel Prognostic Biomarker and Therapeutic Target in NSCLC

Francisco Expósito, Spain

P1.03-25 - The Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients

Quxia Zhang, China

P1.03-26 - Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis

Chunwei Xu, China

P1.03-27 - Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients

Chunwei Xu, China

P1.03-28 - Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with NsclC in Chinese Patients



Chunwei Xu, China

P1.03-29 - An Intronic Variant in EGFR Regulates GBAS Expression and Predicts Survival in Early-Stage Non-Small Cell Lung Cancer

Eungbae Lee, Republic of Korea

P1.03-30 - The Number of Mutated Repair Genes as Predictor for Tumor Mutation Burden of Lung Adenocarcinoma

Yuqing Lou, China

P1.03-31 - Periostin is a Negative Prognostic Factor and Promotes Cancer Cell Proliferation in Non-Small Cell Lung Cancer

Toshimasa Okazaki, Japan

P1.03-32 - Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients

Chunwei Xu, China

P1.03-33 - Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population

Chunwei Xu, China

P1.03-34 - Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI

Yi-Chen Zhang, China

P1.04

16:45 - 18:00

Immunooncology

Exhibit Hall

P1.04-01 - Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC

Young Chae, USA

P1.04-02 - Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade

Linan Fang, ON/Canada

P1.04-03 - Suppressive Immune Cell Profiling in Patients with Non-Small Cell Lung Cancer.

Jiae Koh, Republic of Korea



P1.04-04 - Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity

Chih-Hsiang Leng, Taiwan

P1.04-05 - Elucidating the Role of Leukocyte-Associated Immunoglobulin-Like Receptor 2 (LAIR2) in Lung Cancer Development

Dalam Ly, Canada

P1.04-06 - Clinicopathological Analysis of Pulmonary Pleomorphic Carcinoma

Misa Noguchi, Japan

P1.04-07 - Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms

Nelusha Amaladas, NY/USA

P1.04-08 - Co-Residence of Patient-Derived Immune Cells in Patient-Derived Xenografts from Lung Cancer Patients

Xingxiang Pu, China

P1.04-09 - Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI

Jonathan Riess, CA/USA

P1.04-10 - The Importance of Suppressor and Cytotoxic T Lymphocyte Subsets and Cytotoxic Mechanisms in Non-Small Cell Lung Cancer

Akif Turna, Turkey

P1.04-11 - Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing

Megan Barnett, NSW/Australia

P1.04-12 - Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients with Immunotherapy

Young Chae, USA

P1.04-13 - Combining Clinical and Genomic Data for Predicting Response to Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Michelle Chiu, USA

P1.04-14 - HLA B44 Supertype Associated with Less Favorable Neoantigen Binding in Non-Small Cell Lung Cancer Treated with Immunotherapy

Amy Cummings, CA/USA



P1.04-15 - Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer

Carlo Genova, Italy

P1.04-16 - Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples

Katie Guo, Canada

P1.04-17 - Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients with Metastatic Non-Small-Cell Lung Cancer

Oded Icht, Israel

P1.04-18 - PD-L1 Expression and its Correlation with Tumor TNM Stage in Patients with Non-Small Cell Lung Cancer

Taewon Jang, Republic of Korea

P1.04-19 - Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer

Young Chae, USA

P1.04-20 - Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations

Sukhmani Padda, CA/USA

P1.04-21 - The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Mari Mino-Kenudson, MA/USA

P1.04-22 - CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC).

Ignacio Wistuba, AL/USA

P1.04-23 - Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma

Hui Yu, CO/USA

P1.04-24 - Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy

Alexander Haragan, UK



P1.04-25 - The Implication of Frameshift Mutation Burden in Neoantigen and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC)

Young Chae, USA

P1.04-26 - Prospective Immuno-Biobank in NSCLC

Alfredo Addeo, Switzerland

P1.04-27 - Safety of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) in the Real-Life Setting: A Single-Institution Experience from Argentina.

Maria Bluthgen, Argentina

P1.04-28 - Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study.

Alessandro Russo, Italy

P1.04-29 - Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Antonio Irigoyen Medina, Spain

P1.04-30 - A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI)

Oded Jacobi, Israel

P1.04-31 - Efficacy and Tolerance of Immune-Checkpoint Inhibitors in EGFR, ALK/ROS 1 Non-Small-Cell-Lung-Cancer (NSCLC): GFPC 03-2016 IMAD Study

Olivier Bylicki, France

P1.04-32 - Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC

Alberto Chiappori, FL/USA

P1.04-33 - Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial

Richard Pietras, CA/USA

P1.04-34 - Study on Treatment of Stage IV Solid Tumors with Mutant Neoantigen Specific T Cells

Song Qi, China

P1.04-35 - Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)

Alain Vergnenegre, France



P1.04-36 - Tislelizumab Combined with Chemotherapy as First-Line Treatment in Chinese Patients with Advanced Lung Cancer

Jie Wang, China

P1.05

16:45 - 18:00

Interventional Diagnostics/Pulmonology

Exhibit Hall

P1.05-01 - Incidence and Clinical Relevance of NSCLC Lymph Node Micro-Metastasis Detected by Staging EBUS-TBNA

Adam Belanger, USA

P1.05-02 - Endobronchial Ultrasound-Transbronchial Needle Aspiration for Lymphoma in Patients with Mediastinal Lymphadenopathy

Yu-Deok Choi, Republic of Korea

P1.05-03 - Significance of Lymph Node SUVmax In Predicting Nodal Metastasis By EBUS in Lung Cancer Patients

Michael Gulak, ON/Canada

P1.05-04 - Cone-Beam CT Confirms the Status of Transbronchial Biopsy Under Virtual Bronchoscopic Navigation for Peripheral Lung Lesions

Naoya Kawakita, Japan

P1.05-05 - Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Suspected Malignancy; Current Status and Issues

Hidenao Kayawake, Japan

P1.05-06 - Bronchoscopic Image-Guided Microwave Ablation of Peripheral Lung Tumours - Early Results

Kelvin Lau, UK

P1.05-07 - Clinical Significance of Pleural Indentation of Lung Adenocarcinoma Presented as Ground Glass Opacities

Choon-Taek Lee, Republic of Korea

P1.05-08 - Spread Through Air Spaces (STAS) in Invasive Mucinous Adenocarcinoma of the Lung: Incidence, Prognostic Impact, and Predictive Factors

Min A Lee, Republic of Korea

P1.05-09 - Dielectric Property Test for the Rapid Differential Diagnosis of Lung Nodules/Mass



Di Lu, China

P1.05-10 - Usefulness of Respiratory Dilatation Balloon in Tracheobronchial Stenosis Requiring Silicone Y-Stent Treatment

Shinjiro Mizuguchi, Japan

P1.05-11 - Role of EBUS-TBNA in Evaluation of Mediastinal Lymphadenopathy and Masses in Patients with Known or Suspected Extra-Pulmonary Malignancies

Deepali Jain, India

P1.05-12 - ¹⁸F-FDG PET/CT Findings May Predict Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer Patients

Hisashi Oishi, Japan

P1.05-13 - The Demonstration of the Possibility of the Pleura Cryo Biopsy - A Preliminary Report

Jaroslawn Pierog, Poland

P1.05-14 - Autofluorescence Mode of Thoracoscope Improves Visceral Pleural Invasion Diagnosis in Non-Small Cell Lung Cancer

Toru Sawada, Japan

P1.05-15 - Benign Lung Nodule Resections in the Era of Advanced Imaging and Clinical Guidelines: Imaging Features and How we can Reduce the Resection Rate

Mohamed Sayyoub, MI/USA

P1.05-16 - Clinical Utility of Electromagnetic Navigation Bronchoscopy in the Diagnosis of Lung Cancer

Navneet Singh, USA

P1.05-17 - Clinicopathological Characteristics of Primary Lung Cancers Associated with Emphysematous Bullae

Mikito Suzuki, Japan

P1.05-18 - Predictive Performance of Semi-Quantitative Metabolic Metrics on FDG-PET/CT for the Identification of EGFR Mutations

Taimei Tachibana, Japan

P1.05-19 - CT and PET/CT Parameters of Lepidic Predominant Pattern Lung Adenocarcinoma and Invasiveness on Pathology

Hiromitsu Takizawa, Japan



P1.05-20 - Therapeutic Condition of Photodynamic Therapy Using Taraporfin Sodium for Central Airway Stenosis

Takaaki Tsuchida, Japan

P1.05-21 - CT-Guided Biopsy of Lung Lesions with Outer Cannula Washing Cytology

Fumiyasu Tsushima, Japan

P1.05-22 - New Methods of Brachyradiotherapy Catheter Stabilization in the Airways

Jiri Votruba, Czech Republic

P1.05-23 - Evaluation of the 8th Edition of the TNM Classification for Lung Cancer at a Single Institution

Jia Wang, China

P1.05-24 - Clinical Characteristics and Prognostic Analysis of Multiple Primary Malignant Neoplasms in Patients with Lung Cancer

Huijuan Wang, China

P1.09

16:45 - 18:00

Pathology

Exhibit Hall

P1.09-01 - PD-L1 Testing on NSCLC Cytology Samples in a UK Teaching Hospital

Haider Al-Najjar, UK

P1.09-02 - PD-L1 Expression Pattern in Large Cell Neuroendocrine Carcinoma of the Lung: The GFPC 03-2017 "EPNEC" Study.

Dominique Arpin, France

P1.09-03 - Challenges in PD-L1 Immunoexpression in Liquid Based Cytology Samples of Advanced Stage Non-Small Cell Lung Carcinomas

Deepali Jain, India

P1.09-04 - Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region

Rosalyn Juergens, Canada

P1.09-05 - Why does PD-L1 (22C3) expression rate show difference among regional hospitals?

Yuko Minami, Japan



P1.09-06 - The Incidence of PD-L1 in NSCLC and its Correlation with Driver Mutations in Turkish Patients; A Single Center Experience.

Buge Oz, Turkey

P1.09-07 - PD-L1 Protein Expression is a Predictor of Benefit from Adjuvant Chemotherapy in Resected Non-Small Cell Lung Carcinoma

Naoki Yanagawa, Japan

P1.09-08 - Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study.

Ayesha Baig, QC/Canada

P1.09-09 - Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

Esther Conde, Spain

P1.09-10 - Targeted Sequencing of Pulmonary Enteric Adenocarcinoma Reveals Distinctive Mutation Profile from Conventional Type of Lung Adenocarcinoma

Likun Hou, China

P1.09-11 - Immunohistochemical Assessment of BRCA1 Associated Protein-1 (BAP1) in Pulmonary Mucoepidermoid Carcinomas

Deepali Jain, India

P1.09-12 - Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients with NSCLC Highlights Correlation of ROS1 and PD-L1 Expression

Tae-Jung Kim, Republic of Korea

P1.09-13 - Detection of Actionable Mutations in Plasma cfDNA Samples from NSCLC Patients Using a Novel Amplicon-Based Firefly NGS Assay

Jiatao Lou, China

P1.09-14 - Analysis of Real-World Mutations of Lung Cancer Driver Genes in 3081 Patients from China

Ye Guo, China

P1.09-15 - Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and its Impact on Treatment Decision Making

Valliappan Muthu, India

P1.09-16 - Novel Somatic Gene Mutation of SLC17A9, Detected in Early-Stage Lung Adenocarcinoma

Shingo Sakashita, Japan



P1.09-17 - CTNNB1 (Beta-Catenin) Mutations in Non-Small Cell Lung Carcinoma: A Clinicopathological Study of 18 Cases

Vincent Thomas De Montpréville, France

P1.09-18 - 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma

Chunwei Xu, China

P1.09-19 - Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma

Zheng Wang, China

P1.09-20 - Correlation Between Whole Genomic Copy Number Variant Scoring and Pathological Classification, Staging in Lung Non-Mucinous Adenocarcinoma

Zheng Wang, China

P1.09-21 - Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients

Zyanya Zatarain-Barrón, Mexico

P1.09-22 - Detection of ALK Gene Rearrangement in FFPE Tissues of Non-Small Cell Lung Cancer Using in Situ RNA Hybridization

Xuan Zeng, China

P1.09-23 - Effect of Plasma Input on the Clinical Sensitivity of a Real-Time PCR Assay for the Detection of EGFR Mutation in Plasma ctDNA From NSCLC Patients

Guanshan Zhu, China

P1.09-24 - The Effects of NLR and PLR of Effect on Prognosis in Patients with the Lung Cancer

Fazıl Aydın, Turkey

P1.09-25 - Invasive Size (Not Total Size) Predicts Overall Survival in Invasive Mucinous Adenocarcinomas

Wei-Chin Chang, Taiwan

P1.09-26 - A Case Report of Discordant Markers of Lung Cancer Tumor Cells: An Unusual Immunophenotype of Uncertain Significance

Lisa Giscombe, RI/USA

**P1.09-27 - Clear Cell Adenocarcinoma Subtype is an Independent Predictor of Better Survival in Patients with Lung Adenocarcinoma**

Takefumi Komiya, USA

P1.09-28 - Clinical Utility of Rapid Immunohistochemistry for Differentiation of Solitary Pulmonary Adenocarcinomas

Hayato Konno, Japan

P1.09-29 - In Situ Growth Pattern in Lung Adenocarcinoma Is Divisible into Distinct Categories with Divergent Biological and Survival Implications

John Le Quesne, UK

P1.09-30 - Heterotopic Expression of Ceruloplasmin in Lung Adenocarcinoma and its Possible Clinical Use as a Tumor Biomarker

Ryota Matsuoka, Japan

P1.09-31 - Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and Its Impact on Treatment Decision Making

Valliappan Muthu, India

P1.09-32 - Classification and Mutation Prediction from Non-Small Cell Lung Cancer Histopathology Images Using Deep Learning

Paolo Ocampo, USA

P1.09-33 - Validity of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome

Takahiro Ota, Japan

P1.09-34 - Prognostic Impact of Invasive Size, Actual Tumor Size, and Mucinous Tumor Size in Invasive Mucinous Adenocarcinoma of the Lung.

Tomohito Saito, Japan

P1.09-35 - Clinical Impact of Systematic Inflammation and Histologic Grade in Non-Small Cell Lung Carcinoma (NSCLC)

Nikolaos Tsoukalas, Greece

P1.09-36 - Clinical Significance of Cannabinoid Receptor CB2 Expression in Non-Small Cell Lung Cancer (NSCLC)

Nikolaos Tsoukalas, Greece

P1.09-37 - Tumor Spread Through Air Spaces (STAS) in Stage I Lung Squamous Cell

Hironori Uruga, Japan



P1.09-38 - Pulmonary Epithelioid Hemangioendothelioma (EHE) with Von Recklinghausen Disease

Satoshi Yamamoto, Japan

P1.09-39 - Spread Through Air Spaces Predicts a Worse Survival in Patients with Stage I Adenocarcinomas > 2.0cm After Radical Lobectomy

Lin Yang, China

P1.09-40 - Metastatic Endometrial Sarcoma Presenting as a Spontaneous Pneumothorax and Masquerading as a Pulmonary Blastoma.

Giselle Suero-Abreu, USA

P1.11

16:45 - 18:00

Screening and Early Detection

Exhibit Hall

P1.11-01 - The NELSON Triage Algorithm Applied to a Chinese Biopsied Population: A Pilot Study

Hubert Beaumont, France

P1.11-02 - Pathologic Comparison of Prevalent vs. Incident CT Lung Screen Detected Cancer in NCCN High-Risk Subjects: Are They Different?

Eric Burks, MA/USA

P1.11-03 - MicroRNA with Ability to Reciprocal Regulation of Dicer and Drosha - Plasma Expression Status and Diagnostic Value in Non-Small Cell Lung Cancer

Pawel Krawczyk, Poland

P1.11-04 - Size Measurement Variability of Solid Component of Lung Adenocarcinoma

Kazutoshi Hamanaka, Japan

P1.11-05 - Metabolomic Profiling for Second Primary Lung Cancer Among Lung Cancer Survivors

Summer Han, CA/USA

P1.11-06 - Lung Cancer Probability in New Perifissural Nodules Detected in a Lung Cancer Screening Study

Marjolein Heuvelmans, Netherlands

P1.11-07 - Utility of the Maximum CT Value in Predicting Invasiveness of Pure GGNs

Junji Ichinose, Japan



P1.11-08 - AI Based Malignancy Prediction of Indeterminate Pulmonary Nodules: Robustness to CT Contrast Media

Timor Kadir, UK

P1.11-09 - The Delay of Lung Cancer Diagnosis Due to Misdiagnosing as Pulmonary Tuberculosis

Ana Rima, Indonesia

P1.11-10 - Optimizing Radiomics Features by Minimizing Boundary Effects and Normalizing with Opposite Lung Tissue Characteristics

Saeed Seyyedi, BC/Canada

P1.11-11 - Comparing Lung Cancer Diagnosed by Low Dose CT (LDCT), Incidental Lung Nodule Program (ILNP), and Non-Program-Based Detection

Matthew Smeltzer, TN/USA

P1.11-12 - Interrogation of an Exhaled MicroRNA Panel for Lung Cancer Risk Assessment

Simon Spivack, USA

P1.11-13 - Noninvasive Detection of Early Stage NSCLC EGFR Mutations Using Electric Field Induced Release and Measurement (EFIRM)

Charles Strom, USA

P1.11-14 - Radiological Pleura-Tumor Proximity in Pure-Solid Clinical Stage I Lung Cancer: Its Influence on Lymph Node Metastasis and Recurrence

Toshiki Tanaka, Japan

P1.11-15 - Application of Lung-RADS vs. PAN-CAN Nodule Risk Calculation in the Alberta Lung Cancer Screening Study

Alain Tremblay, Canada

P1.11-17 - Discriminating Less Invasive Lesions of Early-Stage Lung Adenocarcinoma by Three-Dimensional Computed Tomography Analysis

Nobuyuki Yoshiyasu, Japan

P1.11-18 - A Classification-Based Machine Learning Method Reveals Exosomal miRNA Biomarkers for Patients with Pulmonary Ground Glass Nodule

Jia-Tao Zhang, China

P1.11-19 - Expression of TNFR11 in Serum is Correlated with the Significant Risk of Subcentimeter Lung Adenocarcinoma

Yanwei Zhang, China



P1.12

16:45 - 18:00

Small Cell Lung Cancer/NET

Exhibit Hall

P1.12-01 - A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC After Second/Third-Line Chemotherapy

Yun Fan, China

P1.12-02 - Phase II Study of Amrubicin Monotherapy in Elderly or Poor-Risk Patients with Extensive Disease of Small Cell Lung Cancer

Satoshi Igawa, Japan

P1.12-03 - A Prospective Study of Apatinib in Advanced Small Cell Lung Cancer Patients Failed from Two or More Lines of Chemotherapy

Yutao Liu, China

P1.12-04 - A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients

Shun Lu, China

P1.12-05 - Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors

Hiroyuki Ogawa, Japan

P1.12-06 - Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus

Simron Singh, ON/Canada

P1.12-06a - Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy in Small Cell Lung Cancer

Ho-Jin Lee, USA

P1.12-06b - Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy

Ho-Jin Lee, USA

P1.12-07 - Time to the End of Thoracic Radiotherapy Affects to Survival Outcomes Greater than Radiation Dose in Limited Stage Small Cell Lung Cancer

Sung-Ja Ahn, Republic of Korea

P1.12-08 - The Effect of Cisplatin Versus Carboplatin on Cancer Outcomes for Small Cell Lung Cancer Patients in a Population-Based Cohort



David Dawe, Canada

P1.12-09 - The Effect of Site of First Chemotherapy on Small Cell Lung Cancer Patient Outcomes

David Dawe, Canada

P1.12-10 - Patterns of Curative Chemo-Radiotherapy Regimen and Impacts on the Outcome of Limited Stage SCLC in a Canadian Institution: 2010 - 2015 Diagnoses

Anifat Elegbede, Canada

P1.12-11 - 2010 - 2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival

Anifat Elegbede, Canada

P1.12-12 - A Systematic Review and Meta-Analysis of Early and Late Survival Following Anti-Cancer Therapies for Small Cell Lung Cancer

Gavin Jones, UK

P1.12-13 - Impact of Chronic Obstructive Pulmonary Disease on the Survival of Patients with Extensive-Disease Small Cell Lung Cancer

Eun Joo Kang, Republic of Korea

P1.12-14 - Survival of Patients with Small-Cell Lung Cancer Undergoing Surgical Resection

Shinji Kikuchi, Japan

P1.12-15 - Distinctive Clinical Characteristics of SCLC in Never-Smokers

Idrees Mian, USA

P1.12-16 - Management of Elderly Small-Cell Lung Cancer Patients in a Romanian Tertiary Care Center

Lucian Miron, Romania

P1.12-17 - Overall Survival and Recurrence After Surgical Resection of Pure and Mixed Large Cell Neuroendocrine Tumors.

Brooks Udelsman, MA/USA

P1.12-18 - Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation

Lei Zhao, China

P1.12-19 - Clinico-Pathological Characteristics and Treatment Outcome in Small Cell Lung Cancer: A Single Institutional Experience



Sandip Ganguly, India

P1.12-20 - Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial.

Martin Forster, UK

P1.12-21 - Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC)

Lee Schwartzberg, PA/USA

P1.13

16:45 - 18:00

Targeted Therapy

Exhibit Hall

P1.13-01 - Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines

Silvia Garcia - Roman, Spain

P1.13-02 - eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients

Leora Horn, TN/USA

P1.13-03 - Ensartinib Treatment Beyond Disease Progression in Stage IV ALK+ Non-Small Cell Lung Cancer

Leora Horn, TN/USA

P1.13-04 - Integrin B3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK Rearranged NSCLC

Mi-Sook Lee, Republic of Korea

P1.13-05 - Integrin B3 Inhibition Enhances the Antitumor Activity of Alk Inhibitor in Alkrearranged NSCLC

Mi-Sook Lee, Republic of Korea

P1.13-06 - First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK⁺) Non-Small Cell Lung Cancer

Alice Shaw, USA

P1.13-07 - Epithelial-Mesenchymal Transition Induced the Acquired Resistance to ALK Inhibitor Brigatinib in Lung Cancer Cells Harboring with ALK Fusions

Keiko Tanimura, Japan



P1.13-08 - Distribution, Differences in Clinical Characteristics and Resistance Mechanism of ALK Variants in Chinese Lung Cancer Patients.

Xuefeng Xia, China

P1.13-09 - Efficacy and Tolerance of Osimertinib in Real World Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study).

Jean Bernard Auliac, France

P1.13-10 - Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer

Sourav Bandyopadhyay, United States Minor Outlying Islands

P1.13-11 - PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real-World Assessment

Katrina Hueniken, USA

P1.13-12 - EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

Farhad Kosari, USA

P1.13-13 - Potent Anti-Tumor Effect of Ganetespib in Acquired EGFR-TKI Resistance NSCLC Cells

Eisuke Kurihara, Japan

P1.13-14 - The Molecular Landscape of Lung Adenocarcinomas with Activating EGFR Gene Mutations Determined by Targeted-Sequencing

Kamila Wojas-Krawczyk, Poland

P1.13-15 - Detection of EGFR Mutations in cfDNA and Development of Resistance

Grainne O'kane, Canada

P1.13-16 - The Diagnostic Accuracy of Circulating Tumor DNA for the Detection of EGFR-T790M Mutation in NSCLC: A Systematic Review and Meta-Analysis

Francesco Passiglia, Italy

P1.13-17 - Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA & Long-Term Efficacy

Adam Januszewski, UK

P1.13-18 - Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients

Yuankai Shi, China



P1.13-19 - Treatment Cessation for Improved Detection of EGFR-Mutated Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Samer Tabchi, USA

P1.13-20 - MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Silvia Novello, Italy

P1.13-21 - Clinical Efficacy and Safety of Apatinib Combined with EGFR - TKIs in Advanced Non-Small Cell Lung Cancer with EGFR - TKIs Resistance

Ruifen Tian, China

P1.13-22 - Clinical Features and Outcomes of NSCLC Patients with Uncommon EGFR Mutations Treated with EGFR-TKIs

Roxana Tudor, AB/Canada

P1.13-23 - TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC

Paola Ulivi, Italy

P1.13-24 - EGFR-KDD is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population

Yang Shao, Canada

P1.13-25 - Efficacy and Safety of Osimertinib in EGFR T790M-Positive Advanced NSCLC Patients with Brain Metastases (APOLLO Study)

Ligang Xing, China

P1.13-26 - First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease

Qinghua Xu, China

P1.13-27 - A Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC with EGFR Mutations

He Yong, China

P1.13-28 - The Functional MDM4 Genetic Polymorphism as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

Ming Yang, China

P1.13-29 - Overall Response Rate of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC

Joaquim Bosch Barrera, Spain



P1.13-30 - Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor and its Relationship to NSCLC Patient Outcomes in the REVEL Trial

Aafia Chaudhry, NY/USA

P1.13-31 - Safety and Tumour Hypoxia Modifying Effect of Buparlisib with Radiotherapy in NSCLC: A Phase I Dose Escalation Study

Michael Skwarski, UK

P1.13-32 - Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated with PD-1/PD-L1 Therapy

Mi Young Kim, Republic of Korea

P1.13-33 - Ex Vivo 2*2*2 Tumor Tissue Explant Culture for Precision Medicine in Immunotherapy and TKI progressors in Lung Cancer

Nir Peled, Israel

P1.13-34 - Changes in Radiomic Features Between Baseline and Two Weeks Post-Nivolumab Treatment Are Predictive of Pathologic Complete Response

Kaustav Bera, OH/USA

P1.13-35 - Hypoxia Mapping Using Oxygen-Enhanced MRI in Lung Cancer

Ahmed Salem, UK

P1.13-36 - Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

Lecia Sequist, MA/USA

P1.13-37 - Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer

Hai Tran, USA

P1.13-38 - Inter-Organ Heterogeneity on Mechanisms of Targeted Drug Resistance -Central Nervous System (CNS) vs Extra CNS-

Seiji Yano, Japan

P1.13-39 - Epidermal Growth Factor Receptor Mutation Among Non-Small Cell Lung Cancer Patients in Trinidad and Tobago: Frequency and Trends

Aaron Haralsingh, Trinidad And Tobago



P1.13-40 - Rapid, Robust and Durable Responses to Larotrectinib in Patients with TRK Fusion Non-Small Cell Lung Cancer

Anna Farago, MA/USA

P1.13-41 - In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping

Toshio Fujino, Japan

P1.13-42 - Activity of Novel HER2 Inhibitor, Pozitotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance

Takamasa Koga, Japan

P1.13-43 - Molecular and Imaging Predictors of Response to Ado-Trastuzumab Emtansine in Patients with HER2 Mutant Lung Cancers: An Exploratory Phase 2 Trial

Bob Li, NY/USA

P1.13-44 - Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

Joel Neal, CA/USA

P1.13-45 - Coexistence of Activating BRAF and KRAS Mutations in Lung Cancer Patients

Yingyi Wang, China

P1.14

16:45 - 18:00

Thymoma/Other Thoracic Malignancies

Exhibit Hall

P1.14-01 - Current Practices in the Management of Malignant Pericardial Effusions: A Survey Amongst Members of the European Society of Thoracic Surgeons.

Edward Caruana, UK

P1.14-02 - Predicting Stent Failure in Malignant Esophageal Obstruction

Tommi Järvinen, Finland

P1.14-03 - Phase II Trial of Amrubicin and Cisplatin Chemotherapy for Invasive Thymoma: WJOG5509L

Keita Kudo, Japan

P1.14-04 - Stereotactic Body Radiation Therapy for Pleural Recurrences of Thymoma

Cecile Le Pechoux, France



P1.14-05 - The Association of Pulmonary Function with Survival After Treatment in Patients with Esophageal Cancer

Hsien-Chi Liao, Taiwan

P1.14-06 - Treatment Outcomes of Patients with Thymic Carcinoma: A Monocentric Experience of Sequential Regimens Modality

Margaret Ottaviano, Italy

P1.14-07 - Intraoperative Detection of Circulating Tumor Cells in Pulmonary Venous Blood During Metastasectomy for Colorectal Lung Metastases

Severin Schmid, Germany

P1.14-08 - The Usefulness of the Hemiclamshell Thoracotomy in Thoracic Surgery

Masanori Tsuchida, Japan

P1.14-09 - Outcome After Lung Resection for Primary Lung Carcinomas/Metastasis in Patients with Performed Total Laryngectomy for Laryngeal Carcinoma

Huseyin Melek, Turkey

P1.14-10 - Surgical Treatment of a Rare Case of Clear Cell Carcinomatous Transformation of a Diaphragmatic Endometriosis Focus

Angela De Palma, Italy

P1.14-11 - The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors

Shunta Ishihara, Japan

P1.14-12 - GTF2I Mutation in Thymomas: Indian and German Study

Deepali Jain, India

P1.14-13 - PD-L1 Immuno-Expression Assay in Thymomas: A Study from India

Deepali Jain, India

P1.14-14 - Histotyping of Indian Thymomas: A Comprehensive Clinicopathologic Study

Deepali Jain, India

P1.14-15 - Prevalence of Mediastinal Tumors Using Low-Dose Spiral Computed Tomography in Healthy Population

Ikuma Kasuga, Japan

P1.14-16 - DNA Methylation of GNG4, GHSR, HOXD9 and SALL3 Genes Predict Malignant Behavior of Thymic Epithelial Tumors



Reina Kishibuchi, Japan

P1.14-17 - Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model

Sukhmani Padda, CA/USA

P1.14-18 - The Promising Role of Sunitinib Rechallenge in Heavily Pre-Treated Thymic Carcinoma: A Case Report

Giovannella Palmieri, Italy

P1.14-19 - Hemagglutinating Virus of Japan Envelope (HVJ-E: Inactivated Viral Nanoparticles) Against Chemotherapy-Resistant Pleural Mesothelioma

Kazuma Sakura, Japan

P1.14-20 - The Expression of DNA Methylation of GAD1 Gene is an Indicator of Malignant Behavior in Thymic Epithelial Tumor.

Kazuya Kondo, Japan

P1.14-21 - Circulating Biomarkers in Thymic Epithelial Tumors

Clemens Aigner, Germany

P1.14-22 - The Prognostic Role of the Suppressor of Cytokine Signaling-5 (SOCS5) in Esophageal Squamous Cell Carcinoma

Pei-Wen Yang, Taiwan

P1.14-23 - Thymoma: An Epidemiological and Clinico-Pathological Profile in Nepalese Population.

Sandhya Acharya, Nepal

P1.14-24 - External Radiotherapy Concurrent with Cisplatin Plus 5-Fluorouracil in Locally Advanced Carcinoma of Esophagus

Rashmey Pun, Nepal

P1.14-25 - Pulmonary Metastasis from Oral Cancer - Who Survive Without Recurrence After Pulmonary Metasectomy?

Chihiro Takasaki, Japan

P1.14-26 - Long Term Outcome and Clinicopathological Features of Thymic Carcinoma - A Retrospective Study of 25 Cases at a Single Institution

Hiroto Tanaka, Japan



P1.14-27 - Differentiation Between Each Thymic Epithelial Tumor According to WHO Classification Scheme by Using MDCT Findings

Yutthaphan Wannasopha, Thailand

P1.14-28 - Frequent Genetic Alterations and Their Clinical Significance in Patients with Thymic Epithelial Tumors

Song Xu, China

P1.14-29 - Surgical Treatment for Metastatic Lung Tumors from Various Sarcomas

Hiromasa Yamamoto, Japan

P1.14-30 - Prognostic Factors for Sarcoma Patients with Lung Metastasis Who Underwent Extended Pulmonary Resection

Haruchika Yamamoto, Japan

P1.15

16:45 - 18:00

Treatment in the Real World - Support, Survivorship, Systems Research

Exhibit Hall

P1.15-01 - Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience

Biagio Ricciuti, Italy

P1.15-02 - Migration Differences in Small Cell vs Non-Small Cell Lung Cancer

Shruti Bhandari, KY/USA

P1.15-03 - Clinical Characteristics of Long-Term Survivors with Nivolumab in Pretreated Advanced NSCLC from Real-World Data (RWD)

Antonio Calles, Spain

P1.15-04 - Practice Patterns Regarding Multidisciplinary Cancer Management for NSCLC and implemetantion: Results of National Survey in México

Saul Campos-Gomez, Mexico

P1.15-05 - The Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review

Victoria Crossland, UK

P1.15-06 - Integrative Quality Improvement for Management of Lung Cancer in Uganda

Semujju David, Uganda



P1.15-07 - Geriatric Oncology - Lung Cancer in Elderly Patients and Palliative Treatment: Prospective Analysis of A. C. Camargo Cancer Center

Mauro DS Donadio, Brazil

P1.15-08 - Implementation and Feasibility of the Assessment of EGFR Mutation in NSCLC Using Liquid Biopsy at an Argentinean University Hospital

Carolina Gabay, Argentina

P1.15-09 - Trends in Lung Cancer Survival in Lithuania

Vaida Gedvilaite, Lithuania

P1.15-10 - Comparison of Selected Colombian National Administrative Cancer Registry (NACR) Data in Lung Cancer with the U.S.

Robert Hsu, USA

P1.15-11 - Lung Cancer as One of Multiple Cancers: A Population-Based Study in Estonia 1995-2015

Jana Jaal, Estonia

P1.15-12 - Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population

Jeremy Kratz, USA

P1.15-13 - Wait Times for Diagnosis and Treatment of Lung Cancer Across the Province of Quebec, Canada

Catherine Labbe, Canada

P1.15-14 - Pneumonia in Patients with Lung Cancer of South Korea: A Nationwide Population Based Study

Hyun Woo Lee, Republic of Korea

P1.15-15 - Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Chong-Kin Liam, Malaysia

P1.15-16 - ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

Huamao Lin, MA/USA

P1.15-17 - Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study



Hui Liu, China

P1.15-18 - The Impact of Patient Age on Clinical Outcomes in NSCLC: A National Study

Yanyan Lou, FL/USA

P1.15-19 - Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real-World Data

Shun Lu, China

P1.15-20 - Diagnosis and Treatment Delay Among Patients with Lung Cancer in Mexican Population

Omar Macedo-Pérez, Mexico

P1.15-21 - Creating an Optimal Care Coordination Model to Improve Multidisciplinary Care for Lung Cancer Patients on Medicaid

Amanda Kramar, USA

P1.15-22 - Patterns of Palliative and Psychosocial Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients

Tahir Mehmood, Pakistan

P1.15-23 - Factors Affecting Treatment in Non-Small Cell Lung Cancer Patients

Phuong Ngo, KY/USA

P1.15-24 - Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients

Virginia Calvo, Spain

P1.15-25 - Has Lung Cancer Radiotherapy Utilisation Changed over Time in New South Wales, Australia?

Shalini Vinod, Australia

P1.15-26 - A Review of Colombian National Administrative Cancer Registry (NACR) Data to Evaluate Healthcare Delivery and Biologics Use

Brian Pico, FL/USA

P1.15-27 - Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada.

Soo Jin Seung, Canada

P1.15-28 - Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada.



Soo Jin Seung, Canada

P1.15-29 - Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer

Yu Yang Soon, Singapore

P1.15-30 - Survival of Patients with Advanced NSCLC Treated with First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016

Sitthi Sukauichai, Thailand

P1.15-31 - Survival and Patterns of Care Comparing Black and White Patients with All Stages of NSCLC: An NCDB Analysis

Melissa Vyfhuis, USA

P1.15-32 - Real World EGFR Mutation Profile from 1699 Non-Small Cell Lung Cancer Patients in Eastern China

Wei Wang, China

P1.15-33 - Real-World Data on Prognostic Factors for Overall Survival in NSCLC Patients Treated with Bevacizumab Combination Therapy

Shang-Gin Wu, Taiwan

P1.15-34 - Treatment Patterns and Outcomes of Stage III Non-Small Cell Lung Cancer (NSCLC): Real World Evidence of How our Patients Fare

Dimas Yusuf, Canada

P1.15-35 - Real World Outcome of Different Administrations Endostar Combined with Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC

Yongchang Zhang, China

P1.15-36 - A Better Real-World Practice for Pemetrexed in First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer

Yongchang Zhang, China

P1.16

16:45 - 18:00

Treatment of Early Stage/Localized Disease

Exhibit Hall

P1.16-01 - Prognostic Variables Associated with Improved Outcomes in Stage III NSCLC Patients Treated with Consolidation Pembrolizumab



Bilal Anouti, IN/USA

P1.16-02 - Support and Information Needs for Patients with NSCLC Receiving Concurrent Chemo-Radiotherapy: Findings from the INSIGHT Study.

Jackie Fenemore, UK

P1.16-03 - Prognostic Significance of PD-L1 in Stage II/III Non-Small Cell Lung Cancer

Mustafa Karaca, Turkey

P1.16-04 - Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC

Mark Socinski, FL/USA

P1.16-05 - Effect of Induction Chemotherapy in the PACIFIC Study

David Spigel, TN/USA

P1.16-06 - Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Alexander Spira, VA/USA

P1.16-07 - Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore

Wan Ling Tan, Singapore

P1.16-08 - Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Changli Wang, China

P1.16-09 - Surgical Result of Pathologic Stage III a Non-Small Cell Lung Cancer: Have We Improved?

Ching-Yang Wu, Taiwan

P1.16-10 - Marginal Features Analyses of Lung Adenocarcinoma for Survival Prediction

Geewon Lee, Republic of Korea

P1.16-11 - Monitoring of Early Stage Lung Cancer Using Liquid Biopsies.

Alexander Dobrovic, VIC/Australia

P1.16-12 - Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit from Adjuvant Chemotherapy

Stacy Grieve, Canada

P1.16-13 - Photo Dynamic Therapy (PDT) in Our Hospital



Fumihiko Hoshi, Japan

P1.16-14 - Impact of Smoking on Treatment Outcome in Early Squamous Cell Lung Cancer (T1N0)

Junghee Lee, Republic of Korea

P1.16-15 - Evaluation of Emphysema Severity by 3D-CT for Predicting Postoperative Respiratory Complications and Prognosis of Lung Cancer

Yojiro Makino, Japan

P1.16-16 - Automatic Intratumor Segmentation in CT of NSCLC: An Alternative to PET Metabolic Subregions

Qintao Qiu, China

P1.16-17 - The Role of Quantitative Metabolic Metrics on FDG-PET/CT in Predicting Pathological Invasive Factors in cN0 Lung Adenocarcinoma

Takehiko Tanaka, Japan

P1.16-18 - Role of ERCC1/2 Single Nucleotide Polymorphism (SNP) on Treatment Response in Patients with Lung Cancer Undergoing Radiation Therapy

Yaping Xu, China

P1.16-19 - Neither Maximum Tumor Size nor Solid Component Size Was the Best Prognosticator for Subsolid Nodule

Erjia Zhu, China

P1.16-20 - A Systematic Review and Meta-Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients with Non-Small Cell Lung Cancer

Christopher Cao, NY/USA

P1.16-21 - Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients with Locally Advanced NSCLC

Yuko Kawano, Japan

P1.16-22 - Meta-Analysis of Stereotactic Ablative Radiotherapy Versus Surgery for Early Stage Lung Cancer.

Janusz Kowalewski, Poland

P1.16-23 - Long-Term Survival Analysis of Surgery in Potential Stereotactic Ablative Radiotherapy Candidates of Non-Small Cell Lung Cancer

Shaolei Li, China



P1.16-24 - Impact of Tumor Location & Dosimetric Predictors for Chest Wall Toxicity in Single Fraction SBRT for Stage I Non-Small Cell Lung Cancer

Gregory Videtic, OH/USA

P1.16-25 - A Propensity Score Model for Appropriate Treatment Selection (Sublobar Resection vs. SBRT) In Patients With cStage I NSCLC

Yukinori Matsuo, Japan

P1.16-26 - Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) with 50 Gray in 5 Fractions (50Gy/5f)

Robert Rulach, UK

P1.16-27 - Using Rates of Clinical Brachial Plexopathy after Lung SBRT to Better Characterize the Tolerance of the Brachial Plexus

Kyle Verdecchia, OH/USA

P1.16-28 - The Impact of Spironolactone on the Lung Injury Induced by Concomitant Trastuzumab and Thoracic Radiotherapy

Guler Yavas, Turkey

P1.16-29 - Accelerated Hypofractionated Radiotherapy for Central Lung Tumors Unsuitable for Stereotactic Body Radiotherapy or Concurrent CRT

K Liang Zeng, Canada

P1.16-30 - Quality of Lymphadenectomy During Lobectomy for Non-small Cell Lung Cancer: VATS Versus Thoracotomy

Raquel Alves, QC/Canada

P1.16-31 - Surgically Resected Acinar Adenocarcinoma of the Lung: Analysis of Different Prognostic Groups.

Pietro Bertoglio, Italy

P1.16-32 - Lung Cancer Completeness of Resection in Uniportal Versus Multiportal Video-Assisted Thoracoscopic Surgery Lobectomy

Etienne Bourdages-Pageau, QC/Canada

P1.16-33 - Occult Lymph Node Metastases in Early Stage NSCLC Patients: Where Do We Stand Now? A Proposal for a Preoperative Risk Model

Giuseppe Cipollone, Italy

P1.16-34 - The Impact of Pathology, Staging and Operative Resection on Survival and CT Evidence of Recurrence of Early NSCLC



Richard Finley, Canada

P1.16-35 - Sleeve Lobectomy Versus Pneumonectomy for Non-Small Cell Lung Cancer, a Cumulative Updated Meta-Analysis

Zihua Guo, China

P1.16-36 - Real-Time Ct Guided Video Assisted Thoracoscopic Partial Resection of Peripheral Small-Sized Lung Tumors.

Taisuke Kaiho, Japan

P1.16-37 - Clinicopathological Characteristics and Prognostic Factors of Operable Non-Small Cell Lung Cancer Patients with the Diabetes Mellitus

Kaoru Kaseda, Japan

P1.16-38 - Meta-Analysis of Unplanned Readmissions Following Thoracoscopic Versus Open Lung Cancer Resection

Janusz Kowalewski, Poland

P1.16-39 - A Nomogram for Predicting Survival of TNM8 Stage I Non-Small Cell Lung Cancer Patients to Tailor Potential Chemotherapy Candidates

Wenhua Liang, China

P1.16-40 - Evaluating the Tumor Heterogeneity in Lung Cancer by Constructing Tumor Heterogeneity Index (THI) from Magnetic Resonance Imaging

Hui Liu, China

P1.16-41 - The Role of Surgery in Pulmonary Large Cell Neuroendocrine Carcinoma: A Propensity-Score Matching Analysis of SEER Database

Zhichao Liu, China

P1.16-42 - Indocyanine Green Intersegmental Visualization During Fluorescence Imaging of Thoracoscopic Anatomic Segmentectomy: A Novel Approach

Takuya Matsui, Japan

P1.16-43 - Analyses of Long-Term Outcomes and Prognostic Factors in Surgically Resected ALK-Rearranged Lung Adenocarcinoma

Yosuke Matsuura, Japan

P1.16-44 - Minute Ventilation-To-Carbon Dioxide Slope is Associated with Early and Long-Term Survivals Following Anatomical Pulmonary Resection

Takuro Miyazaki, Japan



P1.16-45 - Thoracoscopic Stapler-Based Complex Segmentectomy Assisted by Virtual Assisted Lung Mapping

Jun-ichi Nitadori, Japan

P1.16-46 - A Population-Based Validation Study of the Proposed 'R-Factor' Classification in a Lung Cancer-Endemic Region of the US.

Raymond Osarogiagbon, TN/USA

P1.16-47 - Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)

Geoffrey Oxnard, AL/USA

P1.16-48 - The Impact of Segmentectomy Versus Lobectomy on Pulmonary Function of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis

Guanping Qiu, China

P1.16-49 - Treatment of NSCLC Patients with Clinical N1 Disease: Is There an Advantage to Neoadjuvant Therapy?

Brendon Stiles, NY/USA

P1.16-50 - The Role of Adjuvant Therapy for Patients with Early Stage Large Cell Neuroendocrine Lung Cancer: A National Analysis

Vignesh Raman, USA

P1.16-51 - Preop Nutrition-Enhanced Recovery After Surgery Protocol for Thoracic Cancer Resections Decreases Hospital Days and Charges

Lary Robinson, FL/USA

P1.16-52 - Long-Term Impact of Postoperative Complications Following Lung Resection Among Patients with Non-Small Cell Lung Cancer

Shuichi Shinohara, Japan

P1.16-53 - County-Level Variations and Contributing Factors in Receipt of Surgery for Early-Stage Non-Small Cell Lung Cancer in the US

Raymond Osarogiagbon, TN/USA

P1.16-54 - The Significance of Multiple Lung Cancer Occurrence in Surgically-Treated Clinical Stage I Lung Cancer

Hiroshi Sugimura, Japan

P1.16-55 - Surgical Treatment for Lung Cancer. Subaortic (Para-Aortic) Lymph Nodes Involvement - N1 or N2 Disease?

Magdalena Szczesna, Poland



P1.16-56 - Prognostic Ability of New T1 Descriptors in the TNM Classification of Surgically Treated Non-Small Cell Lung Cancer

Tomoyoshi Takenaka, Japan

P1.16-57 - Outcomes of Pulmonary Resection in Elderly Non-Small Cell Lung Cancer Patient

Apichat Tantraworasin, Thailand

P1.16-58 - Hospital Lung Surgery Volume and Patient Outcomes in Victoria

Alesha Thai, Australia

P1.16-59 - A Phase II Study of Adjuvant Chemotherapy with Tegafur-Uracil for Vessel Invasion Positive Stage IA Non-Small Cell Lung Cancer (LOGIK0602)

Tomoshi Tsuchiya, Japan

P1.16-60 - A High Risk of Recurrence After the Resection of Lower Lobe Adenocarcinoma

Kazuhiro Ueda, Japan

P1.16-61 - Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Interim Analysis of Randomized Clinical Trial

Shi Yan, China

P1.16-62 - A Nomogram to Predict Disease-Free Survival After Curative Resection of Non-Small Cell Lung Cancer

Ziping Wang, China

P1.16-63 - The Value of Adjuvant Chemotherapy in Patients with Resected Stage IB Solid Predominant and Solid Non-Predominant Lung Adenocarcinoma

Shuhui Cao, China

P1.16-64 - The Histological Predominant Pattern Could Predict Site of Recurrence and Metastasis in Surgically Treated Stage I Adenocarcinoma of the Lung

Francesco Guerrera, Italy

P1.17

16:45 - 18:00

Treatment of Locoregional Disease - NSCLC

Exhibit Hall

P1.17-01 - Robustness of an Image-Based Data Mining Approach in Lung Cancer Patients

Alan McWilliam, UK



P1.17-02 - Low Prognostic Nutritional Index Predicts Poor Survival in Stage IIIB Non-Small Cell Lung Cancer Patients Treated with Chemoradiotherapy

Ali Besen, Turkey

P1.17-03 - Potential Associated SNPs by GWAS with Radiation Pneumonitis (RP) in Patients with Lung Cancer Treated with Radiotherapy

Lehui Du, China

P1.17-04 - Curative Intent Treatment for Stage III NSCLC in England

Susan Harden, UK

P1.17-05 - Accelerated Radiotherapy for Non-Small Cell Lung Cancer: A 12 Year Retrospective Review of Two Dose Fractionation Schedules

Matthew Hatton, UK

P1.17-06 - Salvage Surgery After Chemotherapy and/or Radiotherapy Including SBRT and Proton: Consecutive Analysis of 46 Patients

Aki Kobayashi, Japan

P1.17-07 - The Prognostic Value of Volumetric Changes of the GTV Measured on CBCT During Radiotherapy for CCRT in NSCLC Patients

Jose Belderbos, Netherlands

P1.17-08 - Genetic Predictors of Response to Chemoradiation in Stage III Non-Small-Cell Lung Cancer

Leo Luo, USA

P1.17-09 - V30 May Better Predict Radiation Pneumonitis After Intensity-Modulated Radiation Therapy for Lung Cancer

Yinnan Meng, China

P1.17-10 - Consolidation Chemotherapy in Stage III Non-Small Cell Lung Cancer: Still a Critical Piece of the Puzzle

Pranshu Mohindra, MD/USA

P1.17-11 - Pattern and Survival Impact of Neoadjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC) in a Prospective Lung Resection Cohort

Meredith Ray, USA

P1.17-12 - Colleague Peer Review of Radical Lung Radiotherapy Treatment Plans: The Impact on Interval from Decision to Treat to Treatment Delivery

Gerard Walls, UK



P1.17-13 - The Role of Post-Operative Radiation Therapy in Patients with Locally Advanced NSCLC after Nodal Down-Staging with Systemic Chemotherapy

Annemarie Shepherd, NJ/USA

P1.17-14 - Outcomes of Hypofractionated Radiation Therapy (HFRT) with Concurrent Chemotherapy in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC)

Annemarie Shepherd, NJ/USA

P1.17-15 - Perioperative Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers

Junichi Soh, Japan

P1.17-16 - Correlation of Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy with Pathological Complete Response of Lung Cancer

Shigeo Takahashi, Japan

P1.17-17 - The Impact of Induction Chemoradiotherapy Followed by Surgery for N1 Involved Non-Small Cell Lung Cancer

Yuta Takahashi, Japan

P1.17-18 - Treatment for Patients with T4 Superior Sulcus Non-Small Cell Lung Cancer: A Propensity-Matched Analysis of SEER Database

Min Fan, China

P1.17-19 - Correlation of Dosimetric and Clinical Factors with Radiation Pneumonitis in Lung Cancer Patients Received Involved-Field IMRT

Lehui Du, China

P1.17-20 - Excluding PTV From Lung Volume May Better Predict Radiation Pneumonitis for IMRT Treated Lung Cancer Patients

Yinnan Meng, China

ISS10

18:00 - 19:30	Symposium Supported by Boehringer Ingelheim: Overcoming Challenges in Thoracic Malignancies: Expert Insights	Plenary Hall
---------------	--	--------------

18:00 - 18:00	Overcoming Challenges in Thoracic Malignancies: Expert Insights	
---------------	---	--



19:30 - 22:30 **Faculty Dinner (By Invitation Only)** **By Invitation Only**

19:30 - 22:00 Faculty Dinner (By Invitation Only)

Tuesday, September 25, 2018

ISS11

07:00 - 08:00 **Symposium Supported by Pfizer: Future Options for ALK+ Metastatic NSCLC** **Room 105**

07:00 - 08:00 **Future Options for ALK+ Metastatic NSCLC**

ISS12

07:00 - 08:00 **Symposium Supported by Roche: Selecting the Right Cancer Immunotherapy Regimen for the Right Patient in First-line Lung Cancer** **Room 106**

07:00 - 08:00 **Selecting the Right Cancer Immunotherapy Regimen for the Right Patient in First-line Lung Cancer**

ISS13

07:00 - 08:00 **Symposium Supported by Medscape: Progress of the NSCLC Revolution: Questioning the Experts** **Room 107**

07:00 - 08:00 **Progress of the NSCLC Revolution: Questioning the Experts**

MTE11

07:00 - 08:00 **Biology of Small Cell Lung Cancer (Ticketed Session)** **Room 203 BD**
Topics: Biology

07:00 - 07:30 **MTE11.01 - Novel Therapeutic Targets in SCLC**
Julien Sage, CA/USA

07:30 - 08:00 **MTE11.02 - Biological Subsets of SCLC**
Charles Rudin, NY/USA



MTE12

07:00 - 08:00 **IO in the Real World - High Risk Populations and Patient Support (Ticketed Session)** **Room 206 AC**
Topics: Immunooncology

07:00 - 07:40 **MTE12.01 - Is IO an Option for Patients with Contraindications (Auto-immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)**
Andrew Robinson, Canada

07:40 - 08:00 **MTE12.02 - How can we Minimize Toxicity for our High-Risk Patients?**
Massey Nematollahi, Canada

MTE13

07:00 - 08:00 **Clonal Evolution and Targeted Therapy (Ticketed Session)** **Room 201 BD**
Topics: Targeted Therapy

07:00 - 07:30 **MTE13.01 - Clonal Evolution and Targeted Therapy**
Ramaswamy Govindan, MO/USA

07:30 - 08:00 **MTE13.02 - Clonal Evolution and Targeted Therapy**
Janessa Laskin, Canada

MTE14

07:00 - 08:00 **Nodule Management (Pro Con Debate and Case Presentations) (Ticketed Session)** **Room 206 F**
Topics: Screening and Early Detection

07:00 - 07:30 **MTE14.01 - Nodule Management (Pro Con Debate and Case Presentations)**
Stephen Lam, Canada

07:30 - 08:00 **MTE14.02 - Nodule Management (Pro Con Debate and Case Presentations)**
Matthijs Oudkerk, Netherlands

MTE15

07:00 - 08:00 **Who is Too High Risk for a VATS Resection? (Ticketed Session)** **Room 205 B**
Topics: Treatment of Early Stage/Localized Disease



07:00 - 07:30 **MTE15.01 - Identifying High Risk Patients: What Makes a Patient Too High Risk for Surgery and Who Decides?**

Hisao Asamura, Japan

07:30 - 08:00 **MTE15.02 - Who is Too High Risk for a VATS Resection?**

Pieter E Postmus, UK

MTE16

07:00 - 08:00 What Is Changing in the Management of Pulmonary Neuroendocrine Tumours? (Ticketed Session) Room 205 AC

Topics: Small Cell Lung Cancer/NET

07:00 - 07:30 **MTE16.01 - Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy**

Sumitra Thongprasert, Thailand

07:30 - 08:00 **MTE16.02 - The Management of Small Cell Lung Cancer following First Line Treatment Failure**

Glenwood Goss, ON/Canada

MTE17

07:00 - 08:00 Living with and Beyond Lung Cancer: An Education for Advocates (Ticketed Session) Room 206 BD

Topics: Advocacy

07:00 - 08:00 **MTE17.01 - Living with and Beyond Lung Cancer: An Education for Advocates**

Winfield Boerckel, NY/USA; Maureen Rigney, DC/USA

MTE18

07:00 - 08:00 Case-Based Management of Patients with Inadequate Tissue for Molecular Tests (Ticketed Session) Room 201 F

Topics: Advanced NSCLC

07:00 - 08:00 **MTE18.01 - Case-Based Management of Patients with Inadequate Tissue for Molecular Tests**

Benjamin Levy, NY/USA; Adrian Sacher, Canada



SH01

07:00 - 08:00	Highlight of the Previous Day Sessions Moderation: W. Eberhardt, Germany	Plenary Hall
----------------------	--	---------------------

07:00 - 07:12	SH01.01 - Radiation
---------------	---------------------

07:12 - 07:24	SH01.02 - Surgery
---------------	-------------------

07:24 - 07:36	SH01.03 - Access, Outcomes, Survivorship Viola Zhu, USA
---------------	--

07:36 - 07:48	SH01.04 - Advanced Lung Cancer
---------------	--------------------------------

07:48 - 08:00	SH01.05 - Q&A
---------------	---------------

SH02

07:00 - 08:00	Highlight of the Previous Day Sessions Moderation: B. Melosky, Canada; N. Van Zandwijk, Australia	Room 202 BD
----------------------	---	--------------------

07:00 - 07:12	SH02.01 - Targeted tx
---------------	-----------------------

07:12 - 07:24	SH02.02 - Mesothelioma Anne Tsao, USA
---------------	--

07:24 - 07:36	SH02.03 - IO Gregory Riely, USA
---------------	------------------------------------

07:36 - 07:48	SH02.04 - Pathology/Biology/Diagnostics Rafael Rosell, Spain
---------------	---

07:48 - 08:00	SH02.05 - Q&A
---------------	---------------



PL02

08:15 - 09:45	Presidential Symposium - Top 5 Abstracts	Plenary Hall
	Topics: Advanced NSCLC, Mesothelioma, Screening and Early Detection, Small Cell Lung Cancer/NET, Treatment of Early Stage/Localized Disease Moderation: F. Shepherd, Canada; G. Scagliotti, Italy; M. Tsao, Canada	
08:15 - 08:25	PL02.01 - Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC Scott Antonia, FL/USA	
08:25 - 08:30	PL02.02 - Discussant - PL02.01 Everett Vokes, USA	
08:30 - 08:40	PL02.03 - Brigatinib vs Crizotinib in Patients with ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L) Ross Camidge, USA	
08:40 - 08:45	PL02.04 - Discussant - PL02.03 Fiona Blackhall, UK	
08:45 - 08:55	PL02.05 - Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial Harry De Koning, Netherlands	
08:55 - 09:00	PL02.06 - Discussant - PL02.05 John Field, UK	
09:00 - 09:10	PL02.07 - IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC Stephen Liu, DC/USA	
09:10 - 09:15	PL02.08 - Discussant - PL02.07 Natasha Leighl, ON/Canada	
09:15 - 09:25	PL02.09 - Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial Giorgio Scagliotti, Italy	
09:25 - 09:30	PL02.10 - Discussant - PL02.09 Ross Soo, Singapore	
09:30 - 09:45	PL02.11 - Q&A	



PR02

09:45 - 11:00	Press Conference	Plenary Hall
----------------------	-------------------------	---------------------

09:45 - 11:15	Press Conference	
---------------	------------------	--

EXH01

09:55 - 10:25	AstraZeneca Exhibit Showcase Session - The Visions and Science for Earlier Treatment	Exhibit Showcase Theater
----------------------	---	---------------------------------

09:55 - 10:10	EXH01.01 - Developing and Preparing for Earlier Treatments in Lung Cancer David Berman, USA	
---------------	---	--

10:10 - 10:25	EXH01.02 - Early Detection and Monitoring of Lung Cancer J Carl Barrett, MA/USA	
---------------	---	--

ES02

10:30 - 12:00	Quality Care in Lung Cancer Topics: Nursing and Allied Professionals Moderation: P. Labuc, UK; N. Nouriany, Canada	Room 206 BD
----------------------	---	--------------------

10:30 - 10:45	ES02.01 - Expanding PROs in Daily Practice Kahren White, NSW/Australia	
---------------	--	--

10:45 - 11:00	ES02.02 - PRO: To Medicate: Managing Breathlessness Alexandre Chan, Singapore	
---------------	---	--

11:00 - 11:15	ES02.03 - CON: Not to Medicate: Managing Breathlessness Catherine Granger, Australia	
---------------	--	--

11:15 - 11:30	ES02.04 - Molecular Testing 101 for Nurses Beth Eaby-Sandy, PA/USA	
---------------	--	--



11:30 - 11:45 **ES02.05 - Structured Approach for Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer**
Andrea Serena, Switzerland

11:45 - 12:00 **ES02.06 - Q&A**

GR01

10:30 - 12:00 Thymic Malignancies Tumor Board **Room 206 F**
Topics: Thymoma/Other Thoracic Malignancies
Moderation: V. Fang, China; G. Giaccone, USA

10:30 - 10:45 **GR01.01 - Pathology**
Anja Roden, MN/USA

10:45 - 11:00 **GR01.02 - Surgical Oncology**
Pier Luigi Filosso, Italy

11:00 - 11:15 **GR01.03 - Surgical Oncology**
David Waller, UK

11:15 - 11:30 **GR01.04 - Medical Oncology**
Nicolas Girard, France

11:30 - 11:45 **GR01.05 - Radiation Oncology**
Anthony Brade, Canada

11:45 - 12:00 **GR01.06 - Discussion**

MA10

10:30 - 12:00 Considerations in Immunotherapy / Real World **Room 105**
Topics: Advanced NSCLC, Treatment in the Real World - Support, Survivorship, Systems Research
Moderation: K. Jao, Canada; R. Juergens, Canada

10:30 - 10:35 **MA10.01 - Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters**
Xabier Mielgo-Rubio, Spain



- 10:35 - 10:40 **MA10.02 - Impact of Antibiotics on Outcome of Metastatic Non Small Cell Lung Cancer Patients Treated with Immunotherapy**
Giulia Galli, Italy
- 10:40 - 10:45 **MA10.03 - Plasmatic Evaluation of the Intestinal Barrier and Blood Microbiota, and Antibiotic Use in Non-Small Cell Lung Cancer Patients Treated with Nivolumab**
Etienne Giroux Leprieur, France
- 10:45 - 11:00 **MA10.04 - Discussant - MA 10.01, MA 10.02, MA 10.03**
Bertrand Routy, Canada
- 11:00 - 11:05 **MA10.05 - Effect of Early Steroids use in Advanced NSCLC Patients Treated with Immunotherapy**
Giovanni Fucà, Italy
- 11:05 - 11:10 **MA10.06 - Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab**
Biagio Ricciuti, Italy
- 11:10 - 11:25 **MA10.07 - Discussant - MA 10.05, MA 10.06**
Kenneth O'Byrne, ACT/Australia
- 11:25 - 11:30 **MA10.08 - Choice of Taxane and Outcomes in the KEYNOTE-407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC**
Balazs Halmos, NY/USA
- 11:30 - 11:35 **MA10.09 - NECPAL 2: A Multicentre Descriptive Study of Primary and Continuous Attention in Palliative Care in Argentina: Lung Cancer Cohort**
Carolina Gabay, Argentina
- 11:35 - 11:40 **MA10.10 - Lung Cancer Stigma: A Ten-Year View of Patient, Provider, and Public Attitudes About Lung Cancer.**
Jennifer King, DC/USA
- 11:40 - 11:55 **MA10.11 - Discussant - MA 10.08, MA 10.09, MA 10.10**
Antoinette Wozniak, USA
- 11:55 - 12:00 **MA10.12 - Q&A**



MA11

Time	Topic	Room
10:30 - 12:00	Biomarkers of IO Response Topics: Immunooncology Moderation: G.B. Kanakasetty, India; S. Gadgeel, USA	Room 203 BD
10:30 - 10:35	MA11.01 - Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion Jordan Dozier, USA	
10:35 - 10:40	MA11.02 - Increased CD3+ TIL Infiltration and Low FOXP3+/CD8+ TIL Ratio Can Predict Anti-PD-1 Therapeutic Response in Non-Small Cell Lung Cancer Patients Hyojin Kim, Republic of Korea	
10:40 - 10:45	MA11.03 - Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Xiangxue Wang, OH/USA	
10:45 - 11:00	MA11.04 - Discussant - MA 11.01, MA 11.02, MA 11.03 Donald Morris, AB/Canada	
11:00 - 11:05	MA11.05 - Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact Francesco Agustoni, USA	
11:05 - 11:10	MA11.06 - Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression Luis Montuenga, Spain	
11:10 - 11:15	MA11.07 - Expression of LAG-3 and NY-ESO-1 In Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD-1 Blockade in Advanced NSCLC Hee Ryeong Jang, Korea, Republic of	
11:15 - 11:30	MA11.08 - Discussant - MA 11.05, MA 11.06, MA 11.07 Erin Schenk, MN/USA	
11:30 - 11:35	MA11.09 - Single-Cell Characterization of the Immunologic Microenvironment in Advanced-Stage, Oncogene-Driven NSCLC Julia Rotow, USA	



- 11:35 - 11:40 **MA11.10 - Identification of Mismatch Repair Deficient Lung Adenocarcinomas Using Targeted Next-Generation Sequencing**
Navin Mahadevan, MA/USA
- 11:40 - 11:45 **MA11.11 - Discrepancy of Tumor Neoantigen Burden Between Primary Lesions and Matched Metastases in Lung Cancer**
Tao Jiang, China
- 11:45 - 12:00 **MA11.12 - Discussant - MA 11.09, MA 11.10, MA 11.11**
Ignacio Gil-Bazo, Spain

MA12

- | | | |
|---------------|--|-------------|
| 10:30 - 12:00 | Mesothelioma Surgery and Novel Targets for Prognosis and Therapy
Topics: Mesothelioma
Moderation: G. Zalcman, France; C. Pepe, Canada | Room 202 BD |
|---------------|--|-------------|
- 10:30 - 10:35 **MA12.01 - The Information Pathway to Randomisation: Patients Experience of the Mesothelioma and Radical Surgery (MARS2) Feasibility Trial**
Angela Tod, UK
- 10:35 - 10:40 **MA12.02 - Quality of Life Following Pleurectomy Decortication and Extrapleural Pneumonectomy for Pleural Malignant Mesothelioma**
Wil Lieberman-Cribbin, USA
- 10:40 - 10:45 **MA12.03 - The Impact of Malignant Pleural Mesothelioma Histology on the Use of Surgery and Survival in a Population-Based Analysis**
Chi-Fu Yang, NC/USA
- 10:45 - 11:00 **MA12.04 - Discussant - MA 12.01, MA 12.02, MA 12.03**
Marc De Perrot, Canada
- 11:00 - 11:05 **MA12.05 - Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma**
Dean Fennell, UK
- 11:05 - 11:10 **MA12.06 - STELLAR - Final Results of a Phase 2 Trial of TTFIELDS with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma**
Giovanni Ceresoli, Italy



- 11:10 - 11:15 **MA12.07 - gC1qR Expression is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma**
Xiaoyu Li, NY/USA
- 11:15 - 11:30 **MA12.08 - Discussant - MA 12.05, MA 12.06, MA 12.07**
Quincy Chu, Canada
- 11:30 - 11:35 **MA12.09 - Preclinical Investigations of Folate Receptor Targeted Nanoparticles for Photodynamic Therapy of Malignant Pleural Mesothelioma**
Tatsuya Kato, ON/Canada
- 11:35 - 11:40 **MA12.10 - Long-Term Impact of Radiotherapy Before Surgery for Mesothelioma on the Distribution of Memory T Cell Subsets**
Junichi Murakami, Japan
- 11:40 - 11:45 **MA12.11 - Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort**
Puey Ling Chia, Australia
- 11:45 - 12:00 **MA12.12 - Discussant - MA 12.09, MA 12.10, MA 12.11**
Masaki Anraku, Japan

MA13

- | | | |
|----------------------|---|--------------------|
| 10:30 - 12:00 | Interventional Pulmonology
Topics: Interventional Diagnostics/Pulmonology
Moderation: J. Agulnik, Canada; K. Fong, Australia | Room 206 AC |
|----------------------|---|--------------------|
- 10:30 - 10:35 **MA13.01 - CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays**
Kyongmin Beck, Republic of Korea
- 10:35 - 10:40 **MA13.02 - PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs**
Alexander Haragan, UK
- 10:40 - 10:45 **MA13.03 - Heterogeneity Analysis of EBUS-TBNA-Derived Specimens for Evaluation of PD-L1 Expression and Copy Number Alterations in Patients with NSCLC**
Katsuhiro Yoshimura, Japan



- 10:45 - 11:00 **MA13.04 - Discussant - MA 13.01, MA 13.02, MA 13.03**
John Gosney, UK
- 11:00 - 11:05 **MA13.05 - The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy**
Danielle Hylton, Canada
- 11:05 - 11:10 **MA13.06 - Endosonography with Lymph Nodes Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled-Data Analysis**
Long Jiang, China
- 11:10 - 11:15 **MA13.07 - Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer**
Antoni Rosell Gratacos, Spain
- 11:15 - 11:30 **MA13.08 - Discussant - MA 13.05, MA 13.06, MA 13.07**
Nicole Bouchard, Canada
- 11:30 - 11:35 **MA13.09 - Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions**
Sandeep Khandhar, VA/USA
- 11:35 - 11:40 **MA13.10 - Comparison of Pulmonary Nodule Location Between Preprocedural CT and Intra-Procedural Cone-Beam CT During Guided Bronchoscopy**
Michael Pritchett, NC/USA
- 11:40 - 11:45 **MA13.11 - Photodynamic Therapy for Peripheral-Type Lung Cancer in a Multi-Center Clinical Trial**
Jitsuo Usuda, Japan
- 11:45 - 12:00 **MA13.12 - Discussant - MA 13.09, MA 13.10, MA 13.11**
Antoni Rosell, Spain

MA14

10:30 - 12:00	Survivorship, Socioeconomic and End-of-Life Considerations	Room 205 B
	Topics: Treatment in the Real World - Support, Survivorship, Systems Research Moderation: T. Owonikoko, USA; P.M. Schuffenegger, Canada	



- 10:30 - 10:35 **MA14.01 - Life Sustaining Procedures, Palliative Care and Hospital Cost Trends in Dying Lung Cancer Patients in U.S. Hospitals: 2005-2014**
Jinwook Hwang, Republic of Korea
- 10:35 - 10:40 **MA14.02 - Use and impact of a systematic advanced care planning in hospitalized lung cancer patients: a prospective study.**
Anne Claire Toffart, France
- 10:40 - 10:45 **MA14.03 - Aggressiveness of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey**
Olivier Bylicki, France
- 10:45 - 11:00 **MA14.04 - Discussant - MA 14.01, MA 14.02, MA 14.03**
Gouri Shankar Bhattacharyya, India
- 11:00 - 11:05 **MA14.05 - Social Isolation Increases Psychological Distress in Patients With NSCLC**
Bonnie Leung, BC/Canada
- 11:05 - 11:10 **MA14.06 - Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome**
Doreen Ezeife, Canada
- 11:10 - 11:15 **MA14.07 - The Impact of Socioeconomic Status and Geographic Location on Palliative Chemotherapy Uptake in Patients with Metastatic NSCLC**
Zamzam Al-Hashami, Canada
- 11:15 - 11:30 **MA14.08 - Discussant - MA 14.05, MA 14.06, MA 14.07**
Christos Chouaid, France
- 11:30 - 11:35 **MA14.09 - Mortality of Lung Cancer as a Second Primary Malignancy among Cancer Survivors: A Study of Surveillance, Epidemiology, and End Results Database**
Lei Deng, NY/USA
- 11:35 - 11:40 **MA14.10 - QTc Interval-Prolonging Medications in Lung Cancer: Implications for Clinical Trial Eligibility and Routine Clinical Care**
David Gerber, TX/USA
- 11:40 - 11:45 **MA14.11 - Factors Associated with Early Mortality in Non-Small Cell Lung Cancer Patients Following Systemic Anti-Cancer Treatment**
Amanda Gibson, Canada
- 11:45 - 12:00 **MA14.12 - Discussant - MA 14.09, MA 14.10, MA 14.11**



Amanda Tufman, Germany

MS13

10:30 - 12:00	Novel Mediators of Lung Cancer Metastasis Topics: Biology Moderation: O. Arrieta, Mexico; K.-K. Wong, USA	Room 201 F
----------------------	--	-------------------

10:30 - 10:45 **MS13.01 - Liquid Biopsy-mediated Identification of Metastatic Variants**
Philip Mack, CA/USA

10:45 - 11:00 **MS13.02 - Capicua Inactivation Drives Lung Cancer Metastasis**
Trever Bivona, CA/USA

11:00 - 11:15 **MS13.03 - Ubiquilin as a Novel Mediator of Lung Cancer Invasion and Metastasis**
Levi Beverly, USA

11:15 - 11:30 **MS13.04 - Tracking the Evolution of Non-Small-Cell Lung Cancer**
Charles Swanton, UK

11:30 - 11:45 **MS13.05 - Discussant**
David Beer, MI/USA

11:45 - 12:00 **MS13.06 - Q&A**

MS14

10:30 - 12:00	IO in Early Stage NSCLC Topics: Immunooncology Moderation: M. Kris, USA	Room 107
----------------------	--	-----------------

10:30 - 10:45 **MS14.01 - Basic Science Rationale of IO in Early Stage NSCLC?**
Johan Vansteenkiste, Belgium

10:45 - 11:00 **MS14.02 - Adjuvant / Neoadjuvant IO Therapy**
Julie Brahmer, MD/USA

11:00 - 11:15 **MS14.03 - Concerns About IO for the Thoracic Surgeon?**



Bernward Passlick, Germany

11:15 - 11:30

MS14.04 - IO - New Standards in Stage III NSCLC

Rafal Dziadziuszko, Poland

11:30 - 11:45

MS14.05 - Do Biomarkers used in Metastatic Setting Apply in Earlier Stages

Naiyer Rizvi, NY/USA

11:45 - 12:00

MS14.06 - Q&A

MS15

10:30 - 12:00

Disruptive Technology and Lung Cancer Risk

Room 201 BD

Topics: Prevention and Tobacco Control
Moderation: E. Bedard, Canada; D. Arenberg, USA

10:30 - 10:45

MS15.01 - Just Water Vapor? Toxicology Perspectives on Electronic Cigarettes

Maciej Goniewicz, USA

10:45 - 11:00

MS15.02 - PRO- Electronic Cigarettes: A Cessation Tool

K Michael Cummings, SC/USA

11:00 - 11:15

MS15.03 - CON- Electronic Cigarettes: Not Evidence Based Cessation

Alison Wallace, Canada

11:15 - 11:30

MS15.04 - The Rise of Heat-Not Burn Tobacco in Japan: A “Hot” Issue for Tobacco Control

Junji Yoshida, Japan

11:30 - 11:45

MS15.05 - Heat-Not-Burn Tobacco: Real Risk Reduction or Industry’s Next Promise

Carolyn Dresler, MD/USA

11:45 - 12:00

MS15.06 - Q&A

OA10

10:30 - 12:00

Right Patient, Right Target & Right Drug - Novel Treatments and Research Partnerships

Room 106



Topics: Targeted Therapy
Moderation: H. West, USA; J. Patel, USA

- 10:30 - 10:40 **OA10.01 - Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC**
John Bridges, USA
- 10:40 - 10:50 **OA10.02 - Oncogene-Driven Patient Groups: A New Era for Research Partnerships**
Janet Freeman-Daily, WA/USA
- 10:50 - 11:05 **OA10.03 - Discussant - OA 10.01, OA 10.02**
Zosia Piotrowska, MA/USA
- 11:05 - 11:15 **OA10.04 - Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403**
Sarah Goldberg, CT/USA
- 11:15 - 11:25 **OA10.05 - An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation (KCSG-LU15-09)**
Jang Ho Cho, Republic of Korea
- 11:25 - 11:35 **OA10.06 - A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)**
Keunchil Park, Republic of Korea
- 11:35 - 11:45 **OA10.07 - Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial**
Caicun Zhou, China
- 11:45 - 12:00 **OA10.08 - Discussant - OA 10.04, OA 10.05, OA 10.06, OA 10.07**
Linda Coate, Ireland

PC05

- 10:30 - 12:00 Optimizing Clinical Trial Design in NSCLC** Room 205 AC
Topics: Advanced NSCLC
Moderation: P. Garrido, Spain; L. Ubillos, Uruguay
- 10:30 - 10:45 **PC05.01 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: PFS**
Mary O'Brien, UK



10:45 - 11:00	PC05.02 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: OS Yu Shyr, TN/USA
11:00 - 11:05	PC05.03 - Discussion
11:05 - 11:20	PC05.04 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - YES Maurice Pérol, France
11:20 - 11:35	PC05.05 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - NO Rathi Pillai, USA
11:35 - 11:40	PC05.06 - Discussion
11:40 - 11:50	PC05.07 - Let's Not Forget Chemo-Regret Patricia Hollen, USA
11:50 - 12:00	PC05.08 - Discussion

ISS14

12:00 - 13:30	Symposium Supported by Novartis: Expert Perspectives on the Management of NSCLC in Clinical Practice: Are Novel Approaches Realistic?	Plenary Hall
12:00 - 13:30	Expert Perspectives on the Management of NSCLC in Clinical Practice: Are Novel Approaches Realistic?	

MA15

13:30 - 15:00	Colliding Approaches - EGFR and Immunotherapy Topics: Targeted Therapy Moderation: H. Wakelee, USA; N. Rizvi, USA	Room 107
---------------	--	----------



- 13:30 - 13:35 **MA15.01 - Strong PD-L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among Non-Small Cell Lung Cancer Patients with EGFR Mutation**
Shan Su, China
- 13:35 - 13:40 **MA15.02 - Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC**
Charles Rudin, NY/USA
- 13:40 - 13:45 **MA15.03 - PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial**
Suresh Ramalingam, USA
- 13:45 - 14:00 **MA15.04 - Discussant - MA 15.01, MA 15.02, MA 15.03**
Adrian Sacher, Canada
- 14:00 - 14:05 **MA15.05 - The Mutational Profiles of EGFR 19 Exon Deletion and 21 Exon L858R Mutation and Their Association with Primary Response to EGFR-TKIs**
Wenhua Liang, China
- 14:05 - 14:10 **MA15.06 - Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010**
Yi-Chen Zhang, China
- 14:10 - 14:15 **MA15.07 - Different Responses to Osimertinib in Primary and Acquired EGFR T790M-Mutant NSCLC Patients**
Shuyuan Wang, China
- 14:15 - 14:30 **MA15.08 - Discussant - MA 15.05, MA 15.06, MA 15.07**
Charu Aggarwal, PA/USA
- 14:30 - 14:35 **MA15.09 - Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs**
Chunxia Su, China
- 14:35 - 14:40 **MA15.10 - Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M**
Sha Zhao, China
- 14:40 - 14:45 **MA15.11 - Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR-TKIs**
Anne Chiang, CT/USA



14:45 - 15:00 **MA15.12 - Discussant - MA 15.09, MA 15.10, MA 15.11**
Joel Neal, CA/USA

MA16

13:30 - 15:00 Novel Mechanisms for Molecular Profiling **Room 203 BD**
Topics: Advanced NSCLC
Moderation: M. Tehfe, Canada; M. Nishio, Japan

- 13:30 - 13:35 **MA16.01 - Frequency and Genomic Context of Emerging Markers for Molecular Testing in Lung Adenocarcinoma in Cell-Free DNA NGS Analysis**
Vincent Lam, TX/USA
- 13:35 - 13:40 **MA16.02 - Prospective Clinical Validation of the InVisionFirst™ ctDNA Assay for Molecular Profiling of Patients with Advanced NSCLC**
Ramaswamy Govindan, MO/USA
- 13:40 - 13:55 **MA16.03 - Discussant - MA 16.01, MA 16.02**
Geoffrey Oxnard, AL/USA
- 13:55 - 14:00 **MA16.04 - Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations.**
Michael Offin, NY/USA
- 14:00 - 14:05 **MA16.05 - MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)**
Sai-Hong Ou, CA/USA
- 14:05 - 14:10 **MA16.06 - EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non-Small Cell Lung Cancer (NSCLC)**
Xinghao Ai, China
- 14:10 - 14:25 **MA16.07 - Discussant - MA 16.04, MA 16.05, MA 16.06**
Ben Solomon, ACT/Australia
- 14:25 - 14:30 **MA16.08 - Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma**
Ibiayi Dagogo-Jack, MA/USA
- 14:30 - 14:35 **MA16.09 - Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer**
Aurélie Swalduz, France



- 14:35 - 14:40 **MA16.10 - Clinical Utility of Cerebrospinal Fluid Cell-Free DNA for Clarifying Genetic Features of Leptomeningeal Metastases in ALK Rearrangement NSCLC**
Meimei Zheng, China
- 14:40 - 14:55 **MA16.11 - Discussant - MA 16.08, MA 16.09, MA 16.10**
Robert Doebele, CO/USA
- 14:55 - 15:00 **MA16.12 - Q&A**

MA17

- | | | |
|----------------------|---|--------------------|
| 13:30 - 15:00 | New Methods to Improve Lung Cancer Patients Outcomes
Topics: Nursing and Allied Professionals
Moderation: M. Nematollahi, Canada; R. Navon, Israel | Room 205 AC |
|----------------------|---|--------------------|
- 13:30 - 13:35 **MA17.01 - A Sense of Understanding and Belonging When Life Is at Stake - Operable Lung Cancer Patients' Lived Experiences of Participation in Exercise**
Malene Missel, Denmark
- 13:35 - 13:40 **MA17.02 - Early Accrual to a Precision Lung Cancer Survivorship Intervention: The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program**
Jamie Studts, USA
- 13:40 - 13:45 **MA17.03 - Shared Decision-Making for Patients with Advanced Non-Small Cell Lung Cancer**
Mette Jensen, Denmark
- 13:45 - 14:00 **MA17.04 - Discussant - MA 17.01, MA 17.02, MA 17.03**
Anne Fraser, New Zealand
- 14:00 - 14:05 **MA17.05 - Development of a Telephone Clinic for Patients Undergoing Long Term Follow-Up After Thoracic Surgery**
Jenny Mitchell, UK
- 14:05 - 14:10 **MA17.06 - The Specialist Lung Cancer Nurse and Self-Management for People Living with Lung Cancer: A Model of Engagement**
Vanessa Brunelli, Australia
- 14:10 - 14:15 **MA17.07 - Nurse-Led Telehealth Clinic in Treatment Monitoring and Follow Up**
Sarah Cubbin, UK



- 14:15 - 14:30 **MA17.08 - Discussant - MA 17.05, MA 17.06, MA 17.07**
Melissa Culligan, PA/USA
- 14:30 - 14:35 **MA17.09 - Remote Symptom Reporting for Tele-Nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement**
Simranjit Kooner, Canada
- 14:35 - 14:40 **MA17.10 - The Use of Technology in the Delivery of Supportive Care of Lung Cancer Patients After Treatment**
Pamela Rose, UK
- 14:40 - 14:45 **MA17.11 - Multi-Centred, Prospective, Audit to Identify Readmission Causes and Complications Within 30 of Primary Lung Cancer Surgery**
Amy Kerr, UK
- 14:45 - 15:00 **MA17.12 - Discussant - MA 17.09, MA 17.10, MA 17.11**
Mary Duffy, Australia

MA18

- | | | |
|----------------------|---|-------------------|
| 13:30 - 15:00 | Modelling, Decision-Making and Population-Based Outcomes
Topics: Treatment in the Real World - Support, Survivorship, Systems Research
Moderation: F. Moraes, Brazil; A. Louie, Canada | Room 201 F |
|----------------------|---|-------------------|
- 13:30 - 13:35 **MA18.01 - Non-Small Cell Lung Cancer Risk Assessment with Artificial Neural Networks**
Tafadzwa Chaunzwa, MA/USA
- 13:35 - 13:40 **MA18.02 - The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation**
Manjusha Hurry, Canada
- 13:40 - 13:45 **MA18.03 - How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience**
William Evans, ON/Canada
- 13:45 - 14:00 **MA18.04 - Discussant - MA 18.01, MA 18.02, MA 18.03**
Shalini Vinod, Australia
- 14:00 - 14:05 **MA18.05 - Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment**



Michael Bergqvist, Sweden

- 14:05 - 14:10 **MA18.06 - Patterns of Lung Cancer Care in the United States: Developments and Disparities**
Erik Blom, Netherlands
- 14:10 - 14:15 **MA18.07 - Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors**
Lawson Eng, ON/Canada
- 14:15 - 14:30 **MA18.08 - Discussant - MA 18.05, MA 18.06, MA 18.07**
Vera Hirsh, Canada
- 14:30 - 14:35 **MA18.09 - Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC.**
Shirley Jiang, Canada
- 14:35 - 14:40 **MA18.10 - Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool**
David Gandara, CA/USA
- 14:40 - 14:45 **MA18.11 - Implementing a Comprehensive National Audit of Lung Cancer Surgery: The English Lung Cancer Clinical Outcomes Publication (LCCOP) Project**
Doug West, UK
- 14:45 - 15:00 **MA18.12 - Discussant - MA 18.09, MA 18.10, MA 18.11**
Martin Stockler, Australia

MS16

- | | | |
|---------------|---|------------|
| 13:30 - 15:00 | Implementation of Lung Cancer Screening
Topics: Screening and Early Detection
Moderation: G. Nicholas, Canada; H. Groen, Netherlands | Room 206 F |
|---------------|---|------------|
- 13:30 - 13:45 **MS16.01 - CMS Approved ACR Lung Cancer Screening Registry in the United States**
Ella Kazerooni, USA
- 13:45 - 14:00 **MS16.02 - NELCIN B3 Screening Program in China**
Qinghua Zhou, China
- 14:00 - 14:15 **MS16.03 - Recruitment Strategies for the Lung Cancer Screening**
Gail Darling, Canada



- 14:15 - 14:30 **MS16.04 - National Lung Screening Program in Taiwan**
Pan-Chyr Yang, Taiwan
- 14:30 - 14:45 **MS16.05 - Optimal Approach to Integrate Smoking Cessation into Screening Program**
Matthew Callister, UK
- 14:45 - 15:00 **MS16.06 - Q&A**

MS17

13:30 - 15:00 **Life After Lung Cancer: Survivorship** **Room 206 AC**
Topics: Treatment in the Real World - Support, Survivorship, Systems Research
Moderation: D. Dawe, Canada; J. Gray, USA

- 13:30 - 13:45 **MS17.01 - Unmet needs and QOL of Lung Cancer Survivors**
Meredith Giuliani, AB/Canada
- 13:45 - 14:00 **MS17.02 - Financial Toxicity and Out of Pocket Costs**
Bishal Gyawali, MA/USA
- 14:00 - 14:15 **MS17.03 - Surveillance & Second Primary Malignancies in Lung Cancer Survivors**
Virginie Westeel, France
- 14:15 - 14:30 **MS17.04 - How Important Is Tobacco Cessation as Part of Lung Cancer Treatment?**
Clarissa Baldotto, Brazil
- 14:30 - 15:00 **MS17.05 - Discussion**

MS18

13:30 - 15:00 **Management of SCLC Patients Not Represented in Clinical Trials** **Room 206 BD**
Topics: Small Cell Lung Cancer/NET
Moderation: J. Wang, China; E. Vokes, USA

- 13:30 - 13:50 **MS18.01 - Treatment of Patients with Poor Performance Status (ECOG 3-4)**
Luiz H Araujo, Brazil



- 13:50 - 14:10 **MS18.02 - Treatment of Elderly Patients with SCLC**
Karen Kelly, CA/USA
- 14:10 - 14:30 **MS18.03 - Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma**
Nicolas Marcoux, USA
- 14:30 - 14:50 **MS18.04 - Retreatment with Platinum and Etoposide and Treatment Beyond Second Line**
Charles Butts, Canada
- 14:50 - 15:00 **MS18.05 - Q&A**

MS19

- 13:30 - 15:00 Pulmonary Dilemmas with Immunotherapy** Room 201 BD
Topics: Interventional Diagnostics/Pulmonology
Moderation: S. Andarini, Indonesia; L. Raez, USA
- 13:30 - 13:50 **MS19.01 - Drug-Induced Pneumonitis with IO: How worried should we be for our Lung Cancer Patients**
Desiree Hao, AB/Canada
- 13:50 - 14:10 **MS19.02 - What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence**
Chong-Kin Liam, Malaysia
- 14:10 - 14:30 **MS19.03 - Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiopsy for TT Progression**
Kasia Czarnecka-Kujawa, Canada
- 14:30 - 15:00 **MS19.04 - Q&A**

OA11

- 13:30 - 15:00 Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy** Room 205 B
Topics: Thymoma/Other Thoracic Malignancies
Moderation: M. Taremi, Canada; Y. Shargall, Canada



- 13:30 - 13:40 **OA11.01 - Role of Post-Operative Radiation in Different Histologic Subgroups of Thymoma: Result Based on National Cancer Data Base (NCDB)**
Tithi Biswas, OH/USA
- 13:40 - 13:50 **OA11.02 - A Population-Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies: Results from the California Cancer Registry**
David Benjamin, USA
- 13:50 - 14:05 **OA11.03 - Discussant - OA 11.01, OA 11.02**
Andrew Hope, Canada
- 14:05 - 14:15 **OA11.04 - A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma**
Tadashi Sakane, Japan
- 14:15 - 14:25 **OA11.05 - Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)**
Se Hyun Kim, Republic of Korea
- 14:25 - 14:35 **OA11.06 - Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma**
Nathan Kuehne, ON/Canada
- 14:35 - 14:50 **OA11.07 - Discussant - OA 11.04, OA 11.05, OA 11.06**
Giuseppe Giaccone, OR/USA
- 14:50 - 15:00 **OA11.08 - Q&A**

PC06

- 13:30 - 15:00 Controversies in Immunobiomarker Testing** **Room 106**
Topics: Pathology
Moderation: C. Couture, Canada; E. Thunnissen, Netherlands
- 13:30 - 13:50 **PC06.01 - Laboratory Developed Test - PRO**
Dara Aisner, CO/USA
- 13:50 - 14:10 **PC06.02 - Laboratory Developed Test - CON**
Mari Mino-Kenudson, MA/USA
- 14:10 - 14:30 **PC06.03 - Tumor Mutation Burden - PRO**
Lynette Sholl, USA

14:30 - 14:50 **PC06.04 - Tumor Mutation Burden - CON**
Lukas Bubendorf, Switzerland

14:50 - 15:00 **PC06.05 - Q&A**

PC07

13:30 - 15:00 **The Future of Cytotoxic Chemotherapy in Advanced NSCLC** **Room 202 BD**
Topics: Advanced NSCLC
Moderation: S. Brule, Canada; T. Kato, Japan

13:30 - 13:50 **PC07.01 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - For**
Suresh Ramalingam, USA

13:50 - 14:10 **PC07.02 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - Against**
Keunchil Park, Republic of Korea

14:10 - 14:30 **PC07.03 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - IO alone**
Leora Horn, USA

14:30 - 14:50 **PC07.04 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO**
Federico Cappuzzo, Italy

14:50 - 15:00 **PC07.05 - Q&A**

PC08

13:30 - 15:00 **The Great Oligometastatic Debates** **Room 105**
Topics: Oligometastatic NSCLC
Moderation: S. Harrow, USA; M. Johnson, USA

13:30 - 13:40 **PC08.01 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastases (PRO)**
Howard (Jack) West, WA/USA



- 13:40 - 13:50 **PC08.02 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (CON)**
Puneeth Iyengar, USA
- 13:50 - 14:00 **PC08.03 - Discussion**
- 14:00 - 14:10 **PC08.04 - Debate #2: Optimal Therapy for OM Disease: Thoracic Surgery Should Be the Treatment of Choice Whenever Possible**
David Jones, USA
- 14:10 - 14:20 **PC08.05 - Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery**
Matthias Guckenberger, Switzerland
- 14:20 - 14:30 **PC08.06 - Discussion**
- 14:30 - 14:40 **PC08.07 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (PRO)**
Mark Doherty, Canada
- 14:40 - 14:50 **PC08.08 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (CON)**
Marta Scorsetti, Italy
- 14:50 - 15:00 **PC08.09 - Discussion**

ES03

- 15:15 - 16:45** **How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy** **Room 206 AC**
Topics: Mesothelioma
Moderation: R. Stahel, Switzerland; M. De Perrot, Canada
- 15:15 - 15:30 **ES03.01 - Diagnosis of Mesothelioma Based on Cytology Alone**
Jennifer Sauter, NY/USA
- 15:30 - 15:45 **ES03.02 - Role of CT Scan to Follow Pleural Plaques**
Demetris Patsios, Canada
- 15:45 - 16:00 **ES03.03 - When to Repeat Pleural Biopsies**



Catherine Labbe, Canada

16:00 - 16:15 **ES03.04 - Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease**

Christopher Lee, Canada

16:15 - 16:30 **ES03.05 - Role of Surgery in T0 Mesothelioma**

Seiki Hasegawa, Japan

16:30 - 16:45 **ES03.06 - Q&A**

ES04

15:15 - 16:45 Liquid Biopsies in Lung Cancer Room 203 BD

Topics: Targeted Therapy
Moderation: S.-H. Ou, USA; I. Wistuba, USA

15:15 - 15:35 **ES04.01 - Liquid Biopsies in Lung Cancer**

Ming Tsao, Canada

15:35 - 15:55 **ES04.02 - Mechanisms of Resistance to Targeted Therapy**

Christine Lovly, TN/USA

15:55 - 16:15 **ES04.03 - Overcoming Resistance by Improving Treatment Compliance**

Felipe Gomes, Brazil

16:15 - 16:35 **ES04.04 - Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)**

Enriqueta Felip, Spain

16:35 - 16:45 **ES04.05 - Q&A**

ES05

15:15 - 16:45 Collaboration Between Stakeholders to Improve Lung Cancer Research Room 205 AC

Topics: Advocacy
Moderation: B. Addario, USA; T. Sawa, Japan

15:15 - 15:35 **ES05.01 - Linking the Stakeholders: Can Patient Groups, Clinical Researchers and the Pharmaceutical Industry Collaborate to Accelerate Research?**

Janet Freeman-Daily, USA



- 15:35 - 15:55 **ES05.02 - Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?**
Andrea Ferris, USA
- 15:55 - 16:15 **ES05.03 - Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice**
Jesme Fox, UK
- 16:15 - 16:35 **ES05.04 - Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada**
Christina Sit, Canada
- 16:35 - 16:45 **ES05.05 - Q&A**

GR02

- | | | |
|---------------|---|-----------------|
| 15:15 - 16:45 | Management of N2 NSCLC - A Case Based Discussion
Topics: Treatment of Locoregional Disease - NSCLC
Moderation: T. Grodzki, Poland; L. Coate, Ireland | Room 107 |
|---------------|---|-----------------|
- 15:15 - 15:25 **GR02.01 - Case 1: Single Zone N2 (No Pneumonectomy Necessary)**
Anna Wrona, Poland
- 15:25 - 15:45 **GR02.02 - Panel Discussion**
David Harpole, AL/USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA
- 15:45 - 15:55 **GR02.03 - Case 2: Multiple N2 Bulky Primary**
Megan Daly, CA/USA
- 15:55 - 16:15 **GR02.04 - Panel Discussion**
David Harpole, AL/USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA
- 16:15 - 16:25 **GR02.05 - Case 3: Post Operative Management of Incidentally Found N2 Disease**
Masaya Yotsukura, Japan
- 16:25 - 16:45 **GR02.06 - Panel Discussion**



David Harpole, AL/USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA

MA19

15:15 - 16:45	Genomic Markers of IO Response	Room 201 BD
	Topics: Immunooncology Moderation: R. Rosell, Spain; P. Cheema, Canada	
15:15 - 15:20	MA19.01 - Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes Natalie Vokes, USA	
15:20 - 15:25	MA19.02 - Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples Anne-Marie Boothman, UK	
15:25 - 15:40	MA19.03 - Discussant - MA 19.01, MA 19.02 Jonathan W Goldman, USA	
15:40 - 15:45	MA19.04 - The Clinical Implication of Frameshift Indel Mutation Burden in Non-Small Cell Lung Cancer (NSCLC) Young Kwang Chae, USA	
15:45 - 15:50	MA19.05 - Difference of Tumor Mutational Burden Is Associated with Distinct Immune Microenvironment in the T Cell-Inflamed Lung Adenocarcinoma Takahiro Karasaki, Japan	
15:50 - 15:55	MA19.06 - Blood Based Biomarkers: RNA, KRAS and PD-L1 Strongly Matching with Tissue and Showing Correlation with Clinical Responses in NSCLC Patient's Luis Raez, FL/USA	
15:55 - 16:10	MA19.07 - Discussant - MA 19.04, MA 19.05, MA 19.06 Claudia Poleri, Argentina	
16:10 - 16:15	MA19.08 - Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC Joachim Aerts, Netherlands	
16:15 - 16:20	MA19.09 - Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB Kathryn Arbour, NY/USA	



- 16:20 - 16:25 **MA19.10 - Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC**
Ferdinandos Skoulidis, TX/USA
- 16:25 - 16:40 **MA19.11 - Discussant - MA 19.08, MA 19.09, MA 19.10**
Lynette Sholl, USA
- 16:40 - 16:45 **MA19.12 - Q&A**

MA20

- | | | |
|----------------------|---|-------------------|
| 15:15 - 16:45 | Implementation of Lung Cancer Screening
Topics: Screening and Early Detection
Moderation: S. Lam, Canada; C. Berg, USA | Room 206 F |
|----------------------|---|-------------------|
- 15:15 - 15:20 **MA20.01 - Lung Cancer Screenee Selection by USPSTF versus PLCOm2012 Criteria - Preliminary ILST Findings**
Martin Tammemägi, Canada
- 15:20 - 15:25 **MA20.02 - “Reduced” HUNT Lung Cancer Model for Predicting Lung Cancer in the Prospective Danish Lung Cancer Screening Study - Comparison with the NLST.**
Oluf Røe, Norway
- 15:25 - 15:30 **MA20.03 - Surprising Implications of Proposed Risk-Thresholds for Selecting US Ever-Smokers into CT Lung-Cancer Screening**
Hormuzd Katki, MD/USA
- 15:30 - 15:45 **MA20.04 - Discussant - MA 20.01, MA 20.02, MA 20.03**
Amanda Tufman, Germany
- 15:45 - 15:50 **MA20.05 - Who Gets Screened for Lung Cancer? A Simple Adjustment to Current Guidelines to Reduce Racial Disparities**
Melinda Aldrich, USA
- 15:50 - 15:55 **MA20.06 - Lung Cancer Screening Pilot for People at High Risk: Early Results on Cancer Detection and Staging**
Martin Tammemagi, Canada
- 15:55 - 16:00 **MA20.07 - Lung Cancer Screening for Limited-Resource Patients: Preliminary Findings from a Low-dose CT Pilot Program**



Lesley Watson, USA

16:00 - 16:15

MA20.08 - Discussant - MA 20.05, MA 20.06, MA 20.07

Annette McWilliams, Australia

16:15 - 16:20

MA20.09 - Improved Lung Cancer and Mortality Prediction Accuracy Using Survival Models Based on Semi-Automatic CT Image Measurements

Anton Schreuder, Netherlands

16:20 - 16:25

MA20.10 - Lung Cancer Prediction Using Deep Learning Software: Validation on Independent Multi-Centre Data

Heiko Peschl, UK

16:25 - 16:30

MA20.11 - Automatic Nodule Size Measurements Can Improve Prediction Accuracy Within a Brock Risk Model

Timor Kadir, UK

16:30 - 16:45

MA20.12 - Discussant - MA 20.09, MA 20.10, MA 20.11

Heidi Schmidt, Canada

MA21

15:15 - 16:45

Molecular Subtyping, CBL3, and Non-Coding RNA

Room 205 B

Topics: Biology

Moderation: L. Montuenga, Spain; Y. Minami, Japan

15:15 - 15:20

MA21.01 - Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC

Rebecca Feldman, AZ/USA

15:20 - 15:25

MA21.02 - Identification of an E2 Ubiquitin Conjugase CDC34 That Competes with E3 Ligase c-Cbl to Stabilize EGFR and Promotes Lung Carcinogenesis

Guangbiao Zhou, China

15:25 - 15:30

MA21.03 - Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC



Adam Januszewski, UK

15:30 - 15:45

MA21.04 - Discussant - MA 21.01, MA 21.02, MA 21.03

Ravi Salgia, CA/USA

15:45 - 15:50

MA21.05 - Comprehensive Genomic Characterization and Prognostic Nomogram Developed by 295-Gene Panel Targeted Sequencing

Bin Zhang, China

15:50 - 15:55

MA21.06 - Proteins Associated with Survival Differ Depending on Molecular Subtypes, and Mutational- and Smoking-Status in NSCLC Biopsies

Ann Halvorsen, Norway

15:55 - 16:00

MA21.07 - A Nation-Wide Population-Based Mapping of Targetable Alterations in Smoking-Independent Lung Cancer

Maria Planck, Sweden

16:00 - 16:15

MA21.08 - Discussant - MA 21.05, MA 21.06, MA 21.07

Siddhartha Devarakonda, MO/USA

16:15 - 16:20

MA21.09 - Differential Gene Expression in Tumor and Normal Tissue Reveals New Insights in the Biology of Non-Small Cell Lung Carcinoma.

Alan Spatz, QC/Canada

16:20 - 16:25

MA21.10 - Large-Scale Discovery of Novel Human Oncofetal Transcripts in Lung

Brenda Minatel, BC/Canada

16:25 - 16:30

MA21.11 - Epigenomic Mapping of Cell-Free DNA in Patients with Non-Small Cell Lung Cancer

Christine Bestvina, USA

16:30 - 16:45

MA21.12 - Discussant - MA 21.09, MA 21.10, MA 21.11

Geoffrey Liu, Canada

MA22

15:15 - 16:45

New Therapeutics, Pathology, and Brain Metastases for Small Cell and Neuroendocrine Tumour

Room 206 BD

Topics: Small Cell Lung Cancer/NET

Moderation: E. Richardet, Argentina; M. El-Mallah, Canada



- 15:15 - 15:20 **MA22.01 - PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency**
Benjamin Lok, Canada
- 15:20 - 15:25 **MA22.02 - Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer**
Yusuke Inoue, Canada
- 15:25 - 15:30 **MA22.03 - SCLC Circulating Tumour Cell Derived Explants: The Clinical Characteristics of Patients Whose Samples Generate CDX**
Alexander Vickers, UK
- 15:30 - 15:45 **MA22.04 - Discussant - MA 22.01, MA 22.02, MA 22.03**
Céline Mascaux, ON/Canada
- 15:45 - 15:50 **MA22.05 - Impact of Tumor Spread Through Air Spaces (STAS) in Lung Neuroendocrine Tumors (NETs)**
Rania Aly, NY/USA
- 15:50 - 15:55 **MA22.06 - Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?**
Niccolo Daddi, Italy
- 15:55 - 16:00 **MA22.07 - Prognostic Value of Distant Organ-Specific Metastases in Newly Diagnosed Lung Neuroendocrine Tumors: A Population-Based Study**
Min Fan, China
- 16:00 - 16:15 **MA22.08 - Discussant - MA 22.05, MA 22.06, MA 22.07**
Giuseppe Pelosi, Italy
- 16:15 - 16:20 **MA22.09 - Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?**
Brooklyn Mazure, Canada
- 16:20 - 16:25 **MA22.10 - Prevalence and Risk Factors of Brain Metastases in Limited Stage Small Cell Lung Cancer Immediately Before Prophylactic Cranial Irradiation**
Zhengfei Zhu, China
- 16:25 - 16:30 **MA22.11 - Risk of Hippocampal Metastases in Small Cell Lung Cancer: Implications for Hippocampal Sparing Cranial Irradiation**
Rachel Effeney, Australia



16:30 - 16:45 **MA22.12 - Discussant - MA 22.09, MA 22.10, MA 22.11**
Houda Bahig, Canada

MS20

15:15 - 16:45 Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC **Room 202 BD**
Topics: Treatment of Early Stage/Localized Disease
Moderation: B. Li, USA; K. Yasufuku, Canada

15:15 - 15:30 **MS20.01 - Robotic and Innovative Surgery**
Waël Hanna, Canada

15:30 - 15:45 **MS20.02 - The Future of Stereotactic Ablative Radiotherapy (SABR)**
Billy Loo, CA/USA

15:45 - 16:00 **MS20.03 - Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe?**
Jamie Chaft, USA

16:00 - 16:15 **MS20.04 - Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy**
Phillippe Broet, France

16:15 - 16:30 **MS20.05 - Beyond Surgery - Support of the Surgical Patient**
Kate Kuhns, USA

16:30 - 16:45 **MS20.06 - Less Is More: Segmentectomy in the Management of Early Stage NSCLC**
Shun-ichi Watanabe, Japan

MS21

15:15 - 17:00 Giants in Thoracic Oncology **Room 105**
Moderation: R. Feld, Canada; M. Satouchi, Japan

15:15 - 15:25 **MS21.01 - Surgery and its Evolution**
Paul Van Schil, Belgium

15:25 - 15:35 **MS21.02 - Chemotherapy through the 21st Century**
David Johnson, USA



- 15:35 - 15:45 **MS21.03 - Revolution in Radiation**
Ben Slotman, Netherlands
- 15:45 - 15:55 **MS21.04 - Targeted Therapy - The Second Revolution**
Frances Shepherd, Canada
- 15:55 - 16:05 **MS21.05 - Quality of Life - Are we Paying Enough Attention?**
Richard Gralla, NY/USA
- 16:05 - 16:15 **MS21.06 - Immunotherapy - Sequence or Combination?**
Roy Herbst, CT/USA
- 16:15 - 16:25 **MS21.07 - The Growing Role of Biomarkers in Treatment Selection: “The Tissue is the Issue”**
Fred Hirsch, CO/USA
- 16:25 - 16:35 **MS21.08 - Where will we be in 10 years?**
Paul Bunn, Jr., CO/USA
- 16:35 - 17:00 **MS21.09 - Discussion**

OA12

- | | | |
|----------------------|--|-----------------|
| 15:15 - 16:45 | Novel Therapies in MET, RET and BRAF
Topics: Targeted Therapy
Moderation: N. Pavlakis, Australia; Y. Kobayashi, Japan | Room 106 |
|----------------------|--|-----------------|
- 15:15 - 15:25 **OA12.01 - Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14-Skipping Mutations**
Enriqueta Felip, Spain
- 15:25 - 15:35 **OA12.02 - Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer**
Alexander Drilon, NY/USA
- 15:35 - 15:45 **OA12.03 - Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.**



Denis Moro-Sibilot, France

15:45 - 16:00

OA12.04 - Discussant - OA 12.01, OA 12.02, OA 12.03

Mark Awad, MA/USA

16:00 - 16:10

OA12.05 - Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial.

Julien Mazieres, France

16:10 - 16:20

OA12.06 - Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure

Anastasios Dimou, CO/USA

16:20 - 16:30

OA12.07 - Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

Geoffrey Oxnard, AL/USA

16:30 - 16:45

OA12.08 - Discussant - OA 12.05, OA 12.06, OA 12.07

Thomas Newsom-Davis, UK

P2.01

16:45 - 18:00

Advanced NSCLC

Exhibit Hall

P2.01-01 - The Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Wenhua Liang, China

P2.01-02 - Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study

Nir Peled, Israel

P2.01-03 - Quality of Life Outcomes for FDA-Approved Agents in Advanced Non-Small Cell Lung Cancer

Hamzeh Albaba, ON/Canada

P2.01-04 - Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center

Alla'a Ali, Canada

P2.01-05 - Adenocarcinoma of the Lung: The Woman's Cancer?



Noor Alsaadoun, AB/Canada

P2.01-06 - HSP72 Expression Associates with Survival in EGFR Mutated NSCLC

Idoroenyi Amanam, CA/USA

P2.01-07 - Safety and Efficacy of LATTICE Radiotherapy in Voluminous Non-Small Cell Lung Cancer: A Retrospective Study of 10 Patients Over 7 Year Period

James Melotek, FL/USA

P2.01-08 - Conversion Surgery for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutation After TKI Followed by Cytotoxic Agent

Masaya Aoki, Japan

P2.01-09 - Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing

Edurne Arriola, Spain

P2.01-10 - Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer

So Hyeon Bak, Republic of Korea

P2.01-11 - Characteristics of Non-Small Cell Lung Cancer: Differences by Sex and Hormonal Status in a Hispanic Population

Feliciano Barron, Mexico

P2.01-12 - Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients

Marta Batus, IL/USA

P2.01-13 - Number, Rather Than Location of Metastases, Dictates Outcome in Stage IV, M1b, Non-Small Cell Lung Cancer

Amanda Gibson, Canada

P2.01-14 - Preferred and Achieved Goals of Patients with Metastatic Lung Cancer and Their Oncologists in End-of-Life Therapy

Annemarie Becker, Netherlands

P2.01-15 - A Radiologist-Led Training Workshop for MR Based Normal Tissue and Tumour Delineation for Lung Cancer Radiotherapy.

Sean Brown, UK

**P2.01-16 - Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients**

Jianhua Chang, China

P2.01-17 - MALAT1-Mir-101-SOX9 Feedback Loop Modulates the Chemo-Resistance of Lung Cancer Cell to DDP via Wnt Signaling Pathway

Wei Chen, China

P2.01-18 - Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination

Ying Chen, China

P2.01-19 - Radiomics Features of Contrast Enhanced CT as Prognostic Factors in Resectable Adenocarcinoma of Lung

Jooae Choe, Republic of Korea

P2.01-20 - FLT-PET for Detection of Relapse Following Radiotherapy for Lung Cancer. Preliminary Results

Tine Christensen, Denmark

P2.01-21 - Antigen Cascade Triggering Correlates with Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade with Nivolumab.

PIERPAOLO Correale, Italy

P2.01-22 - Increased Incidence, Morbidity and Mortality Rates for Lung Cancer in Women in Brazil Between 2000 and 2014

Guilherme Costa, Brazil

P2.01-23 - Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)

Mathilde Couetoux Du Tertre, QC/Canada

P2.01-24 - MLPH Activates CDC42/PAK1 Signaling to Promote Epithelial-Mesenchymal Transition via TGF- β in Non-Small Cell Lung Cancer

Xiaorong Dong, China

P2.01-25 - MicroRNA-330-3p Promotes Brain Metastasis of Non-Small Cell Lung Cancer by Activating MAPK/MEK/ERK Signaling Through GRIA3

Xiaorong Dong, China

P2.01-26 - Association of Base Excision Repair Gene Polymorphisms with Response to Chemotherapy of Advanced Non Small-Cell Lung Cancer



Xu Wang, China

P2.01-27 - MR, CT and Cone-Beam CT for Lymph Node Visualisation in Locally-Advanced Lung Cancer

Sean Brown, UK

P2.01-28 - Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010 - 2014 Diagnoses

Anifat Elegbede, Canada

P2.01-29 - Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer

Doreen Ezeife, Canada

P2.01-30 - Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Different Gene Alterations and Brain Metastases

Yun Fan, China

P2.01-31 - Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients - A National-Wide Study

Carlos Gil Ferreira, Brazil

P2.01-32 - Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil

Carlos Gil Ferreira, Brazil

P2.01-33 - Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)

Patrick Forde, MD/USA

P2.01-34 - Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated with Immunotherapy and Ramucirumab Plus Docetaxel.

Marta Batus, IL/USA

P2.01-35 - Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients with Advanced Lung Cancer

Apar Kishor Ganti, NE/USA

P2.01-36 - Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review

Yong Yuan, NJ/USA



P2.01-37 - A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC

David Gerber, TX/USA

P2.01-38 - Sarcopenia is Associated with Metastatic Burden and is a Negative Prognostic Factor in Metastatic Non-Small Cell Lung Cancer

Chad Glisch, WI/USA

P2.01-39 - Can Benefit or Futility in Treating Advanced Nsclc Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?

Richard Gralla, NY/USA

P2.01-40 - Prognostic Importance of Sarcopenia and Inflammatory Statements in Stage III Non Small Cell Lung Carcinoma

Serap Akyürek, Turkey

P2.01-41 - The Role and Mechanism of FBW7 Deficiency in Advanced Non-Small Cell Lung Cancer with Docetaxel Resistance

Qisen Guo, China

P2.01-42 - Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy

Martin Gutierrez, NJ/USA

P2.01-43 - ADSCaN: A Randomised Phase II Study of Accelerated, Dose Escalated, Sequential Chemo-Radiotherapy in Non-Small Cell Lung Cancer (NSCLC)

Matthew Hatton, UK

P2.01-44 - Prognostic Value of TP53 Hot Exon Mutation in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Yong He, China

P2.01-45 - Mutational and Inflammatory Biomarkers for Lung Cancer Patients with Pleural Effusions

Balazs Hegedus, Germany

P2.01-46 - Investigating the Effects of Prior Malignancy on NSCLC Trial Eligibility

Michael Herman, Canada

P2.01-47 - Clinical Outcome After Surgical Resection of Clinical Single-station N2 Non-Small Cell Lung Cancer

Kwanyong Hyun, Republic of Korea



P2.01-48 - Predictive Factors in NSCLC Patients with Stage IIIB/IV Treated with First Line Platinum-Doublet Chemotherapy

Sofi Isaksson, Sweden

P2.01-49 - Comparison of Radiotherapy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer

Abdurrahman Isikdogan, Turkey

P2.01-50 - Thromboembolism in ROS1 Rearranged Non-Small Cell Lung Cancer

Nick Pavlakis, Australia

P2.01-51 - Study of CD26/DPP4 Expression in a Large Series of Non-Small Cell Lung Cancer Patients

Sven Hillinger, Switzerland

P2.01-52 - Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients

Yang W Shao, Canada

P2.01-53 - Local Treatment for Oligoprogression/Oligometastases After Failure to Crizotinib for ALK-Rearranged Stage IV Lung Cancer

Tsz Yeung Kam, Hong Kong

P2.01-54 - Predictive Factors for Thromboembolism in Advanced Lung Cancer Patients on Platinum Chemotherapy: A Prospective Study

Shruti Kate, India

P2.01-55 - Dual-Energy CT Scan to Evaluate Sarcopenia in Lung Cancer in Comparison with Conventional CT Scan

Eun Young Kim, Republic of Korea

P2.01-56 - Metastases in Residual PET Uptake of Lymph Nodes After Treatment: Added Value of CT Radiomic Approach for Prediction

Chu Hyun Kim, Republic of Korea

P2.01-57 - Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients

Yong Chan Ahn, Republic of Korea

P2.01-58 - Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort



Alyssa Klein, MD/USA

P2.01-59 - The Cost of Lung Cancer in the County of Gävleborg - Sweden

Hirsh Koyi, Sweden

P2.01-60 - Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients

Lara Kujtan, USA

P2.01-61 - Body Mass Index over Time is Associated with Overall Survival in Advanced NSCLC Patients Treated with Immunotherapy.

Stephanie Labomascus, IL/USA

P2.01-62 - Extracellular Vesicle-Based Egfr Genotyping in Bronchoalveolar Lavage Fluid from Non-Small Cell Lung Cancer Patients

Jong Sik Lee, Republic of Korea

P2.01-63 - Are Heart Doses Associated with Survival in NSCLC Treated with Post-Operative Radiotherapy? A National Population-Based Study

Chia Ching Lee, Singapore

P2.01-64 - Prognostic Value of PET-CT after Induction Chemoradiotherapy and Curative Surgery in IIIA-N2 NSCLC: A Multi-Institutional Analysis

Jong Hoon Lee, Republic of Korea

P2.01-65 - Assessment of Individual and Combined of Five Serum Tumor Markers for Lung Cancer

Yuping Li, China

P2.01-66 - Comparison of EGFR Mutation Status in Tissue and Plasma Cell-Free DNA Detected by ARMS in Advanced Lung Adenocarcinoma Patients

Yuping Li, China

P2.01-67 - The Prognostic Analysis of Lung Cancer Patients with Occult Malignant Pleural Disease at Thoracotomy

Shaolei Li, China

P2.01-68 - Capture-Based Sequencing Depicts Evolution Characteristics of Pulmonary Sarcomatoid Carcinoma

Xuewen Liu, China

**P2.01-69 - EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer**

Xiyi Lu, China

P2.01-70 - Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study

Uri Weinberg, Switzerland

P2.01-71 - Clinical Outcome of Induction Chemoradiotherapy Followed by Surgery for the Patients with cN2 Non-Small Cell Lung Cancer

Akihiro Miura, Japan

P2.01-72 - Bronchial Sleeve vs Pneumonectomy: Complications, Recurrences and Survival

Marc Boda, Spain

P2.01-73 - Automated Image Analysis Tool for Tumor Volume Growth Rate to Guide Precision Cancer Therapy: EGFR-Mutant NSCLC as a Paradigm

Mizuki Nishino, USA

P2.01-74 - Docetaxel-Related Febrile Neutropenia (FN) And Patient Reported Symptoms/ QOL (PROs) in East Asian (EA) and Non-EA Patients

Sotaro Enatsu, Japan

P2.01-75 - Study of Molecular Alterations in Cytological Smears by FISH In Patients with Advanced Non Small Cell Lung Carcinoma (NSCLC).

Julieta Pandolfi, Argentina

P2.01-76 - The Impact of Concordance with a Lung Cancer Diagnosis Pathway Guideline on Treatment Access in Patients with Stage IV Lung Cancer

Luke Jeagal, ON/Canada

P2.01-77 - Interconversion of Two Commonly Used Performance Tools: An Analysis of 5844 Paired Assessments in 1501 Lung Cancer Patients

Kuruswamy Prasad, India

P2.01-78 - Validation of InVisionFirst ctDNA NGS Profiling via ddPCR Testing in Patients with Non-Small Cell Lung Cancer (NSCLC)

Michael Pritchett, NC/USA

P2.01-79 - Neurological Death is Common in Patients with EGFR Mutant Non-Small Cell Lung Cancer



Matthew Ramotar, Canada

P2.01-80 - Performance Status and Resource Utilization in Patients Receiving Palliative Care with Stage IV Non-Small Cell Lung Cancer

Candice Wilshire, USA

P2.01-81 - Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience

Witold Rzyman, Poland

P2.01-82 - Neutrophil-to-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors

Diana Saravia, USA

P2.01-83 - Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Mehmet Ali Sendur, Turkey

P2.01-84 - Patterns of Central Nervous System Metastases in EGFR Mutated or ALK Rearranged Non Small Cell Lung Cancer Patients

Mansi Sharma, India

P2.01-85 - The Efficacy of the Traditional Chinese Medicine as Maintenance Therapy for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Peng Shen, China

P2.01-86 - Genetic Profiling of Circulating Cell-Free DNA from Cerebrospinal Fluid and Plasma in ALK-Positive Lung Cancer with Brain Metastases

Liang Shi, China

P2.01-87 - Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data

Qiuling Shi, USA

P2.01-88 - C-Reactive Protein (CRP) as a Predictive Marker for Survival in Patients with Advanced NSCLC Treated with First Line Pembrolizumab Monotherapy

Yuji Shibata, Japan

P2.01-89 - Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer

Nensi Shrestha, New Zealand



P2.01-90 - PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients with or without EGFR Mutation

Teerada Siripoon, Thailand

P2.01-91 - Treatment Patterns in Patients with Stage IIIB-IV NSCLC in Clinical Practice: Retrospective Analysis of a UK Trust Database

Michael Snee, UK

P2.01-92 - “All-In-One” Window: A New Way of Looking at Chest CT Studies in Thoracic Oncology

Annemie Snoeckx, Belgium

P2.01-93 - The Analysis of the Soluble Programmed Death-1 of Lung Cancer Patients with Different Characteristics

Xia Song, China

P2.01-94 - Diagnostic Patterns of Non-Small Cell Lung Cancer at Princess Margaret Cancer Centre

Mike Sung, Canada

P2.01-95 - Assessment the Fitness for Chemotherapy of NSCLC Patients using 6MWT

Zsuzsanna Szalai, Hungary

P2.01-96 - Dysgeusia Associated with Nutritional and Quality of Life Parameters in Non-Small Cell Lung Cancer Patients Naïve to Chemotherapy

Jenny Turcott, Mexico

P2.01-97 - Prognostic Factors in Resected Lung Mucinous Adenocarcinoma: Clinical and Pathological Features

Daisuke Ueda, Japan

P2.01-98 - Single-Isocenter Volumetric-Modulated Arc Radiosurgery for Non-Small-Cell Lung Cancer Patients with Multiple Brain Metastases

Megumi Uto, Japan

P2.01-99 - Can NGS NSCLC Testing Be Implemented Without in House Expertise? Clinical Utility of the First FDA-Approved Lung Cancer NGS End-To-End Solution

Anagh Vora, CA/USA

P2.01-100 - Different Genetic Mutations Enriched in Circulating Tumor DNA Predict Different Metastatic Sites in Lung Adenocarcinoma Patients



Liyun Miao, China

P2.01-101 - Dynamic Monitoring of Gene Alterations with ctDNA by NGS for EGFR Mutated Lung Adenocarcinoma Treated with Gefitinib in BENEFIT Study (CTONG 1405)

Jie Wang, China

P2.01-102 - Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients

Zhaoxia Wang, China

P2.01-103 - Neutrophil-to-Lymphocyte Ratio as a Predictor of Immunotherapy Treatment Outcomes in Advanced Non-Small Lung Cancer

Xiao Wang, USA

P2.01-104 - Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value

Chanida Vinayanuwattikun, Thailand

P2.01-105 - Tumor Treating Fields Plus Standard of Care for Non-Small Cell Lung Cancer Following Platinum Failure: Phase 3 LUNAR Study

Uri Weinberg, Switzerland

P2.01-106 - A Comparative Analysis of Genomic Alterations by Tumor Tissue and Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer

Go-un Woo, Republic of Korea

P2.01-107 - Analysis of Mutation Detection by ctDNA on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients

Renhua Guo, China

P2.01-108 - Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy

Yu Yang, China

P2.01-109 - Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Guangjian Yang, China

P2.01-110 - Unique Genomic Profile Revealed by Malignant Pleural Effusion

Zhihua Guo, China



P2.01-111 - Clinical Features and Prognosis of Eighty-Five Patients with Primary Pulmonary Lymphoepithelioma-Like Carcinoma

Qin Yin, China

P2.01-112 - Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients with Lung Cancer Treated with Nivolumab

Takashi Yokoi, Japan

P2.01-113 - Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients with Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)

Luo-Sheng Yong, Taiwan

P2.01-114 - The Correlation Among PD-L1 Expression, TMB and Lung Immune Prognostic Index in Chinese Patients with Advanced Lung Adenocarcinoma

Pei Yuan, China

P2.01-115 - Evaluation of EGFR T790M of Cell Free Circulating DNA in Plasma by Droplet Digital PCR for Progressive Non-Small Cell Lung Cancer

Zhihong Zhang, China

P2.01-116 - The Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel

Kai Zhang, China

P2.01-117 - Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Xuefeng Xia, China

P2.01-118 - LINE-1 Retrotransposition Promotes the Occurrence and Progression of Lung Squamous Cell Carcinoma

Jinpu Yu, China

P2.01-119 - Phase III Randomized Trial of Palonosetron and Dexamethasone with Aprepitant to Prevent Full Dose Single-Day Cisplatin-Based CINV in Lung Cancer

Yongchang Zhang, China

P2.01-120 - First Study to Evaluate the Efficacy of SB Oral Solution to Prevent Neutropenia and FN Induced by Platinum-Based Chemotherapy in Lung Cancer

Yongchang Zhang, China

P2.01-121 - Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma



Chengzhi Zhou, China

P2.01-122 - Individual Precision Surgery for Locally Advanced Non-Small Cell Lung Cancer Based on Molecular Staging and Typing: The Chinese Experience.

Qinghua Zhou, China

P2.01-123 - Translational Medicine of Lung Cancer Metastasis: From Bench to Bedside

Qinghua Zhou, China

P2.01-124 - SIB-IMRT in Symptomatic Brain Metastases for NSCLC: A Randomized Controlled Study of WBRT Comparing 25Gy and 30Gy

Jian Zhu, China

P2.01-125 - EGFR Mutations by NGS in Advanced Squamous Cell Lung Cancer

Govind Babu, India

P2.01-126 - MicroRNA-330-3p Modulates Tumor Vascular Normalization After Hypofractionated Radiotherapy by Targeting p-STAT3/ HIF-1 Alpha Pathway

Xiaorong Dong, China

P2.01-127 - Efficacy of Endostar Combined with Whole Brain Radiotherapy in Patients with NSCLC Brain Metastases

Xiaorong Dong, China

P2.01-128 - Low Positivity Rate in T790M Detection with ctDNA in NSCLC and Post EGFR-TKI Progression - Timing or Sensitivity?

Carlos Gil Ferreira, Brazil

P2.01-129 - Potential Impact of KRAS Molecular Profiling of Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Nagla Karim, OH/USA

P2.01-130 - Detection of Actionable Mutation Status in Advanced Non-Small Cell Lung Cancer by Next-Generation Sequencing of Circulating Tumor DNA

Xia Song, China

P2.01-131 - Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer

Jiexia Zhang, China

P2.01-132 - Comparison Molecular Profiles in NSCLC by Using Different NGS Platforms and Different Variant Frequency Cutoff

Thanyanan Reungwetwattana, Thailand



P1.16-

16:45 - 18:00

Biology

Exhibit Hall

P2.03-01 - Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study

Hector Galindo, Chile

P2.03-02 - Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)

Ramon Palmero, Spain

P2.03-03 - Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective

Kirstin Perdrizet, Canada

P2.03-04 - Next Generation Sequencing in Lung Cancer Using the OncoPrint Comprehensive Assay: The Canadian Publicly Funded Experience

Kirstin Perdrizet, Canada

P2.03-05 - Biologic Profiling of Brain Metastasis from Non-Small Cell Lung Cancer

Tomohito Saito, Japan

P2.03-06 - Serum Syndecan-1 Levels in Patients with Nonsmall Cell Lung Cancer

Ibrahim Tek, Turkey

P2.03-07 - Radiomic Signatures Linked to Genetic Alterations as Detected by Next-Generation Sequencing: A Radiogenomics Analysis of Early-Stage NSCLC

Sibo Tian, GA/USA

P2.03-08 - Molecular Spectrum of Patients with MSH2 Mutations in Chinese Non-Small Cell Lung Cancer

Chunwei Xu, China

P2.03-09 - The Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

Chunwei Xu, China

P2.03-10 - Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS



Chunwei Xu, China

P2.03-11 - PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients

Chunwei Xu, China

P2.03-12 - EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Shun Lu, China

P2.03-13 - SWATH MS Analysis of Serine Hydrolase Activity in Human Lung Adenocarcinoma for Biomarker Discovery

Sven Hillinger, Switzerland

P2.03-14 - PKC α -PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Masaoki Ito, Japan

P2.03-15 - Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC

Niki Karachaliou, Spain

P2.03-16 - TGF- β Induced EMT and Stemness Characteristics are Associated with Epigenetic Regulation in Lung Cancer

Seung Joon Kim, Republic of Korea

P2.03-17 - EGFR T790M Mutation may not be Generated through Selection by EGFR-TKI from Randomly Occurring Mutations In vitro Using ENU

Yoshihisa Kobayashi, Japan

P2.03-18 - X-Inactivation Specific Transcript (XIST)-Mediated miRNA Sequestration In NSCLC

Erin Marshall, BC/Canada

P2.03-19 - RET-Mediated Activation of Ezrin is Associated with Cell Motility and Survival in a Subset of Lung Adenocarcinomas

Serisha Moodley, Canada

P2.03-20 - Factor XIII α -Expressing Inflammatory Monocytes Promote Lung Squamous Cancer through Fibrin Cross-Linking

Chad Pecot, USA

P2.03-21 - Mechanistic Investigation of DRD1 in Lung Cancer



Leila Toulabi, MD/USA

P2.03-22 - OCT4&SOX2 Specific CTLs Plus PD-1 Inhibitor Had Synergistic Effect on Killing CSC And Treating Drug-Resistant Lung Cancer Mice

Fang Hu, China

P2.03-23 - MicroRNA-30e Inhibits Cell Proliferation and Invasion in Non-Small Cell Lung Cancer via Directly Targeting SOX9

Lei Zhao, China

P2.03-24 - CD90 Enhances Metastasis by Epithelial-Mesenchymal Transdifferentiation in Lung Adenocarcinoma

Xiangdong Zhou, China

P2.03-25 - Loss of Expression Rather Than Cytoplasmic Mislocalization of RUNX3 Predicts Worse Outcome in Non-Small Cell Lung Cancer

Xiaohui Chen, China

P2.03-26 - A Prospective Cohort Study of TMB and Determinants of ctDNA Detection by Comprehensive Genomic Profiling in Stage I Lung Adenocarcinomas

Kezhong Chen, China

P2.03-27 - Polymorphisms in Folate Metabolism Related Genes Affect the Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer

Sun Ha Choi, Republic of Korea

P2.03-28 - Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer

Carlo Genova, Italy

P2.03-29 - Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma

Shigeto Nishikawa, Japan

P2.03-30 - Proteins Involved in Necroptosis and DNA Damage Repair and Survival of Stage I Non-Small-Cell Lung Cancer Patients

Jeong-Seon Ryu, Republic of Korea

P2.03-31 - LncRNA RGMB-AS1 Affects Lung Adenocarcinoma Prognosis by Regulating Microtube Associated Genes: A Genome-Wide Analysis in Silicon

Xiaoshun Shi, China



P2.03-32 - Genome-Wide Analysis of m6A-Modified RNA Binding Proteins Associated with Lung Cancer Survival

Xiaoshun Shi, China

P2.03-33 - Anti-Aging Gene, Klotho is a Predictive Factor of Pemetrexed for Lung Cancer Treatment

Kyoshiro Takegahara, Japan

P2.03-34 - The Relationship Between Treatment Response and Serum EGFR Level in Nonsmall Cell Lung Cancer

Ibrahim Tek, Turkey

P2.03-35 - Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features

Chunwei Xu, China

P2.03-36 - DNA Methylation: A More Sensitive Marker for Treatment Monitoring?

Yu Chen, China

P2.03-37 - The Efficiency of Octamer-4 Specific Cytotoxic T Cells Induce By CD40-B Cells in Killing Lung Cancer Stem-Like Cells

Fang Hu, China

P2.04

16:45 - 18:00

Immunooncology

Exhibit Hall

P2.04-01 - Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.

Luis Antonio Cabrera-Miranda, Mexico

P2.04-02 - Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab

Carlo Genova, Italy

P2.04-03 - NF- κ B and HIF-1 α Play Important Roles in Regulating PD-L1 Expression by EGFR or KRAS Mutants in Non-Small Cell Lung Cancer Cells



Jie Wang, China

P2.04-04 - Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4⁺T Cell, CD8⁺T Cell and FOXP3⁺T Cell in Lung Cancer

Yasuto Jin, Japan

P2.04-05 - Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.

Pawel Krawczyk, Poland

P2.04-06 - Increased Plasma Cell % and Decreased B-Cells in Tumor Immune Infiltrates Are Associated with Worse Prognosis in Lung Adenocarcinomas

Hee Eun Lee, MN/USA

P2.04-07 - Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues

Xu Wang, China

P2.04-08 - Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer

Judit Moldvay, Hungary

P2.04-09 - Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Marcelo Negrao, USA

P2.04-10 - Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Francesco Passiglia, Italy

P2.04-11 - An IL-8/IFN-gamma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC

Francesco Passiglia, Italy

P2.04-12 - A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.

Sara Pilotto, Italy

P2.04-13 - The Immune Checkpoint, HVEM Contribute to Immune Escape in Non-Small Cell Lung Cancer of Lacking PDL1 Expression

Shengxiang Ren, China

**P2.04-14 - Tumor Mutational Burden Assessed by a Targeted NGS Assay Predicts Benefit from Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer**

Sacha Rothschild, Switzerland

P2.04-15 - Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions

Kenichi Suda, CO/USA

P2.04-16 - Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients

Ryosuke Tsugitomi, Japan

P2.04-17 - Pre-Therapy Radiomic Features Can Distinguish Hyperprogression from Other Response Patterns to PD1/PD-L1 Inhibitors in NSCLC

Pranjal Vaidya, USA

P2.04-18 - The Association Between IDO Activity and Clinical Prognosis in Patients with Non-Small Cell Lung Cancer After Radiotherapy

Yaping Xu, China

P2.04-19 - Correlation of Clinicopathological Characteristics with Tumor Mutation Burden in Chinese Patients with NSCLC

Shun Lu, China

P2.04-20 - Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC

Mehmet Altan, USA

P2.04-21 - Real World Experience of Immune Checkpoint Inhibitors In NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK

Kathryn Ellenger, UK

P2.04-22 - Dendritic Cell Based Immunotherapy in Stage IIB-III A Non-Small Cell Lung Cancer Patients: 10-Years Experience.

Natalia Khranovska, Ukraine

P2.04-23 - Immune-Related Adverse Events: The Growing Pains of Immunooncology

Meghan Mooradian, MA/USA

P2.04-24 - Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible?

Inmaculada Ramos García, Spain



P2.04-25 - Randomized Clinical Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone for Early Stage NSCLC

Joe Chang, USA

P2.04-26 - Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC

Grace Dy, USA

P2.04-27 - Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC

James Lorens, Norway

P2.04-28 - Use of Immune Checkpoint Inhibitors (ICIs) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)

Jonathan Thompson, WI/USA

P2.04-29 - Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Yi-Long Wu, China

P2.04-30 - PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma

Xu-Chao Zhang, China

P2.06

16:45 - 18:00

Mesothelioma

Exhibit Hall

P2.06-01 - Short-Term Outcome of Entire Pleural Intensity-Modulated Radiotherapy in a Neoadjuvant Setting for Malignant Mesothelioma

Ji Hyun Hong, Republic of Korea

P2.06-02 - Feasibility of Intensity Modulated Radiotherapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma Patients

Oscar Arrieta, Mexico

P2.06-03 - Can We Predict Pathological Nodal Positivity in Malignant Pleural Mesothelioma from Preoperative Clinical Variables?

Silviu Buderu, UK



P2.06-04 - Throughput of a Specialist Mesothelioma Multidisciplinary Team Meeting at a Radical Treatment Centre in the UK.

Edward Caruana, UK

P2.06-05 - TTFIELDS Applied to the Torso and Upper Abdomen: Safety Meta-Analysis of 176 Patients from four Phase I-II Trials

Giovanni Ceresoli, Italy

P2.06-06 - Role of GITRL-GITR System in Promoting Proliferation of Malignant Mesothelioma

Mei-Lin Chan, ON/Canada

P2.06-07 - Genomic Deletion of BAP1 and CDKN2A are Better MM Diagnostic Biomarkers.

Yuen Yee Cheng, Australia

P2.06-08 - ABT-806 Derived Antibody Drug Conjugates (ADCs) Inhibit Growth of Malignant Mesothelioma In-Vivo

Puey Ling Chia, Australia

P2.06-09 - MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma

Dean Fennell, UK

P2.06-10 - Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress

Nobukazu Fujimoto, Japan

P2.06-11 - A Phase I/II Study of Intrapleural Ad-SGE-REIC Administration in Patients with Refractory Malignant Pleural Mesothelioma

Yasushi Goto, Japan

P2.06-12 - Improving Quality of Care for Pleural Mesothelioma: 2018 National Mesothelioma Audit Results for England and Wales

Susan Harden, UK

P2.06-13 - Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma

Isabelle Opitz, Switzerland

P2.06-14 - Does Size Matter? A Population-Based Analysis of Malignant Pleural Mesothelioma

Jiaxi He, China

**P2.06-15 - Malignant Pleural Mesothelioma in Young Adult People in Uganda**

Nehemiya Igulu Bandese, Uganda

P2.06-16 - YB-1: An Important Driver of Mesothelioma Drug Resistance and a Potential Novel Therapeutic Target

Karin Schelch, Australia

P2.06-17 - Real-World Accuracy of Malignant Pleural Mesothelioma (MPM) Preoperative Magnetic Resonance Imaging (MRI) for Staging the Diaphragm.

Sharyn Katz, USA

P2.06-18 - Comparison of Extubation Time of Pleurectomy/Decortication with Lobectomy Under General Anesthesia Using Desflurane

Keisuke Kawata, Japan

P2.06-19 - Targeting Polyamines as Potential Adjuvant Therapy in Malignant Pleural Mesothelioma Xenograft Models

Sze Kwan Lam, Hong Kong

P2.06-20 - Bacteria as Novel Anti-Mesothelioma Agents.

Sally Lansley, WA/Australia

P2.06-21 - Low Intratumoral Platinum Concentration is Associated with Unfavorable Clinical Outcome in Malignant Pleural Mesothelioma

Viktoria Laszlo, Austria

P2.06-22 - Proposal of a New Local Recurrence Score for Patients with Malignant Pleural Mesothelioma

Isabelle Opitz, Switzerland

P2.06-23 - Association of Two BRM Promoter Polymorphisms and Tobacco Exposure with Malignant Pleural Mesothelioma (MPM) Risk and Survival

Min Joon Lee, Canada

P2.06-24 - The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA

Rami Manochakian, FL/USA

P2.06-25 - Combined Immune Checkpoint Blockade in Malignant Pleural Mesothelioma: In Vivo Validation of in Vitro Results

Jan Van Meerbeeck, Belgium



P2.06-26 - Ribonucleotide Reductase Subunit M1 but not M2 is Associated to Better PFS in Patients with Advanced Stage Mesothelioma

Saé Muñoz-Hernández, Mexico

P2.06-27 - Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma

Kazunori Okabe, Japan

P2.06-28 - Assessment of Chest Wall Motion Using Structured Light Plethysmography (SLP) in Mesothelioma and Benign Pleural Disease

Nicola Oswald, UK

P2.06-29 - Expression of Estrogen Receptor Beta (ERβ) and its Prognostic Value in the Pleural Mesothelioma.

Jeronimo Rodriguez-Cid, Mexico

P2.06-30 - Association of Histopathological Patterns of Mesothelioma and Response to Treatment with Chemotherapy

Jeronimo Rodriguez-Cid, Mexico

P2.06-31 - Inhibition of Heat Shock Protein 70 Function Suppresses Proliferation in Mesothelioma Cells

Kosuke Sakai, Japan

P2.06-32 - YB-1 - A Key Factor in Mesothelioma Aggressive Growth and Behaviour

Karin Schelch, Australia

P2.06-33 - Heterogeneity in Care Pathways for Patients with Malignant Pleural Mesothelioma Presenting at a Quaternary Thoracic Oncology Center in Quebec

Aya Siblini, Canada

P2.06-34 - Inhibition of the HGF/c-Met Pathway for Malignant Mesothelioma with an Intra-Thoracic Injection of the NK4 Expressing Adenoviral Vectors

Yuji Tada, Japan

P2.06-35 - Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma: SPARCS Data

Maaïke Van Gerwen, USA

P2.06-36 - EORTC 1205: Randomized Phase II Study of Pleurectomy/Decortication Preceded or Followed by Chemotherapy in Early Stage MPM

Jan Van Meerbeeck, Belgium



P2.06-37 - Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma

Takuya Watanabe, Japan

P2.06-38 - Mesothelioma Stem Cells May Be the Critical Factor of Treatment Failure

Licun Wu, ON/Canada

P2.06-39 - Next Generation Sequencing Reveals Genetic Landscape of Malignant Mesothelioma

Xuefeng Xia, China

P2.06-40 - VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression

Marjorie Zauderer, NY/USA

P2.06-41 - Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC

Yu Zhi Zhang, UK

P2.06-42 - AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma.

Federica Zito Marino, Italy

P2.09

16:45 - 18:00

Pathology

Exhibit Hall

P2.09-01 - Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma

Hui Yu, CO/USA

P2.09-02 - Comprehensive Assessment of PD-L1 Immunohistochemistry on Paired Tissue and Cytology Specimens in Non-Small Cell Lung Cancer

Andréanne Gagné, Canada

P2.09-03 - Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection

Nobuyasu Kurihara, Japan

**P2.09-04 - PD-L1 Expression in Primary Lung Adenocarcinoma and its Relation with EGFR / KRAS Mutation and Clinicopathological Features**

Lin Li, China

P2.09-05 - Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001

Aaron Lisberg, CA/USA

P2.09-06 - Expression of PD-L1 on Routine Non-Small Cell Lung Carcinoma Sections: Comparative Assessment of SP263 (Ventana) and 22C3 (DAKO pharmDx)

Anne Marie Quinn, UK

P2.09-07 - Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?

Hangjun Wang, QC/Canada

P2.09-08 - Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer

Ying Wang, BC/Canada

P2.09-09 - Precision and Repeatability of VENTANA DLL3 (SP347) Assay Immunohistochemistry Assay in Fine Needle Aspirations of Small Cell Lung Cancer

Brittany Admire, AZ/USA

P2.09-10 - qRT-PCR as an Efficient and Reliable Diagnostic Screening Approach for the Detection of EML4-ALK Fusion Gene in NSCLC Samples: A Pilot Study

Anuradha Choughule, India

P2.09-11 - TMB Estimated with Targeted NGS in Early Stage Squamous Cell Carcinoma: Correlation with PD-L1 Expression and Lymphocyte Density

Susana Hernandez, Spain

P2.09-12 - EGFR Mutation Status in Squamous Cell Carcinoma or Non-Small Cell Carcinoma Favor Squamous Cell Carcinoma Diagnosed from Small Lung Biopsies

Hsiang-Ling Ho, Taiwan

P2.09-13 - Correlation of ROS1 (SP384) Immunohistochemistry with ROS1 Rearrangement Determined by Fluorescence in Situ Hybridization

Catherine Le, AZ/USA

P2.09-14 - The Detection of EGFR Gene Mutation from Washing Solution of Devices used for the Bronchoscopic Examination

Rie Nakahara, Japan



P2.09-15 - A Next Generation Sequencing (NGS) RNA-Scan Multiplex Panel (QIAseq) to Identify Gene-Rearranged Non-Small Cell Lung Cancer

Rebecca Tay, UK

P2.09-16 - Heterogeneity Analyses of MSLCs—Especially in the EGFR Mutation-Positive Ones

Yinghui Xu, China

P2.09-17 - A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research

Theresa Boyle, CO/USA

P2.09-18 - A Clinicopathologic Analysis of Pulmonary Sclerosing Pneumocytoma in Korea: A Multicenter Study

Han Kyeom Kim, Republic of Korea

P2.09-19 - Utilising Heterogeneity: Using a Digital Database of Lung Cancers and Immune Profile to Complement Subjective Assessment

Alexander Haragan, UK

P2.09-20 - Minor Components of Solid Pattern is a Significant Poor Prognostic Factor in Pathological Stage I Lung Adenocarcinoma

Miao Huang, China

P2.09-21 - Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report

Silvia Novello, Italy

P2.09-22 - Relevance of Results of Intraoperative Pleural Lavage Cytology and Histological Subtype in Lung Adenocarcinoma

Masashi Mikubo, Japan

P2.09-23 - A Combination of Podoplanin and E-Cadherin Expression in Lung SqCC may be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.

Ryo Miyata, Japan

P2.09-24 - MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes

Rebecca Mosher, MA/USA

P2.09-25 - Abundant Tumor Promoting Stromal Cells in Lung Adenocarcinoma with Hypoxic Regions



Hiroshi Nakamura, Japan

P2.09-26 - Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma

Takashi Ohno, Japan

P2.09-27 - Prognostic Significance of Vascular Invasion in Pathological Stage IA Lung Adenocarcinoma According to the 8th Edition of the TNM Classification

Joji Samejima, Japan

P2.09-28 - Detection of Isolated Tumor Cells in Regional Lymph Nodes from pN0 Lung Cancer by Negative Selection Using Immunomagnetic Beads

Xizhao Sui, China

P2.09-29 - Automatic Lung Cancer Staging from Medical Reports Using Natural Language Processing

Xizhao Sui, China

P2.09-30 - Clinicopathological Investigation of Four Resected Cases for Pleomorphic Carcinoma of the Lung

Kenichi Taguchi, Japan

P2.09-31 - Cisplatin Suppressed Metastasis of NSCLC by Inhibiting Macrophage M2-Like Polarization

Yanjun Xu, China

P2.09-32 - Detached Epithelial Cell Cluster Size in Lung Adenocarcinoma is a Marker of Poor Prognosis

Akihiko Yoshizawa, Japan

P2.10

16:45 - 18:00

Prevention and Tobacco Control

Exhibit Hall

P2.10-01 - Success of a Pharmacy-Driven Smoking Cessation Program

Catherine Burdalski, USA

P2.10-02 - Variations in Smoking Cessation Activities at Ontario's Regional Cancer Centres

William Evans, ON/Canada



P2.10-03 - Feasibility and Acceptability of E-Cigarettes as an Aid to Quitting Smoking in Lung Cancer Patients: A Pilot Study

Stephen Harrow, UK

P2.10-04 - Pattern and Factors Associated with Intention to Quit Tobacco Use in a Rural Community of Anambra State of Nigeria

Uzochukwu Ofonakara, Nigeria

P2.10-05 - Provider Medical Specialty Influences Smoking Cessation Counseling at an Academic Medical Center and Veterans Affairs in U.S. Mid-South

Jennifer Lewis, USA

P2.10-06 - The Risk of Lung Cancer Among Women Who Start Smoking as Teenagers

Malcolm Tagbarha, Nigeria

P2.10-07 - Health Professional's Perception Towards Smoking: A Cross-Sectional Study from Bangalore, India.

Satheesh Thungappa, India

P2.10-08 - Smoking Prevention Project in School Population: My Health Is in My Own Hands

Tomi Kovacevic, Serbia

P2.10-09 - The Beliefs, Orientation, Knowledge, Understanding, Attitudes And Treatment Access To Lung Cancer Amongst Rural Men In Nigeria

Malcolm Tagbarha, Nigeria

P2.10-10 - Lung Cancer Survival in Younger Patients (<40 Years): Analysis of Surveillance, Epidemiology and End Results Program Data

Marisa Bittoni, OH/USA

P2.10-11 - Impact of Smoking on Multiple Primary Cancers Survival - A Retrospective Analysis

Anna Doboszyńska, Poland

P2.10-12 - Prevalence, Pattern and Factors Associated with Dual Tobacco Use in a Rural Community in South Eastern Nigeria

Uzochukwu Ofonakara, Nigeria

P2.10-13 - When Lung Cancer Was Rare: An Historical Study of Prevalence from 1760

Luc Ollivier, France

P2.10-14 - The Evaluation of Relationship Between Radon Gas and Lung Cancers in Trabzon



Fazıl Aydın, Turkey

P2.10-15 - RADON: #1 Cause of Lung Cancer in Non-Smokers

Kelley Bush, ON/Canada

P2.10-16 - Finding the Relations Between Lung Cancer and Associated Risk Factors in Pakistani Population

Arooj Fatima, Pakistan

P2.10-17 - Environmental Tobacco Smoke Exposure and EGFR Mutations in Non-Smokers with Lung Cancer: A Dose-Response Analysis of Published Data

Wenhua Liang, China

P2.11

16:45 - 18:00

Screening and Early Detection

Exhibit Hall

P2.11-01 - Blood Transcriptomics Enables Detection of Pre-Invasive & Minimally-Invasive Lung Adenocarcinoma

Baohui Han, China

P2.11-02 - Direct Comparison of New Solid Nodules Detected in Women and Men During Incidence Screening Rounds of the NELSON Trial

Joan Walter, Netherlands

P2.11-03 - Cardiovascular Risk Prediction in a Community-Based Lung Cancer Screening Programme

Haval Balata, UK

P2.11-04 - Treatment Capacity Required for Implementing Lung Cancer Screening in the United States

Erik Blom, Netherlands

P2.11-05 - Recruitment Strategies for the Lung Cancer Screening Pilot for People at High Risk

Gail Darling, Canada

P2.11-06 - A New Histoplasmosis Antibody Enzyme Immunoassay for the Diagnosis of Lung Benign Nodules

Stephen Deppen, TN/USA

P2.11-07 - Lung Cancer in a Tertiary Care Setting: So Near, Yet So Far



Kranti Garg, India

P2.11-08 - Tumor Autoantibody Panel Can Improve the Accuracy of Early Diagnosis in Lung Cancer Presenting with GGNs /Solid Nodules

Yayi He, China

P2.11-09 - Uncommon EGFR Mutation Analysis from Urine of Lung Cancer Patients

Prista Hikmawati, Indonesia

P2.11-10 - Potential Utility of a Positive EarlyCDT®-Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules

James Jett, CO/USA

P2.11-11 - Identification of the Genetic Determinants of Susceptibility to Lung Cancer in a Moroccan Cohort

Houda Kaanane, Morocco

P2.11-12 - Metabolomic Analysis in Lung Cancer for Screening and Early Detection

Naohiro Kajiwara, Japan

P2.11-13 - Precise Early Detection of Lung Cancer and Blood Cell Circuit

Oleg Kshivets, Russian Federation

P2.11-14 - Malignancy Associated Change and The LuCED® Test for Detection of Early Stage Lung Cancer

Michael Meyer, AZ/USA

P2.11-15 - Identifying Patients for Whom Lung Cancer Screening is Preference-Sensitive: A Microsimulation Study

Rafael Meza, MI/USA

P2.11-16 - Comparison of Two Lung Cancer Screening Programs in One Medical Center - Does Experience of the Screening Team and Indications Affect the Results?

Marcin Ostrowski, Poland

P2.11-17 - MicroRNAs in Exhaled Breath Condensate and Bronchial Brushings as Biomarkers for Early Diagnosis of Lung Cancer

Bijay Pattnaik, India

P2.11-18 - A Comprehensive Lung Cancer Screening Program: 5 Years in Review



April Plank, NY/USA

P2.11-19 - MicroRNAs as Liquid Biopsy Biomarkers for Early Detection in Lung Cancer.

Patricia Reis, Brazil

P2.11-20 - Lung EpiCheck TM - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer

Joanna Chorostowska-Wynimko, Poland

P2.11-21 - Factors Predicting Attrition in Community-Based Healthcare Network Lung Cancer Screening Programs

Candice Wilshire, WA/USA

P2.11-22 - Use of Electronic Medical Records for Tobacco Use and Lung Cancer Screening Documentation in a Large Urban Academic Medicine Practice

Giselle Suero-Abreu, USA

P2.11-23 - Risk Perception Among a Lung Cancer Screening Population

John Goffin, ON/Canada

P2.11-24 - Impact of Screening Interval Length on New Nodules Detected in Incidence Rounds of CT Lung Cancer Screening: the NELSON Trial

Joan Walter, Netherlands

P2.11-25 - Lung Cancer Screening Implementation in Community Practice: Kaiser Permanente Washington Experience 2015-2018

Karen Wernli, USA

P2.11-26 - First of its Kind Multi-Pronged Training for PCPs in an Epicenter of Lung Cancer - What Was Achieved in Two Years?

Celeste Worth, KY/USA

P2.11-27 - A Rapid Access Lung Cancer Clinic Reduces Variation in Lung Cancer Diagnostic and Treatment Services.

Robert Zielinski, NSW/Australia

P2.11-28 - A Focus Group and Interview Study to Explore the Information-Needs of Lung Cancer Screening Participants

Mamta Ruparel, UK

P2.11-29 - Impact of an Information-Film to Promote Informed Decision-Making in Individuals Taking Part in a Lung Cancer Screening Demonstration Pilot



Mamta Ruparel, UK

P2.11-29a - Modified Lung-RADS Improves Performance of Screening LDCT in a Population with High Prevalence of Non-Smoking-Related Lung Cancer

En-Kuei Tang, Taiwan

P2.12

16:45 - 18:00

Small Cell Lung Cancer/NET

Exhibit Hall

P2.12-01 - Efficacy of Belotecan as Second-Line Treatment for Recurrent Small Cell Lung Cancer: A Phase IIb Randomized Multicenter Study

Jin-Hyoung Kang, Republic of Korea

P2.12-02 - Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)

Muhammad Furqan, USA

P2.12-03 - Phase I/II Trial Of ¹⁷⁷Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Chul Kim, USA

P2.12-04 - Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy

Natalya Nazarenko, MA/USA

P2.12-05 - SUKSES (Small Cell Lung Cancer Umbrella Korea Studies): A Phase II Biomarker-Driven Umbrella Study in Relapsed or Refractory SCLC

Keunchil Park, Republic of Korea

P2.12-06 - The Efficacy of Apatinib Plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer

Haifeng Qin, China

P2.12-07 - Utility of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors

Robert Ramirez, USA

P2.12-08 - Network Meta-Analysis of Angiogenesis Inhibitors on Survival of Patients with Small Cell Lung Cancer

Xiaoshun Shi, China

**P2.12-09 - Efficacy and Safety of Carboplatin and Paclitaxel for Patients Preexisting Interstitial Lung Disease with Small Cell Lung Cancer**

Ayumi Uchiyama, Japan

P2.12-10 - Novel Prognostic Model for Limited-Stage Small-Cell Lung Cancer

Hanbo Chen, ON/Canada

P2.12-11 - A Prognostic Model Integrating Immunohistochemistry Markers for Extensive-Disease Small-Cell Lung Cancer

Rui Fu, China

P2.12-12 - Plasma Vitamin D Level is an Independent Prognosis Factor in SCLC Patients Treated with Platinum Plus Etoposide as First-Line Chemotherapy

Xu Wang, China

P2.12-13 - Effectiveness of Hypofractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Propensity Score Analysis

Hanbo Chen, ON/Canada

P2.12-14 - Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer.

Elizabeth Dudnik, Israel

P2.12-15 - Prognostic and Predictive Covariates in Limited-Stage Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial

Corinne Faivre-Finn, UK

P2.12-16 - Significant Tumor Regression and Toxicity with Nivolumab Plus Ipilimumab in Small Cell Lung Cancer Patients Following Radiation

Brendan Gilmore, IL/USA

P2.12-17 - Prophylactic Cranial Irradiation Can Not Provide Survival Benefits for Resected Small Cell Lung Cancer Without Lymph Node Involvement

Baohui Han, China

P2.12-18 - Interstitial Lung Abnormalities are a Risk Factor for Radiation Pneumonitis in Patients with Limited-Stage Small-Cell Lung Cancer

Fangjuan Li, China

P2.12-19 - Prophylactic Cranial Irradiation in Extensive Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Wenya Li, China



P2.13

16:45 - 18:00

Targeted Therapy

Exhibit Hall

P2.13-01 - Brigatinib Use in England - Where Next?

Fabio Gomes, UK

P2.13-02 - ALK-Translocation and Brain Metastases: A Retrospective Study. Correlation Between Clinical Outcome, Disease Burden and Management.

Oscar Grundberg, Sweden

P2.13-03 - Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients

Maximilian Hochmair, Austria

P2.13-04 - Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.

Di Ma, China

P2.13-05 - Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients with Advanced ALK-Positive NSCLC.

Di Ma, China

P2.13-06 - TP53 Status in Relation to Response to Anti-ALK Agents in Patients with EML4-ALK-Translocated NSCLC

Paola Ulivi, Italy

P2.13-07 - CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer

Kaihua Lu, China

P2.13-08 - Phase 1 Study of the AXL Inhibitor DS-1205c in Combination with Osimertinib in Subjects with Metastatic or Unresectable EGFR-Mutant NSCLC.

Pasi Jänne, MA/USA

P2.13-09 - Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials

Luiz H Araujo, Brazil

P2.13-10 - Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC



Lauren Byers, TX/USA

P2.13-11 - EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP1)

Andrés Cardona, Colombia

P2.13-12 - The deNovo T790M Mutation Recovered by ddPCR is Associated with a Poor Response to 1st and 2nd Generation EGFR-TKI in Lung Adenocarcinoma.

Yoon Soo Chang, Republic of Korea

P2.13-13 - Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis

Parneet Cheema, Canada

P2.13-14 - The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy

Joanna Chorostowska-Wynimko, Poland

P2.13-15 - Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms

Yun Fan, China

P2.13-16 - Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China

Wenhua Liang, China

P2.13-17 - Non-Small Cell Lung Cancer in the Very Young: More EGFR/ALK Mutation Rate Than the Elder

ChienHui He, Taiwan

P2.13-18 - A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digital PCR and Next-Generation Sequencing

Eiji Iwama, Japan

P2.13-19 - Prognostic Value Inferred from the Quantitative Measurement of EGFR Mutation Using PNA-Clamping Method in Advanced EGFR Mutant NSCLC Patients

Mi-hyun Kim, Korea, Republic of

P2.13-20 - The Comparative Effectiveness of Gefitinib Versus Erlotinib on the Intracranial Progression-Free Survival in Patients with Brain Metastasis

Yao-Wen Kuo, Taiwan

**P2.13-21 - MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC**

Xue Lin Kwang, Singapore

P2.13-22 - Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation

Jae Cheol Lee, Republic of Korea

P2.13-23 - Osimertinib Treatment Result of Plasma T790M Positive in Different Clinical Failure Modes After First-Line EGFR TKI for EGFR Mutant NSCLC

Haiyan Li, China

P2.13-24 - Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients

Jordi Remon, France

P2.13-25 - Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland

Paula Scott, UK

P2.13-26 - Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI

Sandhya Sharma, NY/USA

P2.13-27 - Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients with EGFR Mutant NSCLC

Ross Soo, Singapore

P2.13-28 - Comparison of ddPCR and NGS in Liquid Biopsy to Pathology Results in EGFR-Mutated NSCLC

Christi Steendam, Netherlands

P2.13-29 - IL-22 Confers Resistance To EGFR-TKIs In Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification

Xiyi Lu, China

P2.13-30 - High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study

Shucai Zhang, China

P2.13-31 - p. (Leu747Pro) Mutation Leads to Misdiagnosis in EGFR Mutation Assessment - Analysis in a Cohort of 1841 Polish NSCLC Patients

Joanna Chorostowska-Wynimko, Poland



P2.13-32 - TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2

Jouhara Chouitar, MA/USA

P2.13-33 - A Case Report of Exceptional Clinical Response to MEK Inhibition in a Patient with NRAS Mutation Positive NSCLC

Donna Graham, UK

P2.13-34 - Long Intergenic Non-Coding RNA 00665 Induces Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer

Xiyi Lu, China

P2.13-35 - Inhibition of H3K27 Demethylation is Toxic in Poorly Differentiated Small Cell Lung Cancer

Timothy Lochmann, VA/USA

P2.13-36 - Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients with Oncogenic Driver Mutations in China

Shun Lu, China

P2.13-37 - Chloroquine overcomes acquired resistance to icotinib in vitro and in vivo through STAT3/STMN1 pathway

Xin Lyu, China

P2.13-38 - Impact of Tyrosine Kinase Inhibitor (TKI) Dose on Outcomes of Patients with Lung Cancer

Emily Miao, USA

P2.13-39 - A Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination with Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients

Zorawar Noor, CA/USA

P2.13-40 - ABP 215 and Bevacizumab in NSCLC Patients: Time Course and Magnitude of Response in the Phase 3 Comparative Trial (MAPLE)

Valdimir Hanes, CA/USA

P2.13-41 - A Novel Mitochondria-Based Targeting to Restore Therapeutic Response in Cisplatin- and Gefitinib-Resistant Human Lung Cancer Cells

Qinghua Zhou, China



P2.13-42 - Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Joop De Langen, Netherlands

P2.13-43 - Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC

Pasi Jänne, MA/USA

P2.13-44 - Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228

Paul Paik, NY/USA

P2.13-45 - SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC

Lecia Sequist, MA/USA

P2.13-46 - Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients

Shao W Yang, Canada

P2.15

16:45 - 18:00

Treatment in the Real World - Support, Survivorship, Systems Research

Exhibit Hall

P2.15-01 - CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer

K Govind Babu, India

P2.15-02 - Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years

Carolina Gabay, Argentina

P2.15-03 - Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey

Luka Brcic, Austria

P2.15-04 - Costs of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey

Olivier Bylicki, France

**P2.15-05 - Prescribing Patterns of Physicians and Financial Implications for Lung Cancer Treatment at the End of Life**

Josephine Feliciano, MD/USA

P2.15-06 - Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association with Outcomes

Leah Backhus, USA

P2.15-07 - Lung Cancer in the Young

Marco Galvez Nino, Peru

P2.15-08 - Impact and Feasibility of a Support Group for Women with Lung Cancer

Paul Wheatley-Price, Canada

P2.15-09 - The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017

Daniel Moldaver, Canada

P2.15-10 - Determinants of Health Utility Scores (HUS) in Patients with ALK Rearranged Non-Small Cell Lung Cancer.

Badr Id Said, Canada

P2.15-11 - Clinical Outcome of Pulmonary Resection for Non-Small Cell Lung Cancer in Extremely Elderly Patients (85-Year-Old or Over)

Hiroaki Inoue, Japan

P2.15-12 - Exparel vs. Bupivacaine for Postoperative Analgesia After VATS Lung Resection: Results of a Randomized Control Trial

Sandeep Khandhar, VA/USA

P2.15-13 - Implementation of a Democratized Approach to Multi-Omic Molecular Profiling Via the LungMATCH Program.

Jennifer King, DC/USA

P2.15-14 - Survivorship of Advanced Lung Cancer Patients with Psychiatric Disorders and Malnutrition Risk

Tomi Kovacevic, Serbia

P2.15-15 - Differentiating Characteristics of Patients Seeking a Second Opinion: A Survey on Non-Small Cell Lung Cancer Patients

Sara Hayes, USA

**P2.15-16 - Clinical Economic Impact of Improved Genotyping in Patients with Advanced Non-Small Cell Lung Adenocarcinoma (NSCLC)**

David Gandara, CA/USA

P2.15-17 - Patient Care in Advanced Lung Cancer: Unmet Needs

Jean-François Morere, France

P2.15-18 - Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia

Aylen Vanessa Ospina Serrano, Colombia

P2.15-19 - Inequality of Access to Novel Lung Cancer Therapies in Europe

Hazel O'sullivan, Ireland

P2.15-20 - Educating the Multispecialty Team on Molecular Testing Related to Immunotherapy

Jeffrey Gregg, CA/USA

P2.15-21 - Post Resection Lung Cancer Surveillance: Comparisons of Practice Between STS, ESTS and JACS Members

Cecilia Pompili, UK

P2.15-22 - Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients with Diabetes Mellitus

Baohui Han, China

P2.15-23 - Are there Ethnic Disparities in the Clinical Outcomes of Non-Small Cell Lung Cancer Hispanic Patients Treated with Immunotherapy?

Luis Raez, FL/USA

P2.15-24 - Comparison of Pemetrexed Administered q 3 Weeks vs q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data from a Single Institution

Sruthi Reddy, USA

P2.15-25 - NIVEX TRIAL (GECF 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients

Delvys Rodríguez-Abreu, Spain

P2.15-26 - Rates and Economic Burden of Adverse Events in Patients with Metastatic NSCLC Treated with EGFR-TKIs

Janakiraman Subramanian, MT/USA



P2.15-27 - Lung Volume Change After Lobectomy Estimated by Three-Dimensional Image Analysis System

Hirofumi Suzuki, Japan

P2.15-28 - Effect of Insurance Types on Tumor Recurrence and Overall Survival in Resectable Non-Small Lung Cancer Patients in Northern Thailand

Nirush Lertprasertsuke, Thailand

P2.15-29 - Eligibility for Anti-Angiogenic Treatments in Patients with Squamous Non-Small Cell Lung Cancer (SQ-NSCLC): EPISQUAMAB Study (GFPC 2015-01)

Alain Vergnenegre, France

P2.15-30 - Marital Status and Survival in Patients with Lung Cancer

Buhai Wang, China

P2.15-31 - The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014

Ying Wang, BC/Canada

P2.15-32 - Novice Training: The Time Course for Developing Competence in Single Port Video-Assisted Thoracoscopic Lobectomy

Ching Feng Wu, Taiwan

16:45 - 16:45

P2.15-33 - Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens After Panel Testing by NGS?

Chunxia Su, China

P2.16

16:45 - 18:00

Treatment of Early Stage/Localized Disease

Exhibit Hall

P2.16-01 - Prognostic Significance of Preoperative Consolidation to Maximum Tumor Diameter Ratio and Suv-Max in Pathological Stage I Lung Adenocarcinoma

Pınar Akın Kabalak, Turkey

P2.16-02 - Predicting Pathological Noninvasiveness in T1 Non-Small Cell Lung Cancer on Chest CT Scan Using Deep Learning Algorithm

Kyongmin Beck, Republic of Korea

P2.16-03 - CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC

Enriqueta Felip, Spain



P2.16-04 - Prognostic Value of Lymphovascular Invasion and Its Effect on Patterns of Recurrence in T1-3N0 Non-Small Cell Lung Cancer

Yeon Sil Kim, Republic of Korea

P2.16-05 - Hypermethylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK Genes Plays a Role in NSCLC Pathogenesis

Milica Kontic, Serbia

P2.16-06 - Development and Validation of a Gene Expression-Based Nomogram to Predict Relapse in Stage I NSCLC: A Retrospective, Multi-Cohort Study

Qixing Mao, China

P2.16-07 - Impact of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study

Yoshiya Matsumoto, Japan

P2.16-08 - Influence of Tumour Location and Histological Sub-Type of Non-Small Cell Lung Cancer on Patient Survival

Alan McWilliam, UK

P2.16-09 - Patterns of Brain Metastases in Stage I-III Non-Small Cell Lung Cancer: An NCDB Analysis

Stephanie Rice, USA

P2.16-10 - Prognostic Impact of Postoperative C-Reactive Protein for Non-Small Cell Lung Cancer Following Lobectomy

Shuichi Shinohara, Japan

P2.16-11 - Prognostic Role of Combined Pulmonary Fibrosis and Emphysema (CPFE) in Patients with Clinical Stage I Lung Cancer.

Yasuhiro Tsutani, Japan

P2.16-12 - Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy

Gavitt Woodard, CA/USA

P2.16-13 - A Proposal of Classification for Subsolid Nodule: Prognostic Impact of T Descriptor

Erjia Zhu, China

P2.16-14 - Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study



Banu Atalar, Turkey

P2.16-15 - Toxicities and Survival after Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors

Banu Atalar, Turkey

P2.16-16 - SABRTOOTH: A Feasibility Study of SABR Versus Surgery in Patients with Peripheral Stage I NSCLC Considered to be at Higher Risk for Surgery.

Kevin Franks, UK

P2.16-17 - Hypo-Fractionated Accelerated Radiotherapy in Central Early Non-Small Cell Lung Cancer: Leeds Cancer Centre Experience.

Kevin Franks, UK

P2.16-18 - Study of Interstitial Lung Disease and Acute Exacerbation in Patients Receiving Radiation Therapy for Lung Cancer in Japan.

Yasuhito Hagiwara, Japan

P2.16-19 - Feasibility and Outcomes of Radiofrequency Ablation as Salvage Modality After Hypofractionated Radiation/SBRT for Early NSCLC

Ritika Harjani Hinduja, Canada

P2.16-20 - Prognostic Utility of PET in Non-Small Cell Lung Cancer After Empiric Stereotactic Body Radiotherapy (SBRT)

Shaakir Hasan, PA/USA

P2.16-21 - Post-Treatment Survival Difference Between Lobectomy and Stereotactic Ablative Radiotherapy in Stage 1 Non-Small Cell Lung Cancer in England

Neal Navani, UK

P2.16-22 - Comparing Two Common Radiotherapy Regimens in Non-Small Cell Lung Cancer - A Retrospective Study

Stephen Harrow, UK

P2.16-23 - Focal Therapy for Small Lung Cancer with Ethanol Release Heat-Generating Polymer

Junichi Shimada, Japan

P2.16-24 - Racial Differences in Treatment and Survival of Stage I NSCLC: A Comparison of Veterans Affairs (VA) and SEER-Medicare Populations

Christina Williams, NC/USA



P2.16-25 - Lower Hilar Lymph Node Upstaging in Early NSCLC Vats Surgery is Related to Tumor Location and Does Not Afect Survival

Marc Boda, Spain

P2.16-26 - Lung Cancer Resection in Patients with Criteria for Lung Cancer Screening Provides Satisfactory Short-Term Results

David Boulate, France

P2.16-27 - Indocyanine Green Virtual Assisted Lung Mapping (ICG-VAL-MAP): Anyone Can Perform a Visible Preoperative Marking Successfully

Toyofumi Chen-Yoshikawa, Japan

P2.16-28 - Comparison of Outcomes of VATS Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Using a Propensity Score Matching Analysis

YooHwa Hwang, Republic of Korea

P2.16-29 - Clinical Outcomes of Surgically Resected Extraabdominal Chest Wall Desmoid Tumors

Seok Kim, Republic of Korea

P2.16-30 - Surgical Strategy for Clinical Stage IA Non-Small Cell Lung Cancer Patients with Risk Factors of Pathological Invasion and/or Metastasis

Terumoto Koike, Japan

P2.16-31 - Examination of the Intersegmental Isolation Method in the Segmental Resection Considering Respiratory Function Preservation

Katsuo Kojima, Japan

P2.16-32 - Survival Implications and Factors Associated with the Anatomic Level of Incomplete Non-Small-Cell Lung Cancer (NSCLC) Resection

Yu-Sheng Lee, TN/USA

P2.16-33 - Adenosquamous Carcinoma of the Lung: Comparison of Surgical Outcomes with Squamous Cell and Adenocarcinoma

Huseyin Melek, Turkey

P2.16-34 - Visceral Pleural Invasion is Closely Associated with Nodal Spread in cStage IA Lung Adenocarcinoma

Tetsuya Mizuno, Japan

P2.16-35 - Analysis of Pre and Intra Operative Factors Related to the Operation Time of Lobectomy in VATS: Is the Shape of Thoracic Cavity a Predictive Factor?

Takuya Nagashima, Japan

P2.16-36 - Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer

Masao Nakata, Japan

P2.16-37 - The Introduction of Robotic Lobectomy for Non-Small Cell Lung Cancer in South East Asia: A 5-Year Single Centre Study

Kingsfield Ong, Singapore

P2.16-38 - Characteristics of Preoperative N Staging in Patients with Optimal Pathologic N Staging of Non-Small Cell Lung Cancer (NSCLC)

Meredith Ray, USA

P2.16-39 - The Application of 3D Medical Image Analyzer and a Fluorescence Guided Surgery for Pulmonary Sublobar Resection

Yasuo Sekine, Japan

P2.16-40 - Impact of Preoperative Pectoralis Muscle Quantity and Density on Outcome After Complete Resection of Non-Small Cell Lung Cancer

Changbo Sun, Japan

P2.16-41 - Intraoperative Computed Tomography After Tumor Marking with Metal Clips for Non-Palpable Lung Tumors

Yoshimasa Tokunaga, Japan

P2.16-42 - Standard Mediastinoscopy Versus Video-Assisted Mediastinoscopic Lymphadenectomy in Clinical N1 Non-Small Cell Lung Cancer

Akif Turna, Turkey

P2.16-43 - Diabetes is a Negative Prognostic Factor in Non-Small Cell Lung Cancer Patients Undergoing Resectional Surgery

Akif Turna, Turkey

P2.16-44 - Long-Term Outcome of Pulmonary Segmentectomy for c-IA Non-Small Cell Lung Cancer

Hironobu Wada, Japan

1

P2.16-45 - Should Patients with Stage IB Non-Small Cell Lung Cancer Receive Adjuvant Chemotherapy?

Jia Wang, China

**P2.16-46 - Clinical Outcomes and Treatment Strategies of Sarcomatoid Carcinoma of the Lung**

Yan Wang, China

P2.16-47 - “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy

Jin Xia, China

P2.16-48 - Outcomes of Stage I Lung Cancer Patients Treated with Segmentectomy via Three-Dimensional Uniportal VATS Versus Two-Dimensional Approach

Chengliang Yang, China

P2.16-49 - Which Nomogram is More Reliable to Predict Recurrence of Pathological Stage IA Lung Adenocarcinoma Treated by Surgery?

Lu Yang, China

P2.16-50 - Do Patients Have Preconceived Ideas on Various Surgical Approaches? Patient Perspective: Open vs. Minimally Invasive Surgery (PROMIS) Survey.

Ching Yeung, ON/Canada

P2.16-51 - Nationwide Trends in Surgical Treatment of Lung Cancer in Estonia, 2000–2015

Tanel Laisaar, Estonia

P2.17

16:45 - 18:00

Treatment of Locoregional Disease - NSCLC

Exhibit Hall

P2.17-01 - Trimodality Therapy (TT) in the Treatment of Stage IIIA Non-Small Cell Lung Cancer (NSCLC)

Tahir Mehmood, Pakistan

P2.17-02 - Cardiopulmonary Exercise Tests in Lung Cancer Patients Treated Radical Radiotherapy and Chemotherapy - Feasibility Study

Nazia Mohammed, UK

P2.17-03 - A Propensity-Matched Analysis of Neoadjuvant Chemoradiotherapy and Adjuvant Chemoradiotherapy for IIIA(N2) Non-Small Cell Lung Cancer

Yaping Xu, China

P2.17-04 - Imiquimod Attenuates Radiation-Induced Pulmonary Fibrosis

Guler Yavas, Turkey

P2.17-05 - Consolidation Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiotherapy



Fatma Basal, Turkey

P2.17-06 - Functional Lung Imaging in Radiotherapy for Lung Cancer: A Systematic Review and Meta-Analysis

Nicholas Bucknell, Australia

P2.17-07 - Concurrent Chemoradiotherapy (ConCRT) using Cisplatin-Vinorelbine in Locally Advanced (LA) Non-Small Cell Lung Cancer (NSCLC)

Haris Charalambous, Cyprus

P2.17-08 - Heart Motion in Lung Radiotherapy: How Representative Are Delineations Based on 3DCT, Average and Maximum Projection Scans?

David Cobben, UK

P2.17-09 - Exploring the Impact of Age on the Efficacy of Adjuvant Chemotherapy After Radical Resection in Non- Small Cell Lung Cancer

Catherine Davidson, UK

P2.17-10 - Daily Low-Dose Cisplatin and High Dose Radiotherapy for Elderly Patients with Stage III NSCLC is Well Tolerated.

E M T Dieleman, Netherlands

P2.17-11 - Impact of Quantitatively Assessed Emphysema on Chest Tube Drainage After Lobectomy for Non-Small Cell Lung Cancer

Tomasz Gil, Poland

P2.17-12 - Eliminating Radiation Resistance of Non-Small Cell Lung Cancer By DHA Trough Abrogating Immunity Escaping via Inhibiting PD-L1 Expression

Xiaomei Gong, China

P2.17-13 - Genome-Wide Copy Number Alterations Profiling Predict Efficacy of Resected Stage II-IIIa Lung Adenocarcinoma

Xiaohong Han, China

P2.17-14 - How Should Positive Margin for Bronchial Stumps (R1) Be Evaluated in Patients Undergoing Bronchoplasty for Lung Cancer?

Kazunori Hata, Japan

P2.17-15 - Mediastinoscopic Assessment of N2 Disease and Optimisation of Surgical Treatment of N2 Disease in NSCLC

George Karimundackal, India

**P2.17-16 - Radical en Bloc Resection for Lung Cancer Invading the Spine**

Masato Kato, Japan

P2.17-17 - Multimodal Treatment in Pathologically Confirmed Single-Station Resectable IIIA-N2 Non-Small Cell Lung Cancer: A Single Center Experience

Margarita Majem, Spain

P2.17-18 - A Prognostic Score for Patients Receiving Multimodal Treatment for Locally-Advanced Non-Small Cell Lung Cancer

Maurice Dantes, Germany

P2.17-19 - Concurrent Chemoradiotherapy with Carboplatin-Paclitaxel Versus Cisplatin-Etoposide for Stage III NSCLC Patients - Review of Literature

Tahir Mehmood, Pakistan

P2.17-20 - Systematic Literature Review of Chemoradiotherapy Versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer

Tahir Mehmood, Pakistan

P2.17-21 - Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer

Sachiko Miura, Japan

P2.17-22 - Cardiac Biomarkers in CART Study (CARDiac Toxicity in Lung Cancer Patients After Chemo-Radiotherapy).

Nazia Mohammed, UK

P2.17-23 - Optimal Therapy of Stage III NSCLC: The Role of Surgery in the Era of Immunotherapy

Sara Moore, BC/Canada

P2.17-24 - Does the Change in Body Mass Index During Induction Chemo/Chemoradiotherapy Affect the Outcome of Surgery in Locally Advanced NSCLC?

Huseyin Melek, Turkey

P2.17-25 - Post-Treatment Neutrophil to Lymphocyte Ratio in Locally Advanced NSCLC Patients Treated with Concurrent Chemoradiotherapy

Eun Young Park, Korea, Republic of

P2.17-26 - Quantifying the Interfractional Motion of the Esophagus During Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer



Hui Liu, China

P2.17-27 - IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy

Naiyer Rizvi, NY/USA

P2.17-28 - Real-World Data: Survival Outcomes of Chemotherapy Regimens Given Concurrently with Radiotherapy for Locally Advanced NSCLC

David Chun Cheong Tsui, Canada

P2.17-29 - Is Collagen Vascular Disease-Associated Interstitial Lung Disease a High Risk for Lung Cancer Surgery?

YUKIO Watanabe, Japan

P2.17-30 - Serum Lipoprotein(A) Correlates with the Effect of Endostar Combined with Concurrent Chemoradiotherapy in Patients with Locally Advanced LSCC

Haihua Yang, China

P2.17-31 - The Effect of the Extended Bilateral Mediastinal Lymph Node Dissection Through a Median Sternotomy for Non-Small-Cell Carcinoma of the Left Lung.

Toshiya Yokota, Japan

P2.17-32 - Dynamic Monitoring Before and After Neo-Adjuvant Crizotinib in Non-Small Cell Lung Cancer: A Brief Report

Chao Zhang, China

P2.17-33 - Role of Adjuvant Therapy in Pulmonary Adenosquamous Carcinoma

Jiaxi He, China

17:00 - 18:00	IASLC Business Meeting	Room 202 BD
---------------	------------------------	-------------

17:00 - 18:00	IASLC Business Meeting	
---------------	------------------------	--

ISS15

18:00 - 19:30	Symposium Supported by AstraZeneca: Stage III NSCLC: Combining Immunotherapies with Standard Treatments... Who, When, Why?	Room 106
---------------	--	----------

18:00 - 19:30	Stage III NSCLC: Combining Immunotherapies with Standard Treatments...Who, When, Why?	
---------------	---	--



19:30 - 23:00 **Conference Dinner (Ticketed Event)** **Plenary Hall**

19:30 - 23:00 Conference Dinner (Ticketed Event)



Wednesday, September 26, 2018

MTE19

07:00 - 08:00 **How I Treat Advanced Stage Thymic Malignancy Patients (Ticketed Session)** **Room 205 AC**
Topics: Thymoma/Other Thoracic Malignancies

07:00 - 08:00 **MTE19.01 - How I Treat Advanced Stage Thymic Malignancy Patients**
Heather Wakelee, CA/USA

MTE20

07:00 - 08:00 **Molecular Testing in Small Samples (Ticketed Session)** **Room 202 BD**
Topics: Pathology

07:00 - 07:30 **MTE20.01 - Molecular Testing in Small Samples**
John Longshore, NC/USA

07:30 - 08:00 **MTE20.02 - Molecular Testing in Small Samples**
Jin-Haeng Chung, Republic of Korea

MTE21

07:00 - 08:00 **Can I Treat Brain Metastasis with Immunotherapy? (Ticketed Session)** **Room 105**
Topics: Immunooncology

07:00 - 07:30 **MTE21.01 - Can I Treat Brain Metastasis with Immunotherapy?**
Sarah Goldberg, CT/USA

07:30 - 08:00 **MTE21.02 - Can I Treat Brain Metastasis with Immunotherapy?**
Caroline Chung, USA



MTE22

07:00 - 08:00 **Incorporation of Smoking Cessation in Clinical Care (Ticketed Session)** **Room 206 BD**
Topics: Prevention and Tobacco Control

07:00 - 07:30 **MTE22.01 - Integration of Cessation and Lung Cancer Screening**
Matthew Steliga, AR/USA

07:30 - 08:00 **MTE22.02 - Cessation and Clinical Lung Cancer Care**
Jamie Ostroff, CO/USA

MTE23

07:00 - 08:00 **Surgical Considerations Following Induction Therapy for Stage IIIA Disease (Ticketed Session)** **Room 201 BD**
Topics: Treatment of Locoregional Disease - NSCLC

07:00 - 07:30 **MTE23.01 - Surgical Considerations Following Induction Therapy for Stage IIIA Disease**
Eric Vallieres, WA/USA

07:30 - 08:00 **MTE23.02 - Surgical Considerations Following Induction Therapy for Stage IIIA Disease**
Jonathan Spicer, QC/Canada

MTE24

07:00 - 08:00 **Multiple Lung Nodules; Resect, Radiate or Watch? (Ticketed Session)** **Room 203 BD**
Topics: Treatment of Early Stage/Localized Disease

07:00 - 07:30 **MTE24.01 - Surgery vs SABR for Early NSCLC**
Thomas D'amico, USA

07:30 - 08:00 **MTE24.02 - Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR)**
David Ball, Australia



MTE25

07:00 - 08:00 **Enhancing the Care of Your Older Adult Population with Lung Cancer (Ticketed Session)** **Room 205 B**
Topics: Nursing and Allied Professionals

07:00 - 08:00 **MTE25.01 - Enhancing the Care of Your Older Adult Population with Lung Cancer**
Martine Puts, Canada

MTE26

07:00 - 08:00 **New Paradigms in Symptom Management in Lung Cancer (Ticketed Session)** **Room 206 AC**
Topics: Treatment in the Real World - Support, Survivorship, Systems Research

07:00 - 07:30 **MTE26.01 - Treatment of Cancer Related Symptoms**
Patricia Rivera, USA

07:30 - 08:00 **MTE26.02 - Symptoms and IO Toxicity Management**
Jarushka Naidoo, USA

MTE27

07:00 - 08:00 **Controversies in Radiotherapy for SCLC (Ticketed Session)** **Room 206 F**
Topics: Small Cell Lung Cancer/NET

07:00 - 08:00 **MTE27.01 - Radiotherapy in ES-SCLC**
Elizabeth Gore, USA

MTE28

07:00 - 08:00 **Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP (Ticketed Session)** **Room 201 F**
Topics: Interventional Diagnostics/Pulmonology

07:00 - 07:30 **MTE28.01 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP**
Navneet Singh, India

07:30 - 08:00 **MTE28.02 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP**
Jason Agulnik, Canada

SH03

07:00 - 08:00	Highlight of the Previous Day Sessions Moderation: C. Sit, Canada; A. Bang, Canada	Room 107
----------------------	--	-----------------

07:00 - 07:12 **SH03.01 - Thymoma & Outcomes**
Shirish Gadgeel, USA

07:12 - 07:24 **SH03.02 - Targeted**

07:24 - 07:36 **SH03.03 - Biology**

07:36 - 07:48 **SH03.04 - Screening**
Stephen Lam, Canada

07:48 - 08:00 **SH03.05 - Q&A**

SH04

07:00 - 08:00	Highlight of the Previous Day Sessions Moderation: P. Garrido, Spain	Room 106
----------------------	--	-----------------

07:00 - 07:12 **SH04.01 - SCLC/NET**

07:12 - 07:24 **SH04.02 - Surgery**

07:24 - 07:36 **SH04.03 - Locally Advanced/IO**
Edgardo Santos, USA

07:36 - 07:48 **SH04.04 - Survivorship & Radiation**

07:48 - 08:00 **SH04.05 - Q&A**



PL03

08:15 - 09:45	Call to Action - Challenges Ahead Moderation: G. Darling, Canada; N. Saijo, Japan	Plenary Hall
08:15 - 08:30	PL03.01 - From Bench to Bedside Charles Swanton, UK	
08:30 - 08:45	PL03.02 - Host Immunity - No Longer a Passive Bystander Julie Brahmer, MD/USA	
08:45 - 09:00	PL03.03 - Beaming into the Future David Palma, Canada	
09:00 - 09:15	PL03.04 - A Cut Above Yolonda Colson, USA	
09:15 - 09:30	PL03.05 - It's All in The Tissue Keith Kerr, UK	
09:30 - 09:40	PL03.06 - The Future of Targeted Therapy Tetsuya Mitsudomi, Japan	

ES06

10:30 - 12:00	Oligometastatic Disease Topics: Oligometastatic NSCLC Moderation: R. Martins, USA; G. Rocco, Italy	Room 202 BD
10:30 - 10:50	ES06.01 - Current Clinical Trials in Oligometastases Anne-Marie Dingemans, Netherlands	
10:50 - 11:10	ES06.02 - Integrating New Systemic Therapy into Trials in OMD Sanjay Popat, UK	
11:10 - 11:30	ES06.03 - Developments in SBRT in the Oligometastatic Paradigm in NSCLC Patrick Cheung, ON/Canada	
11:30 - 11:50	ES06.04 - Surgical Considerations in OMD Jessica Donington, NY/USA	



11:50 - 12:00 ES06.05 - Q&A

MA23

10:30 - 12:00	Early Stage Lung Cancer: Present and Future	Room 105
---------------	--	-----------------

Topics: Treatment of Early Stage/Localized Disease
Moderation: A. Coonar, UK; R. Decker, USA

10:30 - 10:35 **MA23.01 - Buffy Coat Immunooncologic Diagnosis and Prognosis of pStage I Lung Adenocarcinoma**

Harvey Pass, NY/USA

10:35 - 10:40 **MA23.02 - Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer**

Vincent Lam, TX/USA

10:40 - 10:45 **MA23.03 - Risk Assessment for Indeterminate Pulmonary Nodules Using a Novel, Plasma-Protein Based Biomarker Assay**

Anil Vachani, PA/USA

10:45 - 11:00 **MA23.04 - Discussant - MA 23.01, MA 23.02, MA 23.03**

Scott Bratman, Canada

11:00 - 11:05 **MA23.05 - Post-Operative Radiation Improves Overall Survival in Patients with Node-Positive Non-Small Cell Lung Cancer Undergoing Sublobar Resections**

Karl Fabian Uy, MA/USA

11:05 - 11:10 **MA23.06 - Small Residual Setup Errors After Image-Guided Radiotherapy Affect Heart Dose and Are Linked to Overall Survival**

Alan McWilliam, UK

11:10 - 11:15 **MA23.07 - Defining the Role of Adjuvant Therapy for Early Stage Large Cell Neuroendocrine Lung Cancer**

Elliot Wakeam, Canada

11:15 - 11:30 **MA23.08 - Discussant - MA 23.05, MA 23.06, MA 23.07**

Kevin Franks, UK



- 11:30 - 11:35 **MA23.09 - Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy, a Comparison Utilizing the National Cancer Database**
Mark Hennon, NY/USA
- 11:35 - 11:40 **MA23.10 - Cone-Beam Computed Tomography-Guided Microcoil Localization of Pulmonary Nodules During Video-Assisted Thoracic Surgery**
Hideki Ujiie, ON/Canada
- 11:40 - 11:45 **MA23.11 - Lobe-Specific Nodal Dissection for Clinical Stage I and II Non-Small Cell Lung Cancer: Japanese Multi-Institutional Retrospective Study**
Tomoyuki Hishida, Japan
- 11:45 - 12:00 **MA23.12 - Discussant - MA 23.09, MA 23.10, MA 23.11**
Giulia Veronesi, Italy

MA24

- 10:30 - 12:00** **Genomic Evolution, KEAP 3 and More Non-Coding RNA** **Room 205 B**
Topics: Biology, Treatment of Early Stage/Localized Disease
Moderation: P. Yang, USA; R. Salgia, USA
- 10:30 - 10:35 **MA24.01 - Genomic Evolution Trajectory Depicts Invasiveness Acquisition from Pre-invasive to Invasive Adenocarcinoma**
Chao Zhang, China
- 10:35 - 10:40 **MA24.02 - Genomic Alterations in Lung Adenocarcinoma Precursor Lesions**
Dennis Wigle, USA
- 10:40 - 10:45 **MA24.03 - Biologic Profiling of Pre-Metastatic Niche in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer**
Tomohito Saito, Japan
- 10:45 - 11:00 **MA24.04 - Discussant - MA 24.01, MA 24.02, MA 24.03**
Udayan Guha, USA
- 11:00 - 11:05 **MA24.05 - Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naïve EGFR-Mutant Lung Adenocarcinomas**
Michael Cabanero, ON/Canada



- 11:05 - 11:10 **MA24.06 - Long Non-Coding Rna Expression Patterns Delineate Infiltrating Immune Cells in the Lung Tumour Microenvironment**
Adam Sage, BC/Canada
- 11:10 - 11:15 **MA24.07 - A Novel Cis-Acting lncRNA Controls HMGA1 Expression in Lung Adenocarcinoma**
Adam Sage, BC/Canada
- 11:15 - 11:30 **MA24.08 - Discussant - MA 24.05, MA 24.06, MA 24.07**
Alice Berger, USA
- 11:30 - 11:35 **MA24.09 - Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small Cell Lung Cancer with an Altered Metabolism**
Sarah Best, VIC/Australia
- 11:35 - 11:40 **MA24.10 - Interrogating the Metabolic Effects of Keap1 Inactivation in Adenocarcinoma**
Sarah Best, VIC/Australia
- 11:40 - 11:45 **MA24.11 - Loss of Tumour Suppressors is Adequate and Sufficient to Drive Lung Cancer in CRISPR/Cas9 Mice.**
Paola Marignani, Canada
- 11:45 - 12:00 **MA24.12 - Discussant - MA 24.09, MA 24.10, MA 24.11**
Vladmir Cordeiro De Lima, Brazil

MS22

- | | | |
|----------------------|---|-------------------|
| 10:30 - 12:00 | Biology of the Lung and Lung Cancer
Topics: Biology
Moderation: M. Meyerson, USA; G. Liu, Canada | Room 206 F |
|----------------------|---|-------------------|
- 10:30 - 10:45 **MS22.01 - Lung Development and Stem Cells**
Carla Kim, MA/USA
- 10:45 - 11:00 **MS22.02 - Epigenetic Alterations in Lung Cancer Development**
Wan Lam, Canada
- 11:00 - 11:15 **MS22.03 - Non-Coding RNA in Lung Cancer**
Sven Diederichs, Germany



- 11:15 - 11:30 **MS22.04 - Genomics of Resistance and Response in Lung Cancer**
Marc Ladanyi, NY/USA
- 11:30 - 11:45 **MS22.05 - Inflammation in Lung Cancer**
Katerina Politi, USA
- 11:45 - 12:00 **MS22.06 - Transcriptomic-Metabolomic Reprogramming as Resistant Mechanism**
Patrick Ma, WV/USA

MS23

10:30 - 12:00 **What's New in Targeted Therapy?** **Room 106**
Topics: Targeted Therapy
Moderation: V. Hirsh, Canada; A. Dron, USA

- 10:30 - 10:45 **MS23.01 - Novel Combinations of Targeted Therapies**
Pasi Jänne, MA/USA
- 10:45 - 11:00 **MS23.02 - Emerging or Rare Targets - Fusions, Mutational Burden Etc**
Luis Paz-Ares, Spain
- 11:00 - 11:15 **MS23.03 - Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onc Perspectives)**
Marina Garassino, Italy
- 11:15 - 11:30 **MS23.04 - Targeting Driver Oncogenes in Stage 1-3 NSCLC**
Helena Yu, NY/USA
- 11:30 - 11:45 **MS23.05 - Role of Immunotherapy in Patients with Molecular Driven NSCLC**
Benjamin Besse, France
- 11:45 - 12:00 **MS23.06 - Q&A**

MS24

10:30 - 12:00 **Global Perspectives on Tobacco Control** **Room 206 BD**
Topics: Prevention and Tobacco Control
Moderation: R. Haddad, Brazil; D. Carney, Ireland



- 10:30 - 10:45 **MS24.01 - Tobacco Control Impacting the Effectiveness and Cost of Cancer Care**
Graham Warren, USA
- 10:45 - 11:00 **MS24.02 - Legal Action Against the Tobacco Industry in Europe**
Paul Baas, Netherlands
- 11:00 - 11:15 **MS24.03 - The Importance of Physician Involvement in Tobacco Control**
Jacek Jassem, Poland
- 11:15 - 11:30 **MS24.04 - Challenges of Tobacco Control in China**
Caicun Zhou, China
- 11:30 - 12:00 **MS24.05 - Q&A**

MS25

- | | | |
|---------------|---|-------------|
| 10:30 - 12:00 | Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes
Topics: Mesothelioma
Moderation: D. Fennell, UK; A. Mansfield, USA | Room 206 AC |
|---------------|---|-------------|
- 10:30 - 10:45 **MS25.01 - Impact of Tumor Volume on Outcome: What Are the Limitations?**
Anna Nowak, Australia
- 10:45 - 11:00 **MS25.02 - How Should P16, BAP1, and NF2 Mutations Be Integrated in Therapeutic Algorithms?**
Francoise Galateau-Salle, France
- 11:00 - 11:15 **MS25.03 - Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis**
Thomas John, Australia
- 11:15 - 11:30 **MS25.04 - Biomarkers in Clinical Practice: Is It Prime Time?**
Harvey Pass, NY/USA
- 11:30 - 11:45 **MS25.05 - Targeting the Micro-RNA: A New Therapeutic Venture**
Nick Pavlakakis, Australia
- 11:45 - 12:00 **MS25.06 - Q&A**



MS26

10:30 - 12:00	From Textbook to Practice Around the World Topics: Treatment in the Real World - Support, Survivorship, Systems Research Moderation: J. Naidoo, USA; F. Moraes, Brazil	Room 205 AC
10:30 - 10:45	MS26.01 - Translation of Clinical Data to Real World - Asia Dae Ho Lee, Republic of Korea	
10:45 - 11:00	MS26.02 - Translation of Clinical Data to Real World - North America Cheryl Ho, BC/Canada	
11:00 - 11:15	MS26.03 - Translation of Clinical Data to Real World - Europe Fabrice Barlesi, France	
11:15 - 11:30	MS26.04 - Translation of Clinical Data to Real World - Latin America/Africa	
11:30 - 12:00	MS26.05 - Panel Discussion	

MS27

10:30 - 12:00	Therapeutic Implications of Staging Issues Topics: Treatment of Early Stage/Localized Disease Moderation: J. Edwards, Canada; M. Ito, Japan	Room 201 BD
10:30 - 10:45	MS27.01 - Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications Raymond Osarogiagbon, TN/USA	
10:45 - 11:00	MS27.02 - Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary? Anand Swaminath, Canada	
11:00 - 11:15	MS27.03 - Multiple Lung Nodules: M1, T4 or T3? Are They Really Different? Frank Detterbeck, CT/USA	



- 11:15 - 11:30 **MS27.04 - Therapeutic Implications of AJCC 8th Edition T1 Subsets**
Laura Donahoe, Canada
- 11:30 - 11:45 **MS27.05 - The Future of Precision Therapy for Localized Lung Cancer**
Takashi Seto, Japan
- 11:45 - 12:00 **MS27.06 - Q&A**

OA13

- | | | |
|----------------------|--|--------------------|
| 10:30 - 12:00 | Therapeutics and Radiation for Small Cell Lung Cancer
Topics: Small Cell Lung Cancer/NET
Moderation: S. Snow, Canada; T. Tsakiridis, Canada | Room 203 BD |
|----------------------|--|--------------------|
- 10:30 - 10:40 **OA13.01 - The Impact of [¹⁸F] fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial**
Prakash Manorharan, UK
- 10:40 - 10:50 **OA13.02 - Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119**
Taofeek Owonikoko, GA/USA
- 10:50 - 11:00 **OA13.03 - Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial**
Ying Cheng, China
- 11:00 - 11:15 **OA13.04 - Discussant - OA 13.01, OA 13.02, OA 13.03**
Normand Blais, QC/Canada
- 11:15 - 11:25 **OA13.05 - Prophylactic Cranial Irradiation (PCI) for Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 CONVERT Trial**
Cecile Le Pechoux, France
- 11:25 - 11:35 **OA13.06 - Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses**
Xiao Hu, China
- 11:35 - 11:45 **OA13.07 - Survival Outcomes After Whole Brain Radiotherapy for Brain Metastases in Elderly Patients with Newly Diagnosed Metastatic Small Cell Carcinoma.**
Paul Renz, PA/USA



11:45 - 12:00 **OA13.08 - Discussant - OA 13.05, OA 13.06, OA 13.07**
Inga Grills, USA

PC09

10:30 - 12:00 Approaches to Management of Advanced NSCLC Room 107
Topics: Advanced NSCLC
Moderation: G. Bebb, Canada; Y. Goto, Japan

10:30 - 10:45 **PC09.01 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Early**
Qing Zhou, China

10:45 - 11:00 **PC09.02 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Delayed**
Walter Curran Jr., USA

11:00 - 11:15 **PC09.03 - Discussion**

11:15 - 11:30 **PC09.04 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - NSCLC**
Noemi Reguart, Spain

11:30 - 11:45 **PC09.05 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC**
Scott Laurie, Canada

11:45 - 12:00 **PC09.06 - Discussion**

ISS16

12:00 - 13:30 Symposium Supported by AbbVie: Biomarker Driven SCLC Treatment: Fact or Fiction? Plenary Hall

12:00 - 13:30 **Biomarker Driven SCLC Treatment: Fact or Fiction?**



P3.01

12:00 - 13:00

Advanced NSCLC

Exhibit Hall

P3.01-01 - Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients

Yi-Long Wu, China

P3.01-02 - Patients with a Smaller Primary Tumor and Fewer Metastases Could be Cured Even in Advanced Non-Small Cell Lung Cancer

Takuya Aoki, Japan

P3.01-03 - The Cost Benefit from Second Line Immunotherapy in Metastatic NSCLC: ASCO Value Framework Prospective

Ahmed Badawy, Egypt

P3.01-04 - Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience.

Kiran Virik, ON/Canada

P3.01-05 - Mature Progression-Free Survival in Stage IV Non-Small Cell Lung Cancer Patients Treated with Pemetrexed Maintenance Therapy

Marta Batus, IL/USA

P3.01-06 - Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC

Sourin Bhuniya, India

P3.01-07 - Outcome and Prognostic Factors in ALK+ve Metastatic Adenocarcinoma of Lung: Single Center Experience from Eastern India

Bivas Biswas, India

P3.01-08 - Gender Differences in Lung Cancer Survival

Marko Jakopovic, Croatia

P3.01-09 - Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC

Jacqueline Brown, VA/USA

**P3.01-10 - Dyspnea as a Prognostic Factor in Hispanic Patients with Non-Small Cell Lung Cancer Cohort**

Saul Campos-Gomez, Mexico

P3.01-11 - Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Andrés Cardona, Colombia

P3.01-12 - EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil.

Gilberto Castro Jr, Brazil

P3.01-13 - Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)

Anna Chalmers, USA

P3.01-14 - mTORC1 Regulates the Radiosensitivity of NSCLC Cells with Wildtype PI3KCA and KRAS Genes by Affecting EMT

Yuan Chen, China

P3.01-15 - Efficacy of Paclitaxel Plus TS1 Against Non-Small Cell Lung Cancer Previously Treated

Yuh-Min Chen, Taiwan

P3.01-16 - Low Dose Apatinib Combined with EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Mingda Chen, China

P3.01-17 - Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab

Ewa Chmielowska, Poland

P3.01-18 - Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer

Jang Ho Cho, Republic of Korea

P3.01-19 - Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Cliff Molife, USA

P3.01-20 - Advanced NSCLC Treatment and Outcomes After Nivolumab

Girish Mallesara, NSW/Australia

P3.01-21 - Metastatic Lung Carcinoma –An Institutional Experience from Eastern India



Saroj Das Majumdar, India

P3.01-22 - An Exploratory Analysis of PD-L1 Expression and Smoking History in a Cohort of Advanced Non-Small Cell Lung Cancer Patients

Marios Decatris, UK

P3.01-23 - Imaging Modalities for Surveillance and Follow-Up of Patient with Lung Cancer After Adjuvant Chemotherapy

Aya El Helali, UK

P3.01-24 - The Importance to Switch from EGFR-TKI to Cytotoxic Chemotherapy for EGFR Mutation-Positive Adenocarcinoma

Daisuke Eriguchi, Japan

P3.01-25 - Feasibility of Moderate Hypofractionated Thoracic Irradiation for Non-Small Cell Lung Cancer Patients with Very Limited Lung Function

Maurice Dantes, Germany

P3.01-26 - A Framework for Systematic Clinical Evaluation of Technical Innovations in Lung Cancer Patients Treated on the MR-Linac (MRL)

Corinne Faivre-Finn, UK

P3.01-27 - Characterization and Sensitization of Non-Small Cell Lung Cancer Cell Line Variants Selected for Resistance to Osimertinib

Peter Ferguson, Canada

P3.01-28 - The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer

Laila Roisman, Israel

P3.01-29 - St. Iv Lung Adenocarcinoma Treated by First-Line EGFR-Tyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype

Tomasz Gil, Poland

P3.01-30 - Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

Yasushi Goto, Japan

P3.01-31 - Prognostic Factors in Patients with Resected Pathological N2 Non-Small Cell Lung Cancer

Tatsuya Goto, Japan



P3.01-32 - An Open-Label, Non-Randomized, Biomarker Study of Concordance in Non-Invasive and Tissue Tests for T790M Detection in NSCLC

Jeffrey Gregg, CA/USA

P3.01-33 - EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis

Mahmut Gumus, Turkey

P3.01-34 - Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy

Tetsunari Hase, Japan

P3.01-35 - Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study

Jonathon Hill, Australia

P3.01-36 - Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer

Marta Honorio, Portugal

P3.01-37 - Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: TORG 1320

Shinobu Hosokawa, Japan

P3.01-38 - Therapeutic Effects of FMNP-MSD for Hyperthermia on Lung Cancer A549 in Nude Mice

Runlei Hu, China

P3.01-39 - Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress

Chunwei Xu, China

P3.01-40 - Treatment of Super Elderly Patients for Non-Small Cell Lung Cancer in Japan

Tatsuya Ibe, Japan

P3.01-41 - Anatomical and Clinical Basis of #11 LN by Systematic Bilateral Mediastinal Nodal Dissection for Left Lung Cancer through Median Sternotomy

Shingo Ikeda, Japan

P3.01-42 - Phase II Trial Allowed Surgery After Induction Chemotherapy of CBDCA+PTX, Bevacizumab in Patients with Stages IIIA-IV Nonsquamous NSCLC

Kazuhiro Imai, Japan

**P3.01-43 - Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer**

Hisao Imai, Japan

P3.01-44 - CYFRA 21-1 As a Predictor to Response to Chemotherapy and Overall Survival in Patients with Advanced NSCLC

Kashif Iqbal, Pakistan

P3.01-45 - Multifactorial Gene Alterations in EGFR Bypass Pathway are Induced by Afatinib in T790M-Mutant NSCLC Resistant to Osmertinib

Hidenobu Ishii, Japan

P3.01-46 - Prognostic Utility of Advanced Lung Cancer Inflammation Index (ALI) in Thoracic Malignancies: A Meta-Analysis

Syed Jafri, TX/USA

P3.01-47 - Clinical Characteristics and Outcome for Patients with Advanced Lung Adenocarcinoma Treated with First-Line Pemetrexed Plus Platinum

Xue Ji, China

P3.01-48 - The Efficiency of Low-Dose Apatinib in Treatment of Advanced Lung Squamous Cell Carcinoma

Yu-Ming Jia, China

P3.01-49 - Efficiency of Low-Dosage Apatinib Monotherapy in Treatment of Advanced Lung Squamous Cell Carcinoma

Hua Jiang, China

P3.01-50 - Identification of EGFR Mutational Profile in Lung Cancer Moroccan Cohort

Houda Kaanane, Morocco

P3.01-51 - Outcomes with Systemic Chemotherapy in Advanced NSCLC Patients with Performance Status 2 and Above and without Driver Mutation

Harish Kancharla, India

P3.01-52 - The Role of Serum Carcinoembryonic Antigen to Predict the Response of Treatment in Non-Small Cell Lung Cancer Patients

Muhammed Ali Kaplan, Turkey

P3.01-53 - Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients with T790M-Positive NSCLC

Yasuhiro Kato, Japan



P3.01-54 - A Historical Comparison of Patients with Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

Takahisa Kawamura, Japan

P3.01-55 - SF2: A PCYT-2 Inhibitor Prototype is Capable of Inducing Cytotoxicity in NSCLC

Bárbara Kawamura, Brazil

P3.01-56 - Hyperprogression and Pseudoprogression in Patients with Non-Small Cell Lung Cancer on Checkpoint Blocking Immunotherapy

Seoree Kim, Republic of Korea

P3.01-57 - Real-World (RW) Predictors of Immuno-Oncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Bruce Feinberg, OH/USA

P3.01-58 - Relative Abundance of EGFR Mutations in Plasma Predicts Tumor Response to EGFR-TKI in Advanced Lung Adenocarcinoma

Yuping Li, China

P3.01-59 - Comparison of Lobectomy, Segmentectomy and Wedge Resection for Early Stage NSCLC: A Direct and Network Meta-Analysis

Wang Liang, China

P3.01-60 - A Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient with Acquired MET Amplification

Ying Liang, China

P3.01-61 - EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non-Small Cell Lung Cancer

George Fountzilas, Greece

P3.01-62 - A New Method for Non-Invasive Prediction of Radiotherapy: SDH5 Depletion Enhances Radiosensitivity by Regulating P53

Jun Liu, China

P3.01-63 - Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-PD1/PD-L1 Treatment—Data from a Chinese Population

Shun Lu, China

P3.01-64 - Preliminary Data of Diverse Therapies in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring RET-Rearrangement



Chang Lu, China

P3.01-65 - First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs

Jingbo Wang, China

P3.01-66 - Clinicopathological Characteristics and Mutation Status of Pulmonary Invasive Mucinous Adenocarcinoma

Fangliang Lu, China

P3.01-67 - Integrated Network Analysis to Understand the Potential Mechanisms of Hydroxychloroquine in Non-Small Cell Lung Cancer Treatment

Jingyun Chen, China

P3.01-68 - Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients with Advanced NSCLC Harboring EGFR Mutations

Dongqing Lv, China

P3.01-69 - Stereotactic Ablative Radiotherapy Improves Progression-Free Survival & Local Control in Oligometastatic Lung Cancer Patients

Federico Maldonado, Mexico

P3.01-70 - Meta-Analysis of Metformin in Combination with Platinum Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer

Kristen Marrone, USA

P3.01-71 - Results of Extended Resection in T4 Non-Small Cell Lung Cancer

Takeshi Matsunaga, Japan

P3.01-72 - Pulmonary Resection in a Prone Position for Lung Cancer Invading the Spine: Two Cases Report

Shunsaku Miyauchi, Japan

P3.01-73 - Talc Versus Minocycline and OK-432 Pleurodesis for Malignant Pleural Effusion.

EISUKE Mochizuki, Japan

P3.01-74 - Clinical and Radiological Predictors of Efficacy to Nivolumab in NSCLC: A Multi-Institutional, Retrospective Cohort Study.

Rebecca Moor, QLD/Australia



P3.01-75 - RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC

Makoto Nishio, Japan

P3.01-76 - Clinical Background and Response to Chemotherapy in NSCLC Patients with MET Exon14 Skipping Mutation or High MET Gene Copy Number

Kaname Nosaki, Japan

P3.01-77 - Clinical Characteristics of Korean Lung Cancer Patients with Programmed Death-Ligand 1 Expression

In-Jae Oh, Republic of Korea

P3.01-78 - The Cytology Samples and Plasma Specimens were Feasible for the EGFR Molecular Testing.

Tatsuo Ohira, Japan

P3.01-79 - Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients with Brain Metastases

Fumiyoshi Ohyanagi, Japan

P3.01-80 - Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients with NSCLC Harboring EGFR Mutations.

Naoko Okura, Japan

P3.01-81 - Long-Term Outcome of Surgically Resected Unsuspected N2 Lung Adenocarcinoma

Byung Jo Park, Republic of Korea

P3.01-82 - Survival Impact of Surgery in the Treatment of Stage IIIB-IVA Non-Small Cell Lung Cancer

Ji Young Park, Republic of Korea

P3.01-83 - Use of Blood Outgrowth Endothelial Cells as a Cellular Carrier for Oncolytic Vesicular Stomatitis Virus in Preclinical Models of NSCLC

Manish Patel, MN/USA

P3.01-84 - The Association of CDKN2A Gene Mutation with Clinicopathological Features and Prognosis in Advanced Lung Cancer Patients

Xiujuan Qu, China

P3.01-85 - Real-World Gefitinib 1st Line Treatment of Patients with Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience

Davorin Radosavljevic, Serbia



P3.01-86 - Treatment Outcomes with Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients with Advanced NSCLC

Shabnam Rehman, USA

P3.01-87 - Efficacy and Safety of Pembrolizumab in Non-Small Cell Lung Cancer in Our Institution: A Retrospective Study

Nobuhiko Saijo, Japan

P3.01-88 - Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid

María Sereno Moyano, Spain

P3.01-89 - Upfront Surgery Versus Neoadjuvant Treatment Followed by Surgery in Pathologic N2 Non-Small Cell Lung Cancer

Byoung Yong Shim, Republic of Korea

P3.01-90 - A Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bev

Satoshi Shoji, Japan

P3.01-91 - Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape

George Simon, TX/USA

P3.01-92 - Blood Test Parameters as Prognostic Factors In EGFR-Mutated Non-Small Cell Lung Cancer Treated with TKIs

Jelena Spasic, Serbia

P3.01-93 - Osimertinib-Related Hematological and Pulmonary Toxicities in Advanced NSCLC Patients: Combined Analysis of Phase III Trials

Sriman Swarup, TX/USA

P3.01-94 - Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer

Konstantinos Syrigos, Greece

P3.01-95 - EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer

Konstantinos Syrigos, Greece

P3.01-96 - Clinical Characteristics of Non-Small Cell Lung Cancer Harboring Mutations in Exon 20 Of EGFR or HER2



Masayuki Takeda, Japan

P3.01-97 - Which is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC with Nivolumab; A Retrospective Analysis

Akihiro Tamiya, Japan

P3.01-99 - Effect of Pembrolizumab on Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutations

Yoshihiko Taniguchi, Japan

P3.01-100 - Risk of Gastrointestinal and Hepatic Toxicities in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Osimertinib

Kyaw Thein, TX/USA

P3.01-101 - A Retrospective Study of Lung Cancer that has Progressed to Brain Metastasis Alone

Kenjiro Tsuruoka, Japan

P3.01-102 - Potential Predictors of Unexpected Readmission After Lung Resection

Shinsuke Uchida, Japan

P3.01-103 - Efficacy of Crizotinib in Chinese Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Multicenter Retrospective Study

Shouzheng Wang, China

P3.01-104 - EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Chunwei Xu, China

P3.01-105 - Retrospective Analysis of Efficacy and Safety in Chinese Elderly Patients Treated with Nab-Paclitaxel

Shuhang Wang, China

P3.01-106 - Real-World Data to Evaluate the Clinical Benefit of NGS for Directing Lung Adenocarcinoma Treatment

Zhaoxia Wang, China

P3.01-107 - Correlation Study of Bone Metastasis and Cholesterol Level in Patients with Lung Adenocarcinoma

Yan Wang, China

**P3.01-108 - Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC**

Thomas Wehler, Germany

P3.01-109 - Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer

Loretta Williams, USA

P3.01-110 - Defining Aggressive Disease in Patients with Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Cliff Molife, USA

P3.01-111 - Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations

Yutaka Yamada, Japan

P3.01-112 - The Prognosis of Lung Cancer Patients with Unexpected Malignant Pleural Effusion and Without Pleural Dissemination Detected at Thoracotomy

Takashi Yamamichi, Japan

P3.01-113 - A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506)

Qing Zhou, China

P3.01-114 - Dissociation of Heart and Great Vessels for Long Tracheal Tumors and Lung Cancer Invaded Trachea: The Chinese Experience.

Qinghua Zhou, China

P3.01-115 - Liposomal Paclitaxel Versus Gemcitabine: Which is Better?

Xiangdong Zhou, China

P3.01-116 - Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population

Ferdous Begum, Bangladesh

P3.03

12:00 - 13:00

Biology

Exhibit Hall

P3.03-01 - BRAF V600 and Non-V600 Mutations in Chinese Lung Cancer

Yang Gao, China

**P3.03-02 - Single-Cell RNA-Seq in Human Lung Cancer**

Jinhong Kim, NS/Canada

P3.03-03 - Differential Microbiota Features in Lung Tumor and Adjacent Normal Tissues in Lung Cancer Patients

Qixing Mao, China

P3.03-04 - Is the Ciliary Function of the Lesion Bronchus Maintained in Patients with Lung Cancer?

Toshiyuki Sawa, Japan

P3.03-05 - Comparative Transcriptomic Analysis of Lung-iPSC, NSCLC, and SCLC: Potential Implications for iPSC Modeling of Lung Cancer

Vivek Shukla, MD/USA

P3.03-06 - Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes

Tomas Tokar, Canada

P3.03-07 - Co-Occurring Genomic Alterations in EGFR Altered Chinese Lung Adenocarcinoma Patients

Minghui Wang, China

P3.03-08 - Analysis of ESR1 Mutation Spectrum from Non-Small-Cell Lung Cancer in Chinese Patients

Chunwei Xu, China

P3.03-09 - Molecular Spectrum of KIT Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients

Chunwei Xu, China

P3.03-10 - Transcriptomic Differences Between Early and Late Stage Lung Adenocarcinoma

Dongsheng Yue, China

P3.03-11 - Lung Cancer Stem Cells on Immune Modulation in Tumorous Microenvironment

Huei-Wen Chen, Taiwan

P3.03-12 - Cyclic Mechanical Strain and Myoferlin Modulates Lung Adenocarcinoma Cell Proliferation and Erlotinib Resistance

YouJin Cho, USA

**P3.03-13 - Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines**

Inamul Haque, KS/USA

P3.03-14 - Downregulation of FOXM1 Inhibits Tumor Proliferation, Colony Formation and Spheroid Formation of Non-Small Cell Lung Cancer

Yoichi Otaki, Japan

P3.03-15 - Lung Cancer Regulation of Glucose Metabolic Stress Response

Laila Roisman, Israel

P3.03-16 - 3D Morphometric Detection of Mismatch Repair Deficiency in Human Lung Adenocarcinoma Cell Lines using the Cell-CT® Platform

Daniel Sussman, AZ/USA

P3.03-17 - Roles of $\alpha 7nAChR$ Signaling in Lung Cancer

Yu-Feng Wei, Taiwan

P3.03-18 - Collagen Type XI Promotes Lung Adenocarcinoma Dissemination Via Integrin $\alpha 2$ and DDR1

Cédric Zeltz, ON/Canada

P3.03-19 - The Lysyl Oxidase like-1 Promotes NSCLC Tumorigenicity Through Increased Matrix Reorganization and Stiffness

Cédric Zeltz, ON/Canada

P3.03-20 - Circulating Tumor Cell Clustering in Vitro Short-Term Culture Correlates with Poor Survival and Allows Monitoring Response to Treatment

Govind Babu, India

P3.03-21 - CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage Non-Small Cell Lung Cancer Patients

Andrea Fung, Canada

P3.03-22 - IL-1 β as a New Early Predictive Biomarker for Non-Small Cell Lung Cancers Outcome

Carlotta Giorgi, Italy

P3.03-23 - A Propensity Score Matching Cohort Study on Prognosis of the Diversity of MUC1 Expression in Patients with Lung Adenocarcinoma

Chundong Gu, China



P3.03-24 - Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging

Greg Haro, USA

P3.03-25 - Squamous Cell Carcinoma-Associated Bronchial Dysplasias Demonstrate Altered T-helper Lymphocyte Differentiation

Daniel Merrick, CO/USA

P3.03-26 - Tumor Immune Microenvironment in NSCLC is Predictive of Prognosis After Surgery

Åsa Öjlert, Norway

P3.03-27 - Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population from the Ongoing Unicancer SAFIRO2-Lung / IFCT-1301 Trial

Jordi Remon, France

P3.03-28 - LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer

Piyada Sitthideatphaiboon, TX/USA

P3.03-29 - The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer

Hadas Sorotsky, ON/Canada

P3.03-30 - Clinical Significance of Urothelial Carcinoma Associated 1 in Lung Cancer

Hongyu Wu, China

P3.04

12:00 - 13:00

Immunooncology

Exhibit Hall

P3.04-01 - Combined Plasma cfDNA Mutations and a Serum Proteomic Signature may Identify Non-Responders to Anti PD-1 Treatment in NSCLC

Arno Amann, Austria

P3.04-02 - Early Plasma ctDNA Response Anticipates Clinical Response to First-Line Immunotherapy in Advanced NSCLC

Mark Awad, MA/USA

P3.04-03 - Association of Functional Polymorphism in CTLA-4 Gene with Survival in Non-Small Cell Lung Cancer: A Brazilian Study

Marcelo Balancin, Brazil



P3.04-04 - Prognostic Value of MHC-I, PD-L1 and CD8+ TILs Expressions in Patients with Surgically Resected Non-Small Cell Lung Cancer

Xu Wang, China

P3.04-05 - Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer

Zhengwei Dong, China

P3.04-06 - Prognostic Significance of Serum CXCL12 Level in Patients with Surgical Resected Lung Adenocarcinoma

Jung-Jyh Hung, Taiwan

P3.04-07 - Correlation Between PD-L1 Expression and Expression of CDK4 and SPOP in Non-Small Cell Lung Cancer

Masaaki Inoue, Japan

P3.04-08 - Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC

Ticiana Leal, USA

P3.04-09 - Analysis of Repertoire Features of T Cell Receptor in Treat-Naïve EGFR Wild-Type Lung Cancer Patients by High-Throughput Sequencing

Yangyang Liu, China

P3.04-10 - Monocytes and Neutrophils as Predictive Markers of Response to Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer

Kaushal Parikh, USA

P3.04-11 - The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)

Nir Peled, Israel

P3.04-12 - Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.

Domenico Galetta, Italy

P3.04-13 - PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)

Noemi Reguart, Spain

P3.04-14 - TMB and Immune Checkpoint Inhibitor Gene Expression are Unrelated in NSCLC Patients



Christopher Szeto, CA/USA

P3.04-15 - IDO and Tim3 Gene Expression is Correlated in NSCLC Patients with Low PDL1 Gene Expression

Christopher Szeto, USA

P3.04-16 - A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC

Cristina Teixidó, Spain

P3.04-17 - Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Umang Ondhia, ON/Canada

P3.04-18 - The Efficacy and Safety of Solid Tumors Combination Therapy with Immune Checkpoint Inhibitor: A Systematic Review and Meta-Analysis

YiMing Weng, China

P3.04-19 - Do Advanced Lung Cancer Patients Derive Similar Survival Benefits from Immunotherapy? A Systematic Review and Meta-Analysis

Jacques Raphael, ON/Canada

P3.04-20 - Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC

Mike Sung, Canada

P3.04-21 - Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Sha Zhao, China

P3.04-22 - Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy

Alessandra Curioni Fontecedro, Switzerland

P3.04-23 - Phase 1b/2 Study to Evaluate Novel Combinations with Oleclumab (MED19447) in Previously Treated Advanced EGFRm NSCLC

Naiyer Rizvi, NY/USA

P3.04-24 - EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study

Naiyer Rizvi, NY/USA



P3.04-25 - EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50%

Naiyer Rizvi, NY/USA

P3.04-26 - EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%

Naiyer Rizvi, NY/USA

P3.04-27 - An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study

David Schrupp, USA

P3.04-28 - Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents?

Michal Sternschuss, Israel

P3.04-29 - Efficacy of Re-Treatment with Immune Checkpoint Inhibitors in Patients with Pretreated Advanced Non-Small Cell Lung Carcinoma

Takayuki Takahama, Japan

P3.07

12:00 - 13:00	Nursing and Allied Professionals	Exhibit Hall
---------------	----------------------------------	--------------

P3.07-01 - Telephone Preassessment Clinic Incorporating Holistic Needs

Vanessa Beattie, UK

P3.07-02 - Expectations, Standards and Performance Framework to Support the Lung Cancer Support Nurse in Lung Foundation Australia

Vanessa Brunelli, Australia

P3.07-03 - Lung Cancer Clinical Nurse Specialist & Palliative Care Nurse Specialist - A Dual Role

Karen Clayton, UK

P3.07-04 - Massage Chair Encounters Favorably Impact Outpatient Oncology RN's Perceived Level of Stress, BP, HR

Mary Ellen Hand, USA

P3.07-05 - Can Improving Working Partnerships with Primary Care Prevent Avoidable Emergency Admissions for Patients with Lung Cancer?

June Morley, UK



P3.07-06 - Receiving a Diagnosis of MESOthelioma (RADIO Meso): Recommendations for Practice to Improve the Patient Experience

Bethany Taylor, UK

P3.07-07 - Multidisciplinary Supportive Care Assessment in Lung Cancer - A Case Study Example

Faye Dickinson, UK

P3.07-08 - Pain Management in Lung Cancer

Abdallah El Meziane, Morocco

P3.07-09 - Characterization of the Nutritional Status in Lung Cancer Patients: A Retrospective Study

Henrique Queiroga, Portugal

P3.07-10 - What Do People Living with Lung Cancer Want and Need from the Recovery Package

Josie Roberts, UK

P3.07-11 - Survivorship After Lung Cancer Surgery - SOLACE - A Macmillan Funded Project

Charlotte Merriman, UK

P3.07-12 - Improving Cardiac Tamponade Outcomes Through Less Invasive Interventions and Earlier Recognition

Kristie Murphy, NY/USA

P3.07-13 - Non-Oncology Provider Immunotherapy Needs Assessment

Enza Nguyen, CA/USA

P3.07-14 - Collaborations of Pharmacists with Lung Cancer Treatment by Prepared Patients Controlled Analgesia (PCA) for Perioperative Pain Control

Kumiko Tani, Japan

P3.08

12:00 - 13:00

Oligometastatic NSCLC

Exhibit Hall

P3.08-01 - Treatment Outcomes in Oligometastatic Disease of Non-Small Cell Lung Cancer: A Single Center Experience

Pınar Akın Kabalak, Turkey

**P3.08-02 - Oligometastatic Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SBRT), a Single Institution Experience**

Davide Franceschini, Italy

P3.08-03 - Stereotactic Radiotherapy of Lung Cancer with Synchronous Bilateral Noduli or Oligometastatic Disease

Tine Schytte, Denmark

P3.08-04 - OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC - Trial in Progress

Maurizio Infante, Italy

P3.08-05 - Stereotactic Body Radiation Therapy (SBRT) Outcomes in Elderly Patients with Lung Oligometastases

Luis Larrea, Spain

P3.08-06 - Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors

Oscar Juan-Vidal, Spain

P3.08-07 - An Institution Review of Outcomes of Lung Stereotactic Body Radiotherapy in Various Oligometastatic Disease States

Brendan Chia, Singapore

P3.08-08 - Outcomes of Pulmonary Metastasectomy in Breast Cancer: Prognosis Based on the Metastatic Lung Tumor Study Group of Japan

Makoto Endoh, Japan

P3.08-09 - Surgical Resection of Pulmonary Oligo-Recurrence of Non-Small Cell Lung Cancer

Yoshitaka Kitamura, Japan

P3.08-10 - A Retrospective Study of Oligo-Recurrence in Patients with Resected Non-Small Cell Lung Cancer

Taku Nakagawa, Japan

P3.08-11 - Differences in Evaluations of Early Thorax CT's Post Lung Stereotactic Body Radiotherapy (SBRT)

Fazilet Oner Dincbas, Turkey

P3.08-12 - Long-Term Outcome After Adrenalectomy for Isolated Adrenal Metastasis in Otherwise Operable Patients with NSCLC - Two Institutions Study

Danail Petrov, Bulgaria



P3.08-13 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series

Rodney Wegner, USA

P3.08-14 - Long-Term Survival Following Surgical Resection of Isolated Brain Metastasis in Non-Small Cell Lung Cancer.

Wen-jui Wu, Taiwan

P3.08-15 - Lung Squamous Cell Carcinoma with Solitary Ocular Metastasis, Successful Treatment: An Interesting and Rare Case Report

Ye Guo, China

P3.08-16 - Prognostic Value of PDL-1 Expression and Correlation Between Primary Tissue and Brain Metastases in Oligometastatic NSCLC

Vimal Krishnan, Canada

P3.08-17 - Paediatric Motion Management Solutions for Particle Therapy Based Thoracic Stereotactic Ablative Body Radiotherapy (SABR)

Fiona Hegi-Johnson, Australia

P3.08-18 - Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT

Edyta Urbanska, Denmark

P3.08-18a - MR Perfusion and Spectroscopy to Distinguish Radiation Necrosis from Tumor Progression for Brain Metastases Treated with SRS

Christel de Pooter, Belgium

P3.09

12:00 - 13:00

Pathology

Exhibit Hall

P3.09-01 - PDL1 Profile of Filipino Lung Adenocarcinoma Patients Show Moderate Positivity and Low EGFR Correlation

Francisco III Heralde, Philippines

P3.09-02 - Utilization of Laboratory Developed Tests for PD-L1 Evaluation is Dependent on Tumor Type

Jingxin Qiu, NY/USA

P3.09-03 - Alteration of Gut Microbiome in Lung Cancer Patients



Jun Chen, China

P3.09-04 - Assessment of PD-L1 Expression in Cytology Samples: An Analysis of 263 Consecutive NSCLC Biopsies.

Peter Illei, MD/USA

P3.09-05 - Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.

Cristian Ortiz -Villalón, Sweden

P3.09-06 - The Link Between Tumor Promoting Fibrous Microenvironment and Immunosuppressive Microenvironment in Stage I Lung Adenocarcinoma

Takashi Sakai, Japan

P3.09-07 - Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer

Negar Rassaei, USA

P3.09-08 - Tumor Heterogeneity and Molecular Profile of NSCLC in Thai Population

Thanyanan Reungwetwattana, Thailand

P3.09-09 - “Prevalence of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Carcinoma Lungs at a Cancer Center in Nepal”

Banita Gurung, Nepal

P3.09-10 - Circulating Cell-Free DNA (cfDNA) Molecular Profile of Thai NSCLC Patients Using Difference Variant Frequency of NGS

Nareenart Iemwimangsa, Thailand

P3.09-11 - Genomic Organization at Large Scales (GOALS) within Nuclei and Cell Sociology for Predicting Lung Cancer Outcomes

Calum Macaulay, Canada

P3.09-12 - Molecular and Immunohistochemical Correlates of RB1 Inactivation in Small Cell Lung Carcinoma

Navin Mahadevan, MA/USA

P3.09-13 - Molecular Profiling Suggests the Different Mechanisms Among Local Invasiveness in Resected Human Lung Adenocarcinoma

Toshi Menju, Japan

**P3.09-14 - Pathobiology of Notch2 in Lung Cancer**

Yamato Motooka, Canada

P3.09-15 - Genetic Profiling of Idiopathic Pulmonary Fibrosis Associated Non-Small Cell Lung Cancer by Targeted Next-Generation Sequencing

Kohei Otsubo, Japan

P3.09-16 - Transcriptome Profiling for Subtyping NSCLC: Off the Beaten Path (Ologist)

Lars Petersen, Canada

P3.09-17 - Molecular Profile in Lung Adenocarcinoma. A Multicenter Study in Cordoba, Argentina.

Norma Pilnik, Argentina

P3.09-18 - Identification of MET exon 14 Skipping Mutations by FusionPlex™ Solid Tumor Panel

Laura Tafe, NH/USA

P3.09-19 - Matched Thai Lung Cancer Patients Tissue and cfDNA Molecular Profile by NGS

Narumol Trachu, Thailand

P3.09-20 - A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer

Huiping Zhu, USA

P3.09-21 - Mixed Mucoepidermoid Carcinoma and Adenocarcinoma of the Lung: A Case Report and a Literature Review

Yu-Deok Choi, Republic of Korea

P3.09-22 - Correlation Between Maximum Tumour Diameter Measurement on CT-Scan and Histopathological Specimen: An Indian Experience

Manoj Gowda, India

P3.09-23 - Accuracy and Reproducibility of Touch Imprint Cytology in Resected Lung Cancer

Masatoshi Kakihana, Japan

P3.09-24 - The Concordance of Histological Diagnosis from Transbronchial Biopsy and Resected Specimen of Lung Cancers

Yoshiteru Kidokoro, Japan

P3.09-25 - Survival Analysis in Young Adults with Lung Carcinoma



Jessica Nicolau, USA

P3.09-26 - Concordance of Surgical Resections and Fine Needle Biopsy-Derived Cell Block Sections for PD-L1 22C3 Immunohistochemistry

Joerg Schwock, Canada

P3.09-27 - Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

Annikka Weissferdt, TX/USA

P3.11

12:00 - 13:00

Screening and Early Detection

Exhibit Hall

P3.11-01 - Methylation Markers That Correlate with Occult Lymph Node Metastases of NSCLC and a Preliminary Prediction Model

Wenhua Liang, China

P3.11-02 - Lung Cancer Screening in a High Incidence Population: Results of Low-Dose CT Screenings in a Northern Kentucky Community Healthcare System

Royce Calhoun, KY/USA

P3.11-03 - Implementing Lung Cancer Screening in Canada: Evidence on Adherence and Budget Impact from the Pan-Canadian Early Detection Study

Sonya Cressman, BC/Canada

P3.11-04 - Trends and Barriers in Lung Cancer Screening Implementation Across the United States.

Jennifer King, DC/USA

P3.11-05 - Use of Electronic Medical Record (EMR)-Embedded Clinical Decision Support Tools Improves Lung Cancer Screening Rates

John Doty, NC/USA

P3.11-06 - Improving Lung Cancer Screening Completion Rates in a Primary Care Practice in Large Urban Academic Medical Center

Linda Dowling, IL/USA

P3.11-07 - The Quality of Screening: Comparing the Rush Lung Cancer Screening Program to the NLST and the VA Lung Cancer Screening Demonstration Project

Linda Dowling, IL/USA

**P3.11-08 - Lung Cancer Screening at an Academic Medical Center: Early Patterns of Practice**

Linda Dowling, IL/USA

P3.11-09 - Shared Decision Making; A Decision Aid for the Primary Practitioner

Fred Grannis, CA/USA

P3.11-10 - Lung Cancer Screening Shared Decision Making: Decision-Aid for the Patient

Fred Grannis, CA/USA

P3.11-11 - Improving Timeliness of Lung Cancer Diagnostic Services with the Implementation of Coordinated Care via a “Navigation Day”

Michael Gulak, ON/Canada

P3.11-12 - Comparison of Cancer Screening Adherence According to Smoking Status: Korea National Health and Nutrition Examination Survey 2010-2012

Yong Saing Kim, Republic of Korea

P3.11-13 - Liverpool Identifies the Hard to Reach Population at Risk of Developing Lung Cancer.

Martin Ledson, UK

P3.11-14 - Low Rates of Lung Cancer Screening Among Doctors in Mexico

Omar Macedo-Pérez, Mexico

P3.11-15 - Lung Cancer Symptom Perception and Intervention Preferences in the UK’s Most Deprived Communities: A Qualitative Study

Kate Brain, UK

P3.11-16 - Comparative Analysis of Health-Care Resources and Economic Costs of Lung Cancer Patients Treated Medically or Surgically in Catalunya

Laureano Molins, Spain

P3.11-17 - Gender Comparison in Lung Cancer Screening

Simran Randhawa, PA/USA

P3.11-18 - Implementing One Stop Lung Clinic to Improve Diagnostic Timeliness in Lung Cancer Patients in the North of England

Vytis Dudzevicius, UK

P3.11-19 - Improving Lung Cancer Screening Rates in an Underserved Outpatient Clinic

Carlos Rodriguez, USA



P3.11-20 - Patterns and Predictors of Adherence to Recommended Follow-Up After Low-Dose Computed Tomography Screening for Lung Cancer

Lori Sakoda, CA/USA

P3.11-21 - The Development of a Robust Radiology Quality Assurance (QA) Program in a Provincial High-Risk Lung Cancer Screening Pilot (HRLCSP)

Heidi Schmidt, Canada

P3.11-22 - The Path to National Lung Cancer Screening Program in Israel

Shani Shilo, Israel

P3.11-23 - Adherence to Annual Low-Dose CT Lung Cancer Screening at a Large Academic Institution

Lucy Spalluto, TN/USA

P3.11-24 - “To Know or Not to Know ...?” Push and Pull in Ever Smokers Lung Screening Uptake Decision Making Intentions

Janet Tonge, UK

P3.11-25 - Analysis Indicates Low Incremental Cost-Effectiveness Ratio for Implementation of Lung Cancer Screening in Italy

Giulia Veronesi, Italy

P3.11-26 - Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer from a Single-Institution in China

Wei Wang, China

P3.11-27 - Lung Cancer Diagnosed at Age 50-54 Years: Survival as Poor as Older Patients

Ping Yang, AZ/USA

P3.12

12:00 - 13:00

Small Cell Lung Cancer/NET

Exhibit Hall

P3.12-01 - Targeting Mitochondrial Metabolism as a Selective Therapeutic Approach in Small Cell Lung Cancer (SCLC)

Shantanu Banerji, MB/Canada

P3.12-02 - Dynamics of DLL3 and ASCL1 Expression in SCLC Over Disease Course



Anna Farago, MA/USA

P3.12-03 - Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC

Michael Giffin, CA/USA

P3.12-04 - Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Binding hnRNPA2B1 and hnRNPI to Regulate CHK2 Level

Linlang Guo, China

P3.12-05 - The Pattern of PD-L1 Expression in Thoracic Neuroendocrine Tumors

Nagla Karim, OH/USA

P3.12-06 - SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

Taofeek Owonikoko, GA/USA

P3.12-07 - MicroRNA Deregulation in a Typical Carcinoid Tumor: Potential Role of Immune Response and Invasion in Tumorigenesis.

Ana Seneda, Brazil

P3.12-08 - The Role of Contactin 1 on Acquired Resistance to Pegylated Arginase in Small Cell Lung Cancer

Sheng Yan, Hong Kong

P3.12-09 - Smad4 Mutation Confers Acquired Neuroendocrine Phenotype in Transformation of Lung Adenocarcinoma to Small Cell Lung Cancer

Jie Zhang, China

P3.12-10 - Immunogenomic Characteristics of SCLC and LCNEC Redefined Molecular Subgroups

Xue-Tao Li, China

P3.12-11 - Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients

Laura Mezquita, France

P3.12-12 - Genomic Profiling of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC) Reveals Distinct Mutational Landscape

Lin Wu, China

P3.12-13 - Expression of the Immune Checkpoint Axis-PVR/TIGIT in Small Cell Lung Cancer

Hui Yu, CO/USA



P3.12-14 - Genomic Profiling of Chinese Small Cell Lung Cancer and the Implications for Therapy

Hong Zhong, China

P3.12-15 - 68 Ga DOTA PET/CT in Staging of Broncho-Pulmonary Carcinoid Tumors. Is there a Real Benefit?

George Karimundackal, India

P3.12-16 - Prognostic Impact of M Descriptors of the 8th Edition of TNM Classification for Extensive Disease-Small Cell Lung Cancer

Masayuki Shirasawa, Japan

P3.12-17 - A Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC

Salomon Tendler, Sweden

P3.13

12:00 - 13:00

Targeted Therapy

Exhibit Hall

P3.13-01 - Detecting ALK Rearrangements in NSCLC Patients: IHC, FISH or NGS Fusion?

Alfredo Addeo, Switzerland

P3.13-02 - Lymphocytic Plevral Effusion Due to Crizotinib Usage: First Case in Literature

Pınar Akın Kabalak, Turkey

P3.13-03 - Real-World Anaplastic Lymphoma Kinase Testing Practices: Results from a Survey in the United States

A John Iafrate, MA/USA

P3.13-04 - Lorlatinib in Anaplastic Lymphoma Kinase and Proto-Oncogene Tyrosine-Protein Kinase ROS-Positive Non-Small Cell Lung Cancer

Marthe Paats, Netherlands

P3.13-05 - Use of Crizotinib in a Patient with a Ros Mutation Causing Elevated CPK and Resulting in Dose Limiting: Case Report

Ana Cecilia Vasconcelos, Brazil

P3.13-06 - Analysis of ALK Rearrangement Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion



Chunwei Xu, China

P3.13-07 - The Effect of Crizotinib in Patients of Non-Small Cell Lung Cancer with Brain Metastases: A Retrospective Analysis

Jiexia Zhang, China

P3.13-08 - Assessment of EGFR Gene Mutations In cf-DNA in Monitoring of Response to EGFR TKIs in Patients with Lung Adenocarcinoma

Kamila Wojas-Krawczyk, Poland

P3.13-09 - ALTER-0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Baohui Han, China

P3.13-10 - Factors Associated with Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

Amanda Gibson, Canada

P3.13-11 - Advanced Nsclc Treated with Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Peter Berzinec, Slovak Republic

P3.13-12 - A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab

Qian Chu, China

P3.13-13 - Afatinib in Lung Adenocarcinoma Harboring de novo EGFR Exon 20 Insertions.

Marcos Costa, Brazil

P3.13-14 - Identification of Novel Mutations by High-Throughput Sequencing in T790M Wildtype/cMET Unamplified NSCLC with Acquired Resistance to EGFR TKIs

Chenguang Li, China

P3.13-15 - First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

Chong-Kin Liam, Malaysia

P3.13-16 - Concomitant EML4-ALK Rearrangement and EGFR Mutation in Non-Small Cell Lung Cancer Patients: Data from Eastern Indian Hospital.

Prasanta Mohapatra, India

**P3.13-17 - A Retrospective Study: Central Nervous System Response to Osimertinib in Patients with Advanced NSCLC**

Yuxin Mu, China

P3.13-18 - Mechanisms of Acquired Resistance to Afatinib Clarified with Liquid Biopsy

Tomomi Nakamura, Japan

P3.13-19 - Surgery for cIIIB Lung Adenocarcinoma After Response to Erlotinib, Survival and Management of Postoperative Oligoprogressions

Danail Petrov, Bulgaria

P3.13-20 - Frequency of EGFR Mutations in Patients with Adenocarcinoma Lung Cancer. Comparative Study Between Public and Private Mexican Health Services

Jeronimo Rodriguez-Cid, Mexico

P3.13-21 - Apatinib Plus Icotinib as First-Line Therapy for EGFR Co-Mutations NSCLC in Chinese Patients: An Exploratory Study

Yanhong Shang, China

P3.13-22 - Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer.

Hisashi Tanaka, Japan

P3.13-23 - EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.

Xiyi Lu, China

P3.13-24 - Efficacy of EGFR-TKIs Compared with Chemotherapy as First-Line Therapy in Patients with EGFR Rare Mutation Advanced Lung Adenocarcinoma

Huijuan Wang, China

P3.13-25 - Development of a Comprehensive Genomic Profiling System to Detect Actionable Genetic Alterations and Tumor Mutation Burden

Francesca Cavallo, USA

P3.13-26 - Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board

Lisa Chu, CA/USA

P3.13-27 - Clinical Outcomes of Patients with Lung Adenocarcinoma Harboring Concomitant Driver Mutations in a Brazilian Cancer Center



Marcos Costa, Brazil

P3.13-28 - Heterogeneity, Prevalence and Prognostic Significance of PDL1 Expression in Early Resected NSCLC

Michelle Dean, AB/Canada

P3.13-29 - Patient-Derived Xenograft Models (PDX) of Lung Squamous Cell Carcinoma (SCC) for Preclinical Studies

Tae Ho Kim, Republic of Korea

P3.13-30 - Driver Mutation in Heavy Smoker Patient with Squamous Cell Carcinoma Metastatic Lung Cancer: Case Report

Bárbara Maria Luz, Brazil

P3.13-31 - Creating a Precision Medicine Pipeline for Lung Cancers.

Paola Marignani, Canada

P3.13-32 - Drug Sensitivity of Lung Adenocarcinoma Towards Inducers of Epigenetic Modifications

Isabelle Moneke, Germany

P3.13-33 - Lung Adenocarcinoma Harboring RET Fusion and Dramatic Response to Combination of Vandetanib (VAN) and Everolimus (EVE): A Case Report from Brazil

Carolina Haddad, Brazil

P3.13-34 - RET Gene, a New Choice for NSCLC

Yinghui Xu, China

P3.13-35 - Antitumor Effect of Neratinib Targeting HER2-Altered Lung Cancer

Yusuke Ogoshi, Japan

P3.15

12:00 - 13:00

Treatment in the Real World - Support, Survivorship, Systems Research

Exhibit Hall

P3.15-01 - Long-Term Outcomes of Pulmonary Metastasectomy: A 12-Year Dual Centre Experience

Phillip Antippa, Australia

P3.15-02 - Carboplatin Dose Calculated Using Different Formula for eGFR and Their Comparison with Actual Dose Administered in Lung Cancer Patients



Digambar Behera, India

P3.15-03 - Capturing the Patient Experience for the Treatment of EGFR Exon 20 Mutations in Non-Small Cell Lung Cancer

Aaron Galaznik, MA/USA

P3.15-04 - An Interdisciplinary Educational Program Dedicated to Non-Small Cell Lung Cancer Patients to Improve their Quality of Life

Laurence Bigay-Gamé, France

P3.15-05 - Patient Reported Outcomes (PROs) as Performance Measures After Surgery for Lung Cancer

Majken Brønserud, Denmark

P3.15-06 - Capillary Leak Syndrome in a Primary Lung Adenocarcinoma Patient with Thrombocytopenia from Interleukin-11 Treatment

Huafei Chen, China

P3.15-07 - A Literature Review and Assessment of Lung Cancer Quality Indicators

Kim-Lin Chiew, NSW/Australia

P3.15-08 - Patient-Reported Outcomes (PROs) in Patients with Lung Resection: Open Versus Minimal Invasive Surgery

Qiuling Shi, USA

P3.15-09 - Are Lung Cancer Patients Receiving Education Materials? The Healthcare Provider Perspective on Distribution Gaps and Possible Solutions

Andrea Ferris, USA

P3.15-10 - Survival Impact of Peripheral Blood Ratios in Lung Cancer According Clinical Stage

Claudio Flores, Peru

P3.15-11 - Association Between Peripheral Blood Ratios and Clinical Stage Disease in Lung Cancer.

Claudio Flores, Peru

P3.15-12 - Survival Impact of Patient Enrollment in Antineoplastic Drug Trials for Stage IV Non-Small Cell Lung Cancer (NSCLC)

Bernardo Goulart, WA/USA

P3.15-13 - Surgical Management of Huge Pulmonary Arteriovenous Malformations: Our Experience



Fadil Gradica, Albania

P3.15-14 - Using Creative Co-Production to Develop a Treatment Decision Support Tool for People with Malignant Pleural Effusion

Angela Tod, UK

P3.15-15 - ALI Could Be a One of Prognostic Survival Factor for Non-Small Cell Lung Cancer Patients

Yoichiro Hamamoto, Japan

P3.15-16 - Management of Patients with ALK-Translocated NSCLC: A Simulation-Based Assessment of Medical Oncologists' Practice Decisions

Emily Van Laar, USA

P3.15-17 - Lung Cancer Symptom Burden and Quality of Life: Findings from the Cancer Experience Registry

Julie Olson, USA

P3.15-18 - Comparison of Pain Control Effects and Side Effects Early After VATs Lobectomy Between IV-PCA, Epidural-PCA and On-Q

Joonho Jung, Republic of Korea

P3.15-19 - Risk Factors for Osteoporosis in Lung Cancer Patients

Kyung Ho Kang, Republic of Korea

P3.15-20 - Palliative Sedation in Lung Cancer Patients Whom Needs Immediate or Elective Intractable Symptom Control

Fatih Kose, Turkey

P3.15-21 - Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

Chong-Kin Liam, Malaysia

P3.15-22 - Validation of Eurolung Risk Models in a Japanese Population: A Retrospective Single-Center Analysis of 612 Cases

Akihiro Nagoya, Japan

P3.15-23 - Data Mining the Internet and Crowdsourcing in Guiding Patient Decision-Making.

Shaneel Pathak, Canada

P3.15-24 - Ramathibodi Lung Cancer Consortium (RLC) Model: Multidisciplinary Team Approach Improves Lung Cancer Patients' Survival Outcome



Thanyanan Reungwetwattana, Thailand

P3.15-25 - Assessment of Depression Among Advanced Stage Lung Cancer Patients in Developing Country

Guru Sah, Nepal

P3.15-26 - Safety of Nivolumab in Thoracic Malignancies: Results from a Single Institution in Bangladesh

Md Shuayb, Bangladesh

P3.15-27 - Initial Response to First Line Treatment is the Best Predictor of the Patient Survival in Advanced NSCLC

Nazim Turhal, Turkey

P3.15-28 - Prognostic Nutritional Index for Predicting Postoperative Complications After Surgery Thoracic Tumor Involving the Neighboring Structures

Isamu Watanabe, Japan

P3.15-29 - Defining the Symptom Burden of Non-Small Cell Lung Cancer

Meagan Whisenant, USA

P3.15-30 - Treatment Patterns and Survival of Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Era of Novel Therapies

Dimas Yusuf, Canada

P3.15-31 - Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Yongchang Zhang, China

P3.16

12:00 - 13:00

Treatment of Early Stage/Localized Disease

Exhibit Hall

P3.16-01 - A Multi-Omic Study Reveals BTG2 as a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer

David Christiani, MA/USA

P3.16-02 - Phase III Study of Canakinumab (ACZ885) as Adjuvant Therapy in Patients with Surgically Resected NSCLC

Edward Garon, CA/USA

P3.16-03 - Uncommon EGFR Mutations as a Worse Prognostic Factor for Surgically Resected Lung Adenocarcinoma



Kazuki Hayasaka, Japan

P3.16-04 - Comparison of 2D and 3D Consolidation to Tumor Ratios to Predict Less Invasive Lung Adenocarcinoma

Toshihiro Ikeda, Japan

P3.16-05 - A Nanotechnology-Enabled Strategy for Image-Guided Transbronchial and Transpleural Photothermal Therapy of Peripheral Lung Cancer

Tomonari Kinoshita, ON/Canada

P3.16-06 - Does Comprehensive Mutation Analysis Add Prognostic Value in Resected Early Stage Lung Adenocarcinoma?

Peter Kneuert, OH/USA

P3.16-07 - The Impact of Clinical and Molecular Profile of Resected EGFR-Mutant Non-Small Cell Lung Cancer on the Risk of Developing Brain Metastases

Mor Moskovitz, Israel

P3.16-08 - Baseline Quality of Life is Influenced by the Duration of Abstinence from Smoking in Candidates to Lung Cancer Surgery

Cecilia Pompili, UK

P3.16-09 - High Preoperative D-Dimer Level Predicts Early Recurrence After Surgery for Non-Small Cell Lung Cancer

Yuki Shiina, Japan

P3.16-10 - Radiomic Features on CT are Prognostic of Recurrence as well as Predictive of Added Benefit of Adjuvant Chemotherapy in ES-NSCLC

Pranjal Vaidya, USA

P3.16-11 - Pattern of Recurrence of Completely Resected Lung Adenocarcinoma Varies According to EGFR Mutation Status

Katsuya Watanabe, Japan

P3.16-12 - Standard Conventional Lobectomy vs Stereotactic Body Radiotherapy in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC) - A Review

Prakash Balakrishnan, New Zealand

P3.16-13 - Long-Term Outcomes of Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer in Patients Less Than 70 Years of Age

Zhe Chen, Japan

**P3.16-14 - SBRT in Early Stages of Lung Cancer**

Luis Fernández Fornos, Spain

P3.16-15 - Kinetic Energy Distribution for Gated Technique at Lung Ablative Body Radiotherapy (SABR)

Kaile Li, USA

P3.16-16 - Long Term Outcomes of Body Gamma-Ray Stereotactic Ablative Radiotherapy for Patients with Stage I/II Non-Small Cell Lung Cancer

Hongqi Li, China

P3.16-17 - Cardiac Sparing in Stereotactic Body Radiotherapy of Early Stage NSCLC Patients

Barbara Stam, Jose Belderbos; Netherlands

P3.16-18 - Modern Radiotherapy Increases Patient Access to Curative Intent Radiotherapy in Non-Small Cell Lung Cancer

Karen Tumelty, UK

P3.16-19 - Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer

Yaping Xu, China

P3.16-20 - Feasibility of Limited Resection for Peripheral Small-Sized Non-Small Cell Lung Cancer According to FDG Accumulation and Imaging Findings

Masato Aragaki, Japan

P3.16-21 - Robotic Thoracic Surgery in Lung Cancer Resection - A Comprehensive Review

Prakash Balakrishnan, New Zealand

P3.16-22 - Wedge Resection for Small Pulmonary Lesions with Preoperative Bronchoscopic Barium Marking

Tatsuo Furuya, Japan

P3.16-23 - Soft-Tissue Sarcoma of the Chest Wall, Surgical Resection: Analysis Our Cases Period of Time Decembre 2004-July 2017

Fadil Gradica, Albania

P3.16-24 - Prognostic Value of Positive Lymph Node Ratio in Non-Small Cell Lung Cancer

Jiaxi He, China

P3.16-25 - Impact of Diabetes Mellitus on Survival Outcome in Patients with Pathological Stage IA Non-Small Cell Lung Cancer



Shunki Hirayama, Japan

P3.16-26 - Anatomic Segmentectomy in Stage I Non-Small-Cell Lung Cancer Reveals Equivalent Long-Term Outcomes Compared to Lobectomy

Alireza Hoda, Austria

P3.16-27 - Clinical Outcome of Preoperative Intervention Bronchoscopy Followed by Surgery

Yasufumi Kato, Japan

P3.16-28 - Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 70 Years or Older

Osamu Kawamata, Japan

P3.16-29 - Prediction of Lymph Node Metastases in Clinical T1aN0M0 Non-Small Cell Lung Cancer

Tung-Ming Tsai, Taiwan

P3.16-30 - The Impact of the Surgical Approach on Lymph Node Upstaging in Curative Intent Lung Cancer Surgery

Khaled Mardanzai, Germany

P3.16-31 - Younger Patients Operated for Lung Cancer Have Better Overall Survival

Tomasz Marjanski, Poland

P3.16-32 - A Study of Postoperative Recurrence in Pathological Stage 1 Non-Small Cell Lung Cancer Patients

Kotaro Mizuno, Japan

P3.16-33 - Characteristics and Risk Factors of Recurrence After Segmentectomy in Patients With Clinical Stage I Non-Small Cell Lung Cancer

Akihiro Nakamura, Japan

P3.16-34 - The Impact of Preoperative Exercise Therapy on the Surgical Outcomes of Patients with Lung Cancer and COPD: A Systematic Review and Meta-Analysis

Wu Nan, China

P3.16-35 - Stair Climbing Exercise May Ameliorate Pulmonary Function Impairment in Patients at One Month After Lung Cancer Resection

Wu Nan, China

P3.16-36 - Adjuvant Chemotherapy May Improve the Outcome of Patients with Non-Small-Cell Lung Cancer with Metastasis of Intrapulmonary Lymph Nodes.



Wu Nan, China

P3.16-37 - Comparison of Long-Term Outcomes Between VATS and Open Lobectomies for Stage I NSCLC: Propensity Score-Matching Analysis

Risa Oda, Japan

P3.16-38 - Systematic Review and Meta-Analysis of Methods to Predict Postoperative Lung Function Following Lung Cancer Resection

Nicola Oswald, UK

P3.16-39 - Which Surgery for Ground Glass Opacity Lung Nodules?

Sara Ricciardi, Italy

P3.16-40 - Delayed Cut-End Recurrence After Wedge Resection for Pulmonary Ground-Glass Opacity Adenocarcinoma

Keigo Sekihara, Japan

P3.16-41 - Postoperative Pembrolizumab for the Patients with Pathologic Stage I Adenocarcinoma with Solid or Micropapillary Pattern

Sumin Shin, Republic of Korea

P3.16-42 - Early Stage Non-Small Cell Lung Cancer Survival in a Chilean Private Teaching Hospital

Francisco Suárez, Chile

P3.16-43 - Is Sublobar Resection for Stage I Invasive Adenocarcinoma (≤ 2 -cm) Feasible?

Yuriko Terada, Japan

P3.16-44 - Robotic-Assisted Thoracic Surgery for Early-Stage Non-Small-Cell Lung Cancer: Initial Experience in Brazil

Ricardo Terra, Brazil

P3.16-45 - The Rates and Survival of Surgically-Resected Second Primary Lung Cancers in Patients Undergoing Resection of an Initial Primary Lung Cancer.

John Varlotto, MA/USA

P3.16-46 - The Comparison Between Non-Intubated and Intubated Thoracoscopic Resection for Pulmonary Nodule: A Meta-Analysis

Yaokai Wen, China

P3.16-47 - Analysis of The Novel Chest Tube (Coaxial Drain) for Lung Cancer Surgery

Masashi Yanada, Japan



P3.16-48 - Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?

Perran Yumuk, Turkey

P3.17

12:00 - 13:00

Treatment of Locoregional Disease - NSCLC

Exhibit Hall

P3.17-01 - PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients from Brazil

Marclesson Alves, Brazil

P3.17-02 - Increasing Radiation Dose to Central Structures is Associated with Worse Survival Following Thoracic Proton Reirradiation

Jessika Contreras, USA

P3.17-03 - Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated with Combination of Chemotherapy and Conformal Radiotherapy

Simonida Crvenkova, Macedonia

P3.17-04 - Dealing with the N2 Disease in Non- Small Cell Lung Cancer- on the Edge.

Soo-Youn Ham, Republic of Korea

P3.17-05 - Multimodality Treatment for Superior Sulcus Non-Small-Cell Lung Carcinomas

Masahiko Harada, Japan

P3.17-06 - Impact of Integrating PET-CT in Radiotherapy Planning of Non Small Cell Carcinoma Lung: Dosimetric and Radiobiological Comparison

Rakesh Kapoor, India

P3.17-07 - The Beneficial Effect of the High Dose Irradiation During Concurrent Chemoradiotherapy in Locoregional Advanced Non-Small Cell Lung Cancer

Chul Seung Kay, Republic of Korea

P3.17-08 - Assessing Primary Lung Cancer Lesion Using Ratio Metrics of T1 and T2-Weighted Images in Magnetic Resonance Imaging

Hui Liu, China

P3.17-09 - Retrospective Analysis of the Efficacy and Safety of Multimodal Treatment for Locally-Advanced NSCLC in Elderly Patients



Francesca Mazzoni, Italy

P3.17-10 - Outcome of Surgical Resection for Superior Sulcus Tumor: Experience at a Single Institution.

Seiji Omura, Japan

P3.17-11 - Duo Synchronous Primary Lung Tumours Mimicking a Solitary Spiculated Cavitatory Mass on Computed Tomographic Imaging

Kingsfield Ong, Singapore

P3.17-12 - Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

Helen Ross, AZ/USA

P3.17-13 - SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC – A Multicenter Single-Arm Phase II Trial.

Sacha Rothschild, Switzerland

P3.17-14 - A Case of a Patient Harboring an EGFR -T790M Mutation Positive in Squamous Cell Lung Cancer

Carlos Carracedo Gonzales, Peru

P3.17-15 - Therapeutic Outcome of Surgery for Superior Sulcus Tumor

Akira Sakurada, Japan

P3.17-16 - Adenocarcinoma or Epidermoid? The Importance of the Histological Subdivision

Silvia Sequero, Spain

P3.17-17 - Stage III: Analysis to Assist in the Decision of Surgery Against Quimio-Radiotherapy

Silvia Sequero, Spain

P3.17-18 - Towards Individualizing Patient Selection in Proton Therapy for Lung Cancer Using the Model-Based Approach

Suliana Teoh, UK

P3.17-19 - First Relapse and Survival Five Years After Radical Radiotherapy for Lung Cancer.

Gerard Walls, Ireland

P3.17-20 - Impact of Significant Primary Tumor Size Reduction on Radiation Dose to Normal Structures in Patients Receiving Definitive Chemoradiotherapy

Meng Welliver, OH/USA



P3.17-21 - Surgical Treatment for Centrally Located or Hilar Invasive Locally Advanced Lung Cancer.

Motohiro Yamashita, Japan

P3.17-22 - Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Ralph Zinner, PA/USA

P3.17-23 - Role of Surgery in Locoregional Advanced NSCLC; A Case of Aggressive Salvage Surgery After Definitive Chemoradiation

Ryuichi Waseda, Japan

P3.CR

12:00 - 13:00

Case Reports

Exhibit Hall

Topics: Advanced NSCLC, Advocacy, Biology, Immunooncology, Interventional Diagnostics/Pulmonology, Small Cell Lung Cancer/NET, Thymoma/Other Thoracic Malignancies

P3.CR-01 - To Better Understand the Anatomical Proximity of Cardiac Plexus to Prevent Lethal Arrhythmias Associated with Lung Cancer Surgery

Kurumi Fukui, Japan

P3.CR-02 - SBRT of Lung Primary After Complete Resolution of Metastatic Disease in Case of EGFR Mutated Adenocarcinoma Lung: A Case Report

Saroj Majumdar, India

P3.CR-03 - Pulmonary Spindle Cell Neoplasm - Neoadjuvant Treatment and Response

Kyaw Thein, TX/USA

P3.CR-04 - Lung Cancer with Concurrent ROS1 Rearrangement and KRAS Mutation: A Case Report

Youcai Zhu, China

P3.CR-05 - The Role of Patient Engagement in Improved Outcomes in Lung Cancer Care

Anne Marie Cerato, ON/Canada

P3.CR-06 - Effect of Palliative Care and Cancer Rehabilitation on Lung Cancer Survivorship - Patient's Perspective

Satoko Kono, Japan



P3.CR-07 - Comprehensive Genomic Profiles for a Mediastinal Tumor Suspected of Synovial Sarcoma: A Case Report

Kota Araki, Japan

P3.CR-08 - Clonally Related Primary ALK Rearrangement Adenocarcinoma and Associated Metastatic Lesions: A Case Report

Chunwei Xu, China

P3.CR-09 - MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma with MET fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma

Chunwei Xu, China

P3.CR-10 - HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer and Response to Crizotinib

Chunwei Xu, China

P3.CR-11 - ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report

Chunwei Xu, China

P3.CR-12 - A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib

Chunwei Xu, China

P3.CR-13 - Dual Drive Coexistence of EML4-ALK Fusion and TPM3-ROS1 Fusion Lung Adenocarcinoma: A Case Report

Youcai Zhu, China

P3.CR-14 - A Case of EGFR Tyrosine Kinase Inhibitor (TKI), Osimertinib Induced Pneumonitis in a Patient with Recurrent Fevers of Unknown Origin

Young Chae, USA

P3.CR-15 - Squamous Cell Carcinoma Diagnosed While on Immunotherapy for Lung Adenocarcinoma: A Unique Clinical Case.

Marta Soares, Portugal

P3.CR-16 - A Case of Toxic Hepatic Event Occurring in Combination Treatment with Nivolumab and Anti-Tuberculosis in Advanced Lung Cancer

Tae Hoon Kim, Republic of Korea

P3.CR-17 - An Interesting Case of Long-Term Immunotherapy Response in Metastatic NSCLC



Swati Kulkarni, ON/Canada

P3.CR-18 - Central Nervous System Activity of Checkpoint Inhibitor in Non-Small-Cell Lung Cancer

Marta Pereira-Lima, Brazil

P3.CR-19 - Thromboembolic Events Related to Immunotherapy in a NSCLC Patient: A Case Report.

Leticia Maria Neves De Carvalho, Brazil

P3.CR-20 - The Effect of Pembrolizumab In EGFR Mutated Lung Adenocarcinoma Patients With PD-L1 Overexpression: Two Cases Report

Takeshi Uenami, Japan

P3.CR-21 - Utility of Thoracoscopy in Diagnosis of Lung Tumour in Pleural Effusion

Naveen Pandhi, India

P3.CR-22 - Pulmonary Tuberculosis - A Chameleon; Mimicking Lung Cancer on Imaging

Srijna Rana, India

P3.CR-23 - Multilobar Adenocarcinoma: A Case Report and Review of the Literature of Papillary Eccrine Adenocarcinoma Presenting with Respiratory Failure.

J Turner, TN/USA

P3.CR-24 - Surgical Resection of 30 Years' Recurring Pneumonia: 1 Case of Giant Bronchopulmonary Sequestration

Jun Zhang, China

P3.CR-25 - Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan

Arooj Fatima, Pakistan

P3.CR-26 - Mediastinal Lipoma in Adult: A Case Report

Amira Anwar, Indonesia

P3.CR-27 - Surgical Treatment of a Rare Case of Mediastinal Masson's Tumor Mimicking a Thymoma

Angela De Palma, Italy

P3.CR-28 - Simultaneous Presentation of Mediastinal Malignant Peripheral Nerve Sheath Tumor with Intrapulmonary Metastasis, an Extremely Rare Case

Akif Turna, Turkey



P3.CR-29 - En-Bloc Excision of Intrapericardial Thymoma Using Single Port Video-Assisted Thoracoscopic Surgery. A Rare Case

Akif Turna, Turkey

P3.CR-30 - Pleural Diseases on Single Lung After Pneumonectomy for Cancer

Veronica Manolache, Romania

P3.CR-31 - A Case of Thymoma with Autoimmune Hepatitis Following Preoperative Chemotherapy

Tomoki Nishimura, Japan

P3.CR-32 - Amyloid Deposition in Thymic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: A Case Report

Kyung Joo Park, Republic of Korea

P3.CR-33 - Trichoptysis, Hemoptysis and Chest Pain: A Very Rare Presentation of Anterior Mediastinal Teratoma in a Young Patient

Asma Saidane, Tunisia

P3.CR-34 - A Giant Ganglioneuroma of the Thoracic Spine

Asma Saidane, Tunisia

P3.CR-35 - A Rare Giant Thoracic Desmoid Tumor /A Case Report

Asma Saidane, Tunisia

P3.CR-36 - Intrapericardial Thymoma: A Case Report

Akif Turna, Turkey

P3.CR-37 - Extensive Resection for Invasive Atypical Carcinoid of Thymus: 1 Case Report

Jun Zhang, China

ES07

13:30 - 15:00	Beyond the Diagnosis - Collaborative Care for Change Topics: Nursing and Allied Professionals Moderation: M. Guerin, USA; D. Zawisza, Canada	Room 205 B
---------------	---	------------

13:30 - 13:50 ES07.01 - A Moment in Time for the Unplanned Conversations



Kelly Mcguigan, Canada

- 13:50 - 14:00 **ES07.02 - Special Needs and Wellness in Lung Cancer Patients - Australian Perspective**
Maria Ftanou, VIC/Australia
- 14:00 - 14:10 **ES07.03 - Special Needs and Wellness in Lung Cancer Patients - European Perspective**
Rossie Navon, Israel
- 14:10 - 14:30 **ES07.04 - Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma**
Lisa Carter-Harris, USA
- 14:30 - 14:50 **ES07.05 - Research Update: Patient's Perspective on Living with Malignant Pleural Mesothelioma**
Angela Tod, UK
- 14:50 - 15:00 **ES07.06 - Q&A**

ES08

13:30 - 15:00	The Pathologist - An Essential Member of the Patient Care Team Topics: Pathology Moderation: C. Poleri, Argentina; P. Pal, Canada	Room 206 AC
----------------------	--	--------------------

- 13:30 - 13:50 **ES08.01 - Targeted Therapy**
Yasushi Yatabe, Japan
- 13:50 - 14:10 **ES08.02 - Immunotherapy**
Sylvie Lantuejoul, France
- 14:10 - 14:30 **ES08.03 - Mesothelioma, Thymic Epithelial Tumors and Others**
Andrew Nicholson, UK
- 14:30 - 14:50 **ES08.04 - Neoadjuvant Therapy**
Ignacio Wistuba, AL/USA
- 14:50 - 15:00 **ES08.05 - Q&A**

LA01



13:30 - 15:00	IASLC Lectureship Award Session	Room 105
13:30 - 13:40	LA01.01 - Clifton F. Mountain Award - Is There Still a Stage for Improvements in Staging? Johan Vansteenkiste, Belgium	
13:40 - 13:50	LA01.02 - IASLC Lectureship Award for Radiation Oncology - Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future Hak Choy, TX/USA	
13:50 - 14:00	LA01.03 - Heine H. Hansen Award - New Opportunities in Small Cell Lung Cancer Charles Rudin, NY/USA	
14:00 - 14:10	LA01.04 - Adi F. Gazdar Award - Genomic Alterations in Human Lung Cancers Matthew Meyerson, MA/USA	
14:10 - 14:20	LA01.05 - Tsuguo Naruke Award - The Value of Naruke Lymph Node Chart and the Creation of IASLC Chart in Lung Cancer Hisao Asamura, Japan	
14:20 - 14:30	LA01.06 - Daniel C. Ihde Award - The Intersection of Science and Medicine David Carbone, OH/USA	
14:30 - 14:40	LA01.07 - Robert J. Ginsberg Award - Honoring the Tradition of Surgically-Based Clinical Trials Valerie Rusch, NY/USA	
14:40 - 14:50	LA01.08 - Nurse & Allied Health Award - The Right Hand: The Art of Collaboration Kimberly Rohan, IL/USA	
14:50 - 15:00	LA01.09 - Q&A	

MA25

13:30 - 15:00	Oligometastasis: Defining, Treating, and Evaluating	Room 203 BD
	Topics: Oligometastatic NSCLC, Biology Moderation: J. Laba, Canada; Z. Allibhai, Canada	
13:30 - 13:35	MA25.01 - EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC Lizza Hendriks, Netherlands	



- 13:35 - 13:40 **MA25.02 - Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts**
Anne-Marie Dingemans, Netherlands
- 13:40 - 13:45 **MA25.03 - Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion**
Lizza Hendriks, Netherlands
- 13:45 - 14:00 **MA25.04 - Discussant - MA 25.01, MA 25.02, MA 25.03**
Abraham Wu, NY/USA
- 14:00 - 14:05 **MA25.05 - Characteristics & Survival of Resected Stage IV Non-Small Cell Lung Cancer (NSCLC) in the Mid-South Quality of Surgical Resection Cohort**
Nicholas Faris, TN/USA
- 14:05 - 14:10 **MA25.06 - RPA Analysis for Oligometastatic Non-Small Cell Lung Cancer: Smoking Combine T3/4 Patients May Not Be Benefit from Local Consolidative Treatment**
Jia-Tao Zhang, China
- 14:10 - 14:15 **MA25.07 - Effectiveness of Systemic Therapy Combined with Thoracic Radiotherapy for Patients with Oligometastatic NSCLC: A Pooled Analysis**
Jingbo Wang, China
- 14:15 - 14:30 **MA25.08 - Discussant - MA 25.05, MA 25.06, MA 25.07**
Alysa Fairchild, Canada
- 14:30 - 14:35 **MA25.09 - M1b Disease in the 8th Edition of IASLC Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcom**
Hyesun Park, MA/USA
- 14:35 - 14:40 **MA25.10 - Complete Response by PET-CT After Radical Treatment in Oligometastatic Non-Small Cell Lung Cancer Predicts Longer Survival**
Oscar Arrieta, Mexico
- 14:40 - 14:45 **MA25.11 - Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT**
Fabio Moraes, Brazil
- 14:45 - 15:00 **MA25.12 - Discussant - MA 25.09, MA 25.10, MA 25.11**
Michael Macmanus, Australia



MA26

Time	Topic	Room
13:30 - 15:00	New Therapies and Emerging Data in ALK, EGFR and ROS1 Topics: Targeted Therapy, Advanced NSCLC, Pathology Moderation: A. Shaw, USA; G. Simon, USA	Room 201 BD
13:30 - 13:35	MA26.01 - Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC Shun Lu, China	
13:35 - 13:40	MA26.02 - Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study. Elisa Gobbi, Italy	
13:40 - 13:45	MA26.03 - Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement Zosia Piotrowska, MA/USA	
13:45 - 14:00	MA26.04 - Discussant - MA 26.01, MA 26.02, MA 26.03 Caroline McCoach, USA	
14:00 - 14:05	MA26.05 - Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants Meng Qiao, China	
14:05 - 14:10	MA26.06 - Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative Erik Thunnissen, Netherlands	
14:10 - 14:15	MA26.07 - ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists Keith Kerr, UK	
14:15 - 14:30	MA26.08 - Discussant - MA 26.05, MA 26.06, MA 26.07 Dong-Wan Kim, Republic of Korea	
14:30 - 14:35	MA26.09 - Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study Byoung Chul Cho, Republic of Korea	
14:35 - 14:40	MA26.10 - CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC	



Luis Paz-Ares, Spain

14:40 - 14:45 **MA26.11 - Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC**

Yi-Long Wu, China

14:45 - 15:00 **MA26.12 - Discussant - MA 26.09, MA 26.10, MA 26.11**

Liza Villaruz, PA/USA

MA27

13:30 - 15:00 Novel Drugs and PDX Models Room 206 BD
Topics: Targeted Therapy
Moderation: W. Lockwood, Canada; K. Politi, USA

13:30 - 13:35 **MA27.01 - Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids**

Sebastiao Martins-Filho, Canada

13:35 - 13:40 **MA27.02 - Hypofractionated Radiotherapy Normalizes Tumor Vasculature in Non-Small Cell Lung Cancer Xenografts Through p-STAT3/HIF-1 Alpha Pathway**

Xiaorong Dong, China

13:40 - 13:45 **MA27.03 - Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft**

Erin Stewart, Canada

13:45 - 14:00 **MA27.04 - Discussant - MA 27.01, MA 27.02, MA 27.03**

Byoung Chul Cho, Republic of Korea

14:00 - 14:05 **MA27.05 - Drug Loaded Mesenchymal Stem Cells for Targeted Lung Cancer Treatment in Mice**

Yaojiong Wu, China

14:05 - 14:10 **MA27.06 - Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA**

Chad Pecot, USA

14:10 - 14:15 **MA27.07 - Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors**

Hirotosugu Notsuda, ON/Canada



- 14:15 - 14:30 **MA27.08 - Discussant - MA 27.05, MA 27.06, MA 27.07**
Gwyn Bebb, Canada
- 14:30 - 14:35 **MA27.09 - Dual Inhibition of BCL-XL and MCL-1 is Required to Induce Tumour Regression in Lung Squamous Cell Carcinomas Sensitive to FGFR Inhibition**
Marie-Liesse Asselin-Labat, OR/USA
- 14:35 - 14:40 **MA27.10 - EGFR-Targeted Therapy Alters the Tumor Microenvironment In EGFR-Driven Lung Tumors: Rationale for Combination Therapies**
Yijun Jia, China
- 14:40 - 14:45 **MA27.11 - Genomic Sequencing and Editing Revealed the GRM8 Signaling Pathway as Potential Therapeutic Targets of Squamous Cell Lung Cancer**
Panpan Zhang, China
- 14:45 - 15:00 **MA27.12 - Discussant - MA 27.09, MA 27.10, MA 27.11**
Dave Barbie, USA

MS28

- | | | |
|----------------------|--|-----------------|
| 13:30 - 15:00 | IO Combinations in Advanced NSCLC
Topics: Immunooncology
Moderation: C. Langer, USA; E. Santos, USA | Room 106 |
|----------------------|--|-----------------|
- 13:30 - 13:45 **MS28.01 - Understanding the Rationale for Combining IO Agents**
Edward Garon, CA/USA
- 13:45 - 14:00 **MS28.02 - Combination IO+IO**
Myung-Ju Ahn, Republic of Korea
- 14:00 - 14:15 **MS28.03 - Combinatorial IO + Chemo**
Rosalyn Juergens, Canada
- 14:15 - 14:30 **MS28.04 - Combination with Targeted Therapies**
Ross Soo, Singapore
- 14:30 - 14:45 **MS28.05 - Combining IO with Radiation**
Corinne Faivre-Finn, UK

14:45 - 15:00 **MS28.06 - Q&A**

MS29

13:30 - 15:00 Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers Room 206 F

Topics: Screening and Early Detection
Moderation: J. Goffin, Canada; B. Tong, USA

13:30 - 13:45 **MS29.01 - Assessment of Risk Prediction Algorithms for Entry into Screening Programs**
Martin Tammemagi, Canada

13:45 - 14:00 **MS29.02 - Defining Screening Frequency & Duration Using Risk Prediction Algorithms and CT Image Findings**
Kevin Ten Haaf, Netherlands

14:00 - 14:15 **MS29.03 - Polygenic Risk Score for Risk Assessment**
Rayjean Hung, Canada

14:15 - 14:30 **MS29.04 - LuCID Exhaled Breath Analysis**
Marc Van Der Schee, UK

14:30 - 14:45 **MS29.05 - Early Detection Biomarker Development: Is Success on the Horizon?**
Peter Mazzone, USA

14:45 - 15:00 **MS29.06 - Q&A**

MS30

13:30 - 15:00 Modern Day RT in LA NSCLC: Where Is the Evidence? Room 202 BD

Topics: Treatment of Locoregional Disease - NSCLC
Moderation: F. Hegi-Johnson, Australia; Y. Nakayama, Japan

13:30 - 13:45 **MS30.01 - Overview of RT Technology in LA NSCLC (IMRT, VMAT, IGRT)**
Gerard Hanna, UK

13:45 - 14:00 **MS30.02 - What Evidence Is Available to Support RT Technology in LA NSCLC (including Protons)?**
Yong Chan Ahn, Republic of Korea



- 14:00 - 14:15 **MS30.03 - What Evidence Is Available to Support RT Treatment Intensification in LA NSCLC?**
Jeffrey Bradley, MO/USA
- 14:15 - 14:30 **MS30.04 - Perspective**
Maria Werner-Wasik, USA
- 14:30 - 14:45 **MS30.05 - Nutritional Management During Radical Radiotherapy**
Rhys White, UK
- 14:45 - 15:00 **MS30.06 - Q&A**

MS31

13:30 - 15:00 **Clinical Science in Mesothelioma** **Room 205 AC**
Topics: Mesothelioma
Moderation: H. Yang, USA; M. De Perrot, Canada

- 13:30 - 13:45 **MS31.01 - Mechanisms and Targets for BAP1 Activity**
Michele Carbone, HI/USA
- 13:45 - 14:00 **MS31.02 - Clinical Implementation of BAP1 Inhibitors**
Paul Baas, Netherlands
- 14:00 - 14:15 **MS31.03 - Targeting the Hippo Pathway**
David Jablons, USA
- 14:15 - 14:30 **MS31.04 - CAR-T and ADC's in MPM**
Prasad Adusumilli, NY/USA
- 14:30 - 14:45 **MS31.05 - Vaccination and Antibody-Based Therapy in Mesothelioma**
Joachim Aerts, Netherlands
- 14:45 - 15:00 **MS31.06 - Q&A**

MS32

13:30 - 15:00 **SCLC - From Benchside to Bedside - Clinical Science Session** **Room 107**
Topics: Small Cell Lung Cancer/NET
Moderation: A. Adjei, USA; J. Pantarotto, Canada



- 13:30 - 13:45 **MS32.01 - Genetic Mouse Models (GEMMS)**
Trudy Oliver, USA
- 13:45 - 14:00 **MS32.02 - Patient Derived Models (PDX & CTC-Derived)**
Anna Farago, MA/USA
- 14:00 - 14:15 **MS32.03 - Liquid Biopsies for Drug Development in SCLC**
Caroline Dive, UK
- 14:15 - 14:30 **MS32.04 - Molecular Phenotypes of SCLC**
Adi Gazdar, TX/USA
- 14:30 - 14:45 **MS32.05 - Targeting DNA Damage and Repair**
Lauren Byers, TX/USA
- 14:45 - 15:00 **MS32.06 - Epigenetic Targets**
John Poirier, NY/USA

PL04

15:15 - 16:30 **Take Action - Key Messages from WCLC 2018 and Goals for 2019** **Plenary Hall**
Moderation: N. Leighl, Canada; R. Pirker, Austria

- 15:15 - 15:20 **PL04.01 - Medical Oncology**
David Gandara, CA/USA
- 15:20 - 15:25 **PL04.02 - Pathology**
Fred Hirsch, CO/USA
- 15:25 - 15:30 **PL04.03 - Surgery**
Ramon Rami-Porta, Spain
- 15:30 - 15:35 **PL04.04 - Radiation Oncology**
Jose Belderbos, Netherlands
- 15:35 - 15:40 **PL04.05 - Americas**
Clarissa Mathias, Brazil
- 15:40 - 15:45 **PL04.06 - Asia Pacific**



Michael Boyer, ACT/Australia

15:45 - 16:25 **PL04.07 - Discussion and Q&A**

16:25 - 16:30 **PL04.08 - Invitation to WCLC 2019 Barcelona, Spain**